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The diversity of biosynthetic pathways in prokaryotes and eukaryotes has led to 
numerous bioactive natural products (NPs) which occupy a vast chemical space. Despite 
the current challenges in NP research, these molecules are still relevant today as they are 
a major source of human medicine as well as being useful biological tools. The 
elucidation of their biosynthetic pathways has also provided information about the 
biochemical and biophysical properties of fascinating enzyme families such as the α-
oxoamine synthases (AOSs). The AOSs are an expanding group of pyridoxal 5’-
phosphate (PLP)-dependent enzymes, which are involved in the biosynthesis of several 
important NP, including those essential for life. This study reports the characterization 
and structural analysis of a unique AOS denoted as TamD from Pseudoalteromonas 
tunicata. This enzyme plays a major role in tambjamine biosynthesis and consists of 
both an acyl carrier protein (ACP) domain and a PLP-binding catalytic domain. UV/vis 
spectroscopy and mass spectrometry (MS) of the recombinant TamD purified from E. 
coli revealed that the enzyme forms a Schiff base with PLP via Lys380, which is 
responsible for its characteristic yellow colour. It binds L-serine as a natural substrate 
with a Kd of 5.01 ± 0.64 mM. This thesis also reports structural data for TamD from x-
ray crystallography at a resolution of 4.98 Å, which shows four molecules in the 
asymmetric unit (ASU) suggesting the enzyme exist as a dimer. The absence of the N-
terminal region where the ACP domain is located in the crystal strucuture also suggests 
intrinsic flexibility and disorder within that region.  
 
With the increasing demand for new anti-infective therapies, investigations of the 
molecular interactions between NPs and their protein targets are vital in understanding 
the inhibition or activation properties of these molecules. The cysteine transpeptidases 
known as sortases produced by Gram positive bacteria have been identified as attractive 
targets for NP inhibitors. In this thesis, the molecular basis for the inhibition of 
Streptococcus mutans sortase A (SrtA) by the plant flavonoid, trans-chalcone is 




crystallography.  This study reports the first high resolution crystal structure of the 
H139A mutant of S. mutans SrtA, which reveals a unique N-terminal α-helix domain. 
Trans-chalcone was found to inhibit the in vitro activity of S. mutans SrtA in a slow, 
tight–binding manner, with a half maximal inhibitory concentration (IC50) of 5.0 ± 0.6 
µM. The interaction resulted in a covalent adduct with the active site cysteine residue 
(Cys205) via a Michael addition mechanism. Additionally, trans-chalcone showed 
evidence of S. mutans anti-biofilm activity in a concentration dependent manner up to 
250 µM with an efficacy cut-off point at higher concentations.  These results indicate 
that chalcone flavonoids are worth further investigation as potential antibiofilm 
inhibitors.  
 
A renewed interest in plant NPs has also led to a collaborative investigation on the 
antimicrobial potential of garlic-derived allicin, against Burkholderia cepacia complex 
(Bcc), the major bacterial phytopathogen for alliums and an intrinsically multiresistant 
and life-threatening human pathogen. Allicin is the principal antibacterial agent in fresh 
preparations of garlic extracts. This investigation reports the first evidence that allicin 
and allicin-contaning garlic extracts possess inhibitory and bactericidal activities against 
Bcc. The minimum inhibitory concentrations (MICs) of aqueous garlic extract (AGE) 
against 38 Bcc isolates ranged from 0.5 to 3% (v/v). An investigation into the possible 
molecular mechanisms of allicin with a recombinant thiol-dependent peroxiredoxin 
(BCP) from B. cenocepacia revealed that allicin and AGE modify an essential BCP 
catalytic cysteine residue and suggests a role for allicin as a general electrophilic reagent 
that targets protein thiols. Present therapeutic options against these life-threatening 
pathogens are limited; thus, allicin-containing compounds merit further investigation as 
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Chapter 1: General Introduction to Natural Products   
PART I: Biosynthesis of Antibacterial Natural Products 
1.1 Why study Natural Products? 
1.1.1 Pathways and Products 
 
Natural products (NPs) are low molecular weight organic molecules made by bacteria, 
fungi, lichens, marine invertebrates and plants. Their revolutionary applications in the 
pharmaceutical, agricultural, food and cosmetic industries cannot be underestimated.1-3 
Traditionally, NPs have been a major source of new drugs, which led to approximately 
80% of all drugs by 1990 being NPs and NP derivatives.4 However, over the last two 
decades modern drug discovery efforts have been more focused on screening synthetic 
combinatorial libraries,5 resulting in a decline in the use of NPs in the pharmaceutical 
industry. This trend may lead one to question if there is still a role for NPs in the 
discovery of novel compounds and new chemical processes. Whatever doubts the 
current reader might have, it is without reservation that I do propose that NPs are still 
relevant today and remain a source of inspiration for chemists and biologists. There is 
untapped potential in undiscovered compounds from unexplored biological sources that 
are now more accessible, through the advances in synthetic biology, genomics and 
proteomics which allow for manipulation of biosynthetic pathways.6, 7 NPs are also a 
vital source for identifying lead molecules for drug development, as over half of all Food 
and Drug Administration (FDA)-approved drugs are either NPs, semisynthetic 
derivatives of NP scaffolds or synthetic compounds with a NP pharmacophore.4 Current 
research has also shown that NPs serve as important chemical tools for identifying and 
understanding the mechanisms of pharmacologically relevant biological targets.1 The 
use of NPs as enzyme inhibitors or activators has made it possible for us to understand 
complex interactions of many protein targets, as well as identify novel proteins as targets 
for new classes of NPs. 
 
Biosynthetic pathways are nature’s blueprints/route maps to diverse classes of NPs and 




active secondary metabolites. The focus of NP discovery is no longer solely on the end 
products, but also, on the biochemical processes involved in the transformation from 
genes to molecules.1 Biosynthetic pathways consist of genes that encode for several 
proteins that play a role in the enzymatic assembly of NPs. They were classically 
elucidated through feeding studies and radioactive labelling experiments up until the 
1980s.1 Pioneer work on cloning the biosynthetic gene cluster for the antibiotic 
actinorhodin8 and later erythromycin9, 10 have paved the way for further molecular 
studies of polyketide synthases and their ancillary enzymes. The study of biosynthetic 
pathways responsible for the production of polyketides (PKs), non-ribosomal peptides 
(NRPs) and fatty acids (FAs) have resulted in the emergence of several classes of 
enzymes with diverse functions. What is common about these pathways is the use of a 
combination of enzymes from different classes to process covalent acyl-enzyme 
intermediates, iterative cycles of condensation and chemical tailoring of monomer units 
and intermediates to produce a diverse array of NPs.11 With automated bioinformatics 
platforms, it is now easier to predict and identify gene clusters which encode for novel 
NPs and study the function of fascinating enzymes which carry out interesting chemical 
reactions along these pathways.6, 12 
 
 
1.1.2 Antibacterial Resistance 
 
Infectious diseases remain the second-leading cause of death worldwide, with bacterial 
infections claiming the lives of over 17 million globally. Of particular concern is the 
emergence of bacterial strains with resistance to current and newly developed 
antibiotics.13, 14 Since the discovery and use of penicillin and other β-lactams, the rise in 
antimicrobial resistance has been linked to the overuse and misuse of antibiotics through 
selection pressure. Despite this problem, the demand for the development of novel 
antimicrobial therapies has outweighed the rate at which new therapies are being 
developed and approved for clinical use.15 Therefore a renewed interest in NPs as leads 
for antibiotic discovery coupled with the advances in genomics and sequencing 




regarded as superior over synthetic compounds for antibiotic discovery as these 
molecules have evolved to cope with microbial biology, which makes them more likely 
to penetrate the bacterial cell membrane and interact with specific protein targets, in 
comparison to their synthetic counterparts. NPs also occupy a more diverse chemical 
space and offer more structural complexity which is required for the inhibition of many 
antibacterial protein targets, making them suitable candidates for continuous antibiotic 
discovery.4, 13  
 
 
1.1.2.1  Burkholderia cepacia complex (Bcc) 
 
In the last few decades, Burkholderia cepacia complex (Bcc), a group of 17 closely-
related species distributed widely in soil, water and the plant rhizosphere16 has emerged 
as an important opportunistic human pathogen, in particular as a cause of life-
threatening lung infections in individuals with cystic fibrosis (CF) and chronic 
granulomatous disease.17, 18  Unfortunately, a common feature of the Bcc is its intrinsic 
resistance to most antibiotics19; hence antibiotic treatment presents a major challenge. 
Treatment of Bcc infections remains challenging and no particular antibiotic regimen is 
presently recognised.20, 21 Although patient segregation and strict infection control have 
reduced the incidence of Bcc infections in individuals with CF, such infections remain 
an important clinical problem. At present, the most predominant Bcc species responsible 
for CF infections are B. cenocepacia and B. multivorans.17, 22 Most transplant centres 
worldwide exclude individuals infected by B. cenocepacia from access to lung 
transplantation, the only proven treatment for severe CF lung disease. There is an even 
greater need to have alternative therapies with the recent alarming report of a clinical 
trial of inhaled aztreonam that failed to treat CF patients with Burkholderia spp. 
infection.23, 24 Thus, the availability of novel antimicrobial agents against Bcc would 
represent a major clinical advance for patients with Bcc infection. Previous 
investigations of novel NPs against Bcc species have included mushroom extracts25, 
polyketides26, docosahexaenoic omega-3 fatty acid27 and microbe-derived volatile 




within the pharmaceutical industry, the development of novel antimicrobial compounds 
derived from natural sources would be welcomed29, 30; this is particularly relevant to the 
management of lung infections which are the primary cause of morbidity and mortality 





1.2.1 Chemical and Biological Properties 
 
 
Tambjamines are NPs isolated from bacteria and marine invertebrates including 
bryozoans, nudibranchs and ascidians. They belong to the family of 4-methoxypyrrolic 
NPs, which includes the prodiginines31, 32 e.g. prodigiosin, undecylprodigiosin and 
streptorubin B33 (Figure 1). They are structurally characterized by a 2,2’-bipyrrole ring 
system, with ring B having an enamine moiety at the C5 position and a methoxy group 
at the C3 position (Figure 1). The enamine nitrogen usually displays a short alkyl side 
chain, which contributes to diversity within the family. Additionally, some tambjamines 
have a bromide substituent at the C5 position of ring A.34, 35 Tambjamines A-D were  the 
first members of the family to be isolated from nudibranchs in 1982 by Carté and 
Faulkner, during their studies of defense mechanisms of marine invertebrates.36 
Tambjamines were later reported to be produced by the terrestrial bacterium 
Streptomyces BE186591.37, 38 More recently, the marine bacterium Pseudoalteromonas 





Figure 1: Chemical structures of tambjamines and the prodiginines, prodigiosin 
and undecylprodigiosin. Tambjamines are bipyrrolic natural product isolated from 
Streptomyces sp. and the marine bacterial Pseudoalteromonas sp. whereas the 







Tambjamine YP1 isolated from P. tunicata is the only member of the family identified 
so far with an unsaturated alkyl side chain. The lipophilic nature of the alkyl side chain 
has been credited for the increased bioactivity of YP1 in comparison to other 
tambjamines.40 Tambjamines are pharmacologically important molecules as they possess 
antimicrobial, anticancer and immunosuppressive properties. These properties are partly 
due to their ability to intercalate DNA and participate in the oxidative cleavage of 
single-strand DNA.35 The latest research on the biological activity of tambjamines has 
shown that they have good ionophoric properties. Tambjamines can move across cellular 
membranes, disturb the normal ionic balance and alter the intracellular pH, which can 
trigger apoptosis.41, 42 Ecologically, tambjamines provide a natural defense to marine 
invertebrates against predators. Also, the antifouling property of tambjamines produced 
by P. tunicata has made this organism a widely studied model for marine biofilm 
formation studies.43 Since these molecules possess pharmacological properties, their 





Subsequent to the isolation of tambjamine YP1, the gene cluster involved in its 
biosynthesis was identified by Burke et. al. in 2007. So far, this has been the only report 
of the identification of the biosynthetic genes (tam cluster) for the tambjamine class of 
compounds, since their first isolation in 1982.39 This significant step in tambjamine 
research has led to the cloning and expression of the tam cluster in E. coli to produce a 
yellow tambjamine product, identified as YP1. The tam cluster is 34 kb(s) in length and 
consists of 21 open reading frames (Figure 2). Of these, 19 are involved in YP1 
biosynthesis. The genes in the Tam cluster have been assigned functions using sequence 
comparisons to the gene clusters involved in the biosynthesis of prodigiosin, 
undecylprodigiosin and other NPs (Table 1).33, 44, 45   12 of the genes in the Tam cluster 
have been found to be homologous to the genes involved in the biosynthesis of 
prodigiosin in Serratia sp. (pig cluster)32 and undecylprodigiosin in Streptomyces 






Figure 2: Gene Cluster involved in the biosynthesis of tambjamine YP1. The tam 
cluster consists of 21 open reading frames, 19 encode proteins involved in the 
biosynthesis of the bipyrrolic natural product. 
 
A bifurcated pathway has also been proposed for the biosynthesis of tambjamine YP1  
(Figure 3). Although these steps have not been experimentally verified, the first part of 
the pathway is similar to the prodiginine biosynthetic pathway proposed by Walsh46 and 
Challis32 in two independent studies. The proposed enzymatic assembly is initiated by 
the formation of the pyrrole A-ring from L-proline tethered to a peptidyl carrier protein 
(PCP), TamB via a thioester linkage. The conversion occurs via a four-electron 
oxidation process by the activity of a flavin adenine dinucleotide (FAD)-dependent 
dehydrogenase, TamG. The pyrrolyl-2-carboxyl intermediate is then transferred to a 
ketosynthase (KS), TamF which is responsible for the decarboxylative Claisen 
condensation of this moiety and a malonyl unit tethered to the ACP domain of TamD. A 
PLP-dependent decarboxylation step is performed by the α-oxoamine synthase (AOS) 
domain of TamD in the presence of L-serine, to give the second pyrrole ring. 
Subsequent oxidation and methylation by a putative dehydrogenase TamJ and a methyl 
transferase TamP, result in the intermediate product, 4-methoxy-2-2’-bipyrrole-5-
carbaldehyde (MBC).46-48 The final step involves the enzymatic condensation of a 
primary amine with a long alkyl chain, dodec-3-en-1-amine, derived from the fatty acid 
biosynthetic pathway and MBC to give tambjamine YP1.  
 
There is a lot of information in the literature about the production of MBC, a key 
intermediate in the biosynthesis of the prodiginines in S. coelicolor and Serratia 
species.32, 33, 46, 48 The genetic and biochemical analyses from previous studies have 




the tam cluster include those likely to be involved in the production of MBC in the 
biosynthesis of tambjamines in P. tunicate (Table 1).   Of particular interest to this study 
are the pigH and the redN genes, which encodes for a PLP-dependent aminotransferase 
homologous to tamD. Walsh’s study of pigH has revealed that the protein has three 
domains, an unusual pair of acyl carrier protein (ACP) domains and a seryltransferase 
(serT) domain, which is responsible for generating a C2 unit from L-serine used in the 
formation of pyrrole ring B.46 Additionally, Challis’ study of redN gene also revealed 
















Figure 3: Proposed biosynthetic pathway of the tambjamine YP1 from P. tunicata. 
The bifurcated pathway involves the oxidation of L-proline into a pyrrole ring followed 
by the condensation of malonyl with L-serine to give a second pyrrole ring. 
Condensation of the bipyrrolic aldehyde with a long chain amine results in the 















Table 1: Predicted functions of gene products from tam Cluster. Each gene product 
of the tam cluster has been assigned a putative function based on sequence homology 
with protein from the pig and red gene clusters. Gene sequence was obtained from 
Genebank for P. tunicata D2 (NCBI reference sequence: NZ_AAOH01000002.1) 
 












tamA 75 - - AMP binding protein 
tamB 10 pigG redO Peptidyl carrier protein 
tamC 43 - redG Putative oxidase 
tamD 58 pigH redN seryl transferase 
tamE 56 pigI redM L-prolyl-AMP ligase 
tamF 81 pigJ redX Pyrrolyl-β-ketoacyl ACP synthase 
tamG 43 pigA redW L-prolyl-PCP dehydrogenase 
tamH 104 pigE - Putative class III aminotransferase 
tamJ 40 pigM redV HBC dehydrogenase 
tamK 29 - - Hypothetical protein 
tamI 50 - - Putative permease 
tamM 45 - - Putative permease 
tamN 26 - - Putative ABC transporter,  
ATP binding protein 
tamO 45 - - Hypothetical protein 
tamP 37 pigF redI HBC O-methyl transferase 
tamQ 100 pigC redH Terminal condensing enzyme 
tamR 12 pigK redY Hypothetical protein 
tamS 25 pigL redU Phosphopantetheinyl transferase 
tamT 62 - - Putative dehydrogenase 
 
 
1.3 The α-Oxoamine Synthases  
1.3.1 Role in Natural Products Biosynthesis 
 
The α-oxoamine synthases (AOSs) are an expanding family of enzymes which are at the 
heart of the biosynthesis of many interesting NPs. These enzymes are involved in the 
biosynthesis of a diverse selection of primary and secondary metabolites that range from 




molecules sphingolipids49, as well as the cofactors biotin50, vitamin B12, heme, 
chlorophyll and factor 43047. Additionally, these enzymes are involved in the 
biosynthesis of quorum sensing and anti-fouling molecules in bacteria, which include 
the bipyrrolic alkaloids, tambjamines produced by marine bacteria and marine 
invertebrates40, the tripyrrolic alkaloids prodiginines produced by Streptomyces, Serratia 
and Actinomycete sp.32, 46, the tricyclic perhydropurine alkaloid saxitoxin produced by 
marine invertebrates51, fumonisin produced by the filamentous fungus, Fusarium 
verticillioides52 and the autoinducers cholera autoinducer-1 (CAI-1)53 and Legionella 
autoinducer-1 (LAI-1)54 produced by Vibrio cholerae and Legionella pneumophila 
respectively. AOSs are also involved in the synthesis and degradation pathways of the 

























Figure 4: Structures, producers and biological role of molecules from pathways 




1.3.2 Members of the AOS Family 
 
The most well characterised members of the AOS family include serine 
palmitoyltransferase (SPT)56-58, 5-aminolevulinate synthase (ALAS)59, 2-amino-3-
ketobutyrate CoA ligase (KBL)55, 8-amino-7-oxononanoate synthase (AONS)50 and 
Cholera CAI-1 synthase (CqsA)60 (Figure 5 and A1). SPT catalyses the first step of 
sphingolipid biosynthesis. It also carries out a decarboxylative condensation reaction, 
and utilizes L-serine and palmitoyl-CoA as substrates to give the first intermediate of the 
pathway, 3-ketodihydrosphingosine (KDS). This intermediate is then further 
incorporated into the biosynthesis of ceramides, sphingomyelins, etc. SPT is found in 
mammals, yeast and bacteria and mutation of the human enzyme results in a disorder of 
the peripheral sensory neurons known as hereditary sensory neuropathy type 1 
(HSN1).56 AONS is a very important enzyme in the biosynthesis of biotin, a cofactor 
which is required for most carboxylation and transcarboxylation reactions in plants and 
microorganisms. It catalyses the Claisen condensation between L-alanine and pimelyol-
CoA to produce 8-amino-7-oxononanoate (AON).61 KBL is one of the unique AOS 
members. It is responsible for catalyzing the second step of the threonine degradation 
pathway by performing a condensation reaction between glycine and acetyl-CoA to give 
α-amino-β-ketobutyrate (AKB). It is different from other AOSs in that, it does not 
perform a decarboxylative step in its reaction mechanism.55  
 
ALAS is the first enzyme in the biosynthetic pathway of the porphyrin ring of heme and 
other tetrapyrroles. It catalyses the decarboxylative condensation between glycine and 
succinyl-CoA to produce 5-aminolevulinic acid (ALA), the first precursor in tetrapyrrole 
biosynthesis.  ALAS occurs in most prokaryotes and eukaryotes, however mutations in 
the human erythroid ALAS result in a genetic disorder known as sideroblastic anemia.59  
Interestingly, the gene product of ORF34 from the ECO-02301 biosynthetic gene cluster 
in Streptomyces aizunenesis NRRL-B-11277 which is involved in the formation of the 
2-amino-3-hydroxycyclopent-2-enone five membered ring (C5N scaffold) also utilises 





CqsA is the most recent member of the AOS family whose structure has been 
determined in 2010 by Bassler63, Taylor53 and colleagues.  This enzyme is involved in 
the biosynthesis of the quorum sensing molecule, 3-aminotridecan-4-one also known as 
CAI-1 in V.  cholera. 60 The actual mechanism of the enzyme remains unclear as there 
are two possible amino acid substrates reported by Bassler’s group which the enzyme 
may catalytically condense with decanoyl-CoA to give CAI-1. These are (S)-2-
aminobutyrate 60 and (S)-adenosylmethionine (SAM)63. LqsA is the closest homologue 
of CqsA with a 42% sequence identity. It was identified in the opportunistic pathogen L. 
pneumophila in 2008 by Spirig et al., and is responsible for the synthesis of the α-
hydroxyketone signalling molecule LAI-1. It belongs to the lqs gene cluster which 
regulates virulence, biofilm formation and bioluminescence in L. pneumophila.54  More 
recently JqsA, a homologue of LqsA and CqsA, was identified in Janthinobacterium sp. 
HH01 which is involved in violacein biosynthesis through the production of the 
autoinducer JAI-1. The chemical structure of JAI-I has not yet been elucidated. 
However, sequence analysis of JqsA using the NCBI database suggests that the enzyme 
has properties similar to 7-keto-8-aminopelagonic acid (KAPA) synthase which is 
involved in the biosynthesis of biotin. This would suggest that JqsA is likely to function 
as an alanine transferase.64   
 
The arginine transferase, SxtA from the saxitoxin gene cluster is also a member of the 
AOS family. This enzyme is predicted to carry out a condensation reaction characteristic 
of the family. It utilizes the substrates L-arginine and propionyl-ACP to give the 
intermediate 4-amino-3-oxo-guanidinoheptane which is further functionalized by the 
other enzymes in the gene cluster to give saxitoxins.51 Another interesting member of 
the AOS family is Fum8p which was identified in the pathogenic fungus Fusarium 
verticillioides by Gerber in 2008. Fum8p is a part of a fumonisin gene cluster that 
synthesizes the mycotoxin fumonisins. The enzyme is responsible for introducing an 
amino group and two carbons into the fumonisin backbone and off-loading it in a PLP-
dependent fashion from the PKS machinery. This reaction is achieved through a 




The AOSs TamD, RedL and PigH are homologues with a seryl transferase function 
belonging to PKS gene clusters. They are involved in the biosynthesis of the pyrrolic 
NPs tambjamine, undecylprodiginine and prodigiosin respectively. They accept the 
amino acid substrate L-serine and carry out a PLP-dependent condensation with a 
pyrrolyl-β-ketoacyl-S-ACP intermediate to give a bipyrrole product, 4-hydroxy-2-2’-
bipyrrole-5-methanol (HBM). These enzymes are very different from the other AOSs 
because they exist as natural fusion proteins with their ACP partners. RedL and PigH 
have two ACP domains while TamD is predicted to have one ACP domain, based on 
sequence analysis. Although functional studies have been carried out on RedL and PigH, 
no structural information is currently available for these enzymes. RedN on the other 
hand, although a part of the red cluster to which RedL belongs, is much more similar to 
ALAS in terms of sequence homology. It carries out the condensation between glycine 




































































Figure 5: AOS family of enzymes. Each enzyme performs a condensation reaction between an amino 




1.3.3 PLP-Dependent Mechanism 
 
The AOS enzymes catalyse the Claisen-like condensation between their amino acid and 
acyl-CoA thioester substrates, with a concomitant release of carbon dioxide to give α-
oxoamine products (Figure 6).61  Some members of the family utilise an acyl carrier 
protein (ACP)-acylthioester instead of the conventional acyl-CoA substrate (Figure 6). 
So far, KBL is the only member of the family that does not carry out the decarboxylation 





       
 
 
Figure 6: General reaction scheme for AOS enzymes. These PLP-dependent enzymes 
carry out a Claisen condensation of acyl-CoA thioester and amino acid with concomitant 
release of carbon dioxide. 
 
All the members of the AOS family discovered to date are dependent on the PLP 
cofactor for enzymatic activity. These enzymes have a conserved PLP binding site with 
a lysine residue in the active site forming a Schiff base with the cofactor (internal 
aldimine).65 The reaction mechanism utilized by AOS enzymes can be summarized in 
six steps: (A) displacement of catalytic lysine and binding of amino acid substrate to 
PLP to form an external aldimine, (B) abstraction of the α-proton to form a resonance-
stabilised quinonoid intermediate, (C) nucleophilic attack of the quinonoid intermediate 
on the acyl-CoA substrate to form a β-ketoacid product with concomitant loss of CoA, 
(D) decarboxylation of the β-ketoacid to form a quinonoid product, (E) protonation of 
the product quinonoid to form an external aldimine and (F) release of the α-oxoamine 
product from PLP to generate an internal PLP aldimine.56 These steps are shown below 





acid-PLP external aldimine is oriented perpendicular to the PLP ring in accordance with 
































































































































































































































1.4 Acyl Carrier Proteins  
1.4.1 Role in Natural Products Biosynthesis 
 
ACPs are essential for the production of various primary and secondary metabolites. 
They are small acidic proteins comprising of less than 100 amino acids (~9 kDa), that 
are involved in providing starter units and 2-carbon chain extension units derived from 
acyl-CoA needed for molecular assembly of FAs and PKs.67 Their biosynthetic 
homologues are known as peptide carrier proteins (PCPs) and are involved in the 
construction of peptide backbones from amino acid monomers used in NRP 
biosynthesis.68 ACPs are also responsible for directing intermediates between the fatty 
acid synthases (FAS) and the polyketide synthases (PKS), stabilising pathway 
intermediates and regulating these pathways.67, 69 Therefore ACPs can be thought of as 
the “drivers” of NP biosynthesis. 
 
ACPs are expressed in nature in their apo form and are functionally activated by the 
addition of a 4’-phosphopantetheine (4’-PP) prosthetic group derived from CoA, to a 
conserved serine residue via the hydroxyl side chain to produce the holo form of the 
protein (Figure 8). 70 The post-translational modification (PTM) occurs by the enzymatic 
activity of an acyl carrier protein synthase (AcpS) or a phosphopantetheinyl transferase 
(PPTase) in the presence of CoA and magnesium ion (Mg2+).71 The thiol group of the 4’-
PP moiety is responsible for shuttling acyl intermediates of the fatty acid and polyketide 



























Figure 8: Activation of apo-ACP to form functionally holo-ACP with 4’-PP 
prosthetic group.  In the presence of a PPTase and Mg2+ ions, the phophopantetheinyl 




1.4.2 Type I and II ACPs 
 
ACPs can either exist as part of large multifunctional megasynthase complexes (type I 
systems) or as discrete proteins (type II systems). Fatty acid and polyketide biosynthetic 
pathways have both type I and type II ACPs, whereas non-ribosomal peptide synthases 
(NRPSs) exist mainly as megasynthases with type I carrier proteins.70 The structural 
organisation of the type I FAS and PKS are very similar, consisting of up to 12 
functional modules per polypeptide chain. For instance in the FAS system each module 
consists of a ketosynthase (KS), acyltransferase (AT), ketoreductase (KR), enoyl 
reductase (ER) and dehydratase (DH) domain which play a role during biosynthesis 
(Figure 9A).  Each module may contain a single ACP, as seen in animal FAS or more 
than one carrier proteins as in type I PKS and NRPS systems, where the growing PK or 
NRP intermediate is covalently attached via the thioester linkage (Figure 9B-C). 73 
Protein-protein interactions between carrier proteins and other catalytic domains 
involved in FAS, PKS and NRPS pathways are necessary for the formation of 
intermediates and the final product, as the substrates involved in elongation are anchored 




will require the ACP to interact with the AT domain that loads the starter unit, the KS 
domain which carries out condensation to incorporated the starter unit into the growing 
chain and the other domains that chemically modify the chain. Likewise, in NRP 
biosynthesis, the ACP analogue, PCP requires interaction with the adenylation and the 
condensation domains.68 In type I FAS, the ACP domain is very flexible and is able to 
interact with each catalytic domain within the megasynthase in an iterative manner.74, 75 
However, protein-protein interactions between carrier proteins and their enzyme partners 
in type I PKS and NRPS systems are somewhat restricted. This is because each carrier 
protein in these systems is responsible for a specific step within the assembly line 






Figure 9: Typical type I domain arrangement for FAS, PKS and NRPS. The carrier 
protein can interact with each domain in the module. (A) Mammalian FAS 
consisting of two α-chains. (B) A typical PKS elongation cycle will require the ACP to 
interact with other domains. (C) In the NRPS system the adenylation (A) domain 
activates the amnio acid monomer which is incorporated into the growing chain by a 
PCP. The condensation (C) domain then catalyses amide bond formation between the 






Type II FAS and PKS systems carry out the same functions as the type I systems. 
However, in the type II systems, the catalytic domains including the ACPs exist as 
discrete proteins, i.e., separate polypeptides rather than one polypeptide chain. In the 
type II systems, the growing acyl chain that is covalently bound to the ACPs is not 
readily accessible because it is usually buried in the hydrophobic pocket of the protein 
which means that ACP-enzyme interactions are very crucial for the partner enzyme to 
access its target. 
 
Type I and II ACPs are structurally similar with dynamic and flexible properties. These 
intrinsic properties are utilized in protein-protein interactions with several enzyme 
partners in nature. Their structures are greatly stabilized by pantetheinylation and 
acylation.75 ACPs possess a conserved structure among many organisms  even at low 
sequence identity.70 The protein adopts a helical bundle fold, with a characteristic four 
α-helices architecture, with three of these helices running parallel to one another and the 
fourth helix (helix III) lying antiparallel to the others (Figure 10).70, 75 The helices are 
arranged to form a hydrophobic pocket in the centre of the protein, which houses the 
growing acyl chain during FA biosynthesis with an opening to the pocket situated 
between helices II and III.70 The serine residue which undergoes PTM pantetheinylation 
is a part of a conserved three amino acid motif (Asp-Ser-Leu, DSL), which is located in 
the N-terminus region of the second helix.74 ACPs are very dynamic and highly flexible 
proteins with helix I being among the most flexible regions of the ACP followed by 
helices II and III. The dynamic nature is necessary for substrate delivery and interactions 
with enzymes.70  The prosthetic 4’-PP arm of the carrier protein allows the protein to 
span a distance of 20 Å, which also requires additional flexibility in the linker region 
between domains in the type I systems in order for the protein to effectively shuttle 






Figure 10: Crystal structure of apo ACP from E. coli. ACP adopts a helical bundle 
fold, with a characteristic four α-helices architecture, with three of these helices running 




1.4.3 ACP-Enzyme Complexes 
 
The interactions of ACPs with their enzyme partners are essential for sequestration and 
processing of acyl substrates during the biosynthesis of NPs and fatty acids. As 
previously described, the biosynthetic intermediates are usually tethered to the 4’-PP 
arm of the ACP via a thioester linkage. The ACP delivers the substrate in the correct 
orientation to the active site of its enzyme partner avoiding exposure to the solvent, 
preventing the hydrolysis of the delicate thioester bond. This process requires optimal 
contact for efficient delivery. Structural studies of the yeast FAS has led to the 
proposition of a chain transfer mechanism described as the ‘chain-flipping’ mechanism 
by Cronan. This model suggests that the process begins with the acyl-ACP thioester 
being buried initially within the hydrophic pocket of the ACP. The entire chain is then 
flipped into the hydrophobic active site of the respective enzyme partner, where it 






Figure 11: Cartoon depiction of the chain-flipping mechanism of acyl-ACP 
thioester in complex with enzyme partner.76  (A) The acylthioester is housed in the 
hydrophobic pocket of the ACP formed by residues mainly of helices II and IV (the 
prosthetic group is coloured in blue, the thiol in yellow and the acyl chain in black. (B) 
The acyl chain and most of the prosthetic group is flipped from the hydrophobic pocket 
of the ACP into the pocket of the enzyme partner X. (Taken from reference 73) 
 
This mechanism has been supported by the crystallographic data from the structural 
studies of ACP-enzyme complexes. The first ACP-enzyme complex was reported in 
2000 by Parris et al. from the structural studies of Bacillus subtilis ACP with its holo 
AcpS.77 The structure showed that AcpS interacted largely with helix II of the ACP, 
which had the attached 4’-PP arm, through mostly hydrophilic interactions in the form 
of salt bridges between the acidic residues of helix II and arginine residues of AcpS.77 
More recent ACP-enzyme complexes have also been reported. These include acyl-ACP 
in complex with the following partners; FabA (3-hydroxyl-ACP dehydratase), LpxD (N-
acyltransferase), FabI (enoyl reductase), BioH and BioI. The ACP-FabI structure also 
reveals that protein-protein interactions occurs via the acidic residues of helix II of the 
ACP (Asp35, Asp38 and Glu41), which form stable electrostatic interactions with basic 
residues of FabI (Lys201, Arg204 and Lys205). The electron density for the pantetheinyl 
arm of the ACP was absent from the structure, which hindered the prediction of how 







Figure 12: ACP-Enzyme Complexes. (A) E. coli ACP in complex with FabI, the 
FASII enoyl reductase (PDB code: 2FHS) (B) E. coli ACP in complex with FabA, 3-
hydroxyl-ACP dehydratase (PDB code: 4KEH). (C) E. coli ACP in complex with LpxD, 
an acyltransferase involved in Lipid A biosynthesis (PDB code: 4IHF). ACP coloured in 
blue and FabI, FabA and LpxD in green.  
 
Nguyen et al. later reported the structure of a chemically cross-linked acyl-ACP·FabA 
complex, in which the acyl chain occupied the hydrophobic cavity formed between the 
subunits of dimeric FabA (Figure 12B). The structure revealed a collapsed ACP which 
had a similar topology to that of apo-ACP, which suggests a dynamic process involving 
the ACP moving from a sequestered-substrate state to a ‘chain-flipping’ state to position 






showed that the acidic residues of the helices II and III of the ACP that interacted with 
FabA included Glu41, Glu47, Glu53 and Glu60. The acyl-ACP·FabA crystal structures 
also captured the ACP in two different conformations. The first ACP·FabA 
conformation reveals one of the ACPs binding to an arginine-rich groove of FabA and 
the second conformation shows the ACP completely docked with FabA before 
delivering its acyl chain. These snapshots reflect the dynamic and transient nature of the 
ACP-enzyme interactions.79  
 
A very interesting crystal structure of the acyl-ACP·LpxD complex was reported by 
Masoudi which captured the acyl-ACP in three different forms (intact-acyl-ACP, 
hydrolysed-acyl-ACP and holo-ACP) while in complex with LpxD (Figure 12C).80 
These structures showed that the acyl chain had flipped from the hydrophobic pocket of 
the ACP into a hydrophobic channel formed between to monomers of the trimeric LpxD, 
where it is fully extended.80 BioI forms a tight protein-protein complex with acylated-
ACP which is processed during FA biosynthesis to produce pimeloyl-ACP. The crystal 
structure of BioI in complex with ACP acylated with tetradecanoic acid (C14), hexadec-
9Z-enoic acid (9-Z-C16) and octadec-9Z-enoic acid (9-Z-C18) revealed the insertion of 
the entire acyl chain into the active site of BioI upon binding. The phosphopantetheine 
linker interacts with active site residues of BioI through hydrogen bonding of its 
carbonyl oxygen and amide nitrogen with the side chain of active site residues. The 
phosphate group also interacts with BioI residues via water mediated hydrogen bonding. 
Residues from three of the ACP helices (I, II and III) were involved in the binding of the 
protein to BioI through salt bridge interactions between acidic residues of the ACP and 
basic residues of BioI. Other interactions were also observed in the crystal structure 
between non-polar residues of both the ACP and BioI through hydrogen bonding via the 
backbone amide groups. It was concluded that the acylated ACP was necessary to 
stabilize the BioI·ACP complex.81 The complex of BioH with Me-pimeloyl-ACP 
revealed a BioH·ACP interface and enzyme-carrier protein interactions which bear 
similarity to that of the other complexes described previously. The contact of the two 




the basic residues of helices II and III of BioH. Ionic interactions were observed between 
Glu34 and Glu37 of the ACP and Arg138 and Arg142 of BioH, and Arg155 and Arg159 
of BioH with Glu46 and Asp55 of the ACP. Both sites are located at either end of helix 
II of the ACP. These interactions help in stabilizing the ACP in the required position to 
BioH to effectively direct the acyl-thioester chain into the active site.82  
 
In summary, the acidic surface residues of helix II play an important role in the dynamic 
nature of ACPs and their substrate specificity.75 Additionally, NMR studies have shown 
that the conserved DSL motif in the amino acid sequence which houses the site of 
pantetheinylation, located at the beginning of helix II (Figure A3), also assists in protein-
protein interaction between ACPs and their enzyme partners. These interactions make it 
possible for acyl intermediates to be protected by being buried in a hydrophobic core of 
the ACP until it is transferred to the hydrophobic pocket of the respective enzyme 
partner. In contrast, type I PKS and NRPS carrier proteins have been observed to have 
neutral protein surfaces as opposed to a positive surface, which leads to the question of 























Part II: Antibacterial Properties of Plant Natural Products 
1.5 Plant Natural Products 
1.5.1 Back to Our Roots 
 
Historically, plants have been the main source of NPs up until the early 1900s. 
Biodiversity within the plant kingdom has provided us with various classes of NPs 
which have a broad spectrum of biological activities. Several of these compounds are 
still widely used medicines today. These include the salicylates from willow bark, 
morphine from the poppy plant and quinine from cinchona. Several of the drugs 
approved by the FDA for treating cancer are also plant derivatives, which include 
vinblastine and  vincristine from Madagascar periwinkle (Vinca rosea); taxol from 
Pacific yew (Taxus brevifolia) and camptothecin from the Happy tree (Camptotheca 
acuminata).83 However, over the years, less focus has been placed on harnessing plant 
NPs for the discovery of lead compounds due to their increased extinction rates, 
seasonal and environmental variations which affect their access and supply. 
Additionally, plant extracts are usually very complex mixtures with the bioactive 
molecules present only in very small quantities after fractionation.  Despite these 
disadvantages, plants are still a major source of NPs, with 91 plant compounds being 
included in clinical trials up to 2007.3 With advance in genomics and metabolic 
engineering, an alternative approach to using plant NPs is to revisit some of the classical 
families of compounds that have been previously explored and find new ways of 
exploiting their biological activities whether as pure compounds, complex extracts or 
adjuncts to existing synthetic compounds. In this body of work, two families of plant 
NPs were revisted and applied to separate bacterial protein targets, the chalcone 











The flavonoids are a family of polyphenolic NPs produced by plants via the 
phenylpropanoid biosynthetic pathway. Flavonoids possess a hydroxylated phenolic 
backbone, with two aromatic rings (A and B) connected by an α,β-unsaturated system, 
which can also exist as a pyran ring. Flavonoids are further divided into subfamilies 
based on variations of the pyran ring which include the chalcones, flavonones, flavones, 
dihydroflavonols, flavonols, flavans, isoflavonoids, neoflavonoids, anthocyanins and 
cathechins (Figure 13).84 Their biological activities are greatly dependent on the 
structural class, extent of oxidation, degree of conjugation and pattern of substitution 
around the A and B rings.85  
 
Their biosynthesis begins with the deamination of the aromatic amino acid 
phenylalanine to form cinnamate by the activity of the enzyme phenylalanine ammonia 
lyase (PAL). This step is followed by hydroxylation at C-4 by cinnamate 4-hydroxylase 
(C4H) to give 4-coumarate, which is then activated to 4-coumaroyl-CoA by 4-coumarate 
CoA ligase. The resulting CoA product is then condensed with three acetate units 
derived from malonyl-CoA by the activity of chalcone synthase (CHS) followed by 
cyclisation by the same enzyme to give naringenin chalcone. This intermediate is then 
further functionalized into various flavonoids by other enzymes in the pathway (Figure 
14).85 Flavonoids are synthesized by plants as growth regulators and also as defence 
agents in response to environmental stress e.g. oxidative stress and microbial infections. 
They can be found in all parts of plants including the fruit, flower, stem, bark and root as 









Figure 13: Structural backbone of subclasses of flavonoids. The basic structure of the 
flavonoids consists of two aromatic rings A and B connected by a pyran ring. The 
flavonoids also differ based on the extent of oxidation and the presence of substituents 







Figure 14: Biosynthesis of flavonoids. Flavonoids are biosynthesized from 
phenylalanine via the phenylpropanoid pathway. Three units of acetate are incorporated 
from malonyl-CoA which condenses with the 4-coumaroyl-CoA intermediate to produce 





1.5.2.2  Biological Activities 
 
Flavonoids are also known to have a broad spectrum of biological activities including 
antioxidant, anticancer, anti-inflammatory and antibacterial properties.84-87 Dietary 
flavonoids have long been exploited for their associated health benefits, especially for 
their antioxidant activity. The ability of flavonoids to scavenge radicals and chelate 
metal ions has been associated with the antioxidant property displayed by these 
molecules. One such mechanism by which this occurs is through the inhibition of 
enzymes involved in the generation of reactive oxygen species (ROS) which include 
microsomal monooxygenase, glutathione S-transferase, mitochondrial succinoxidase and 
NADH oxidase.85 Additionally, flavonoids have also been explored for their 
antimicrobial properties, which not only occur in vivo to protect the plant against 
infections but also in vitro. The structural features of flavonoids make it possible for 
them to interact with several protein targets and inactivate microbial adhesins, enzymes, 
cell envelop transport proteins and disrupt microbial cell membranes. Catechins have 
been reported to inactivate cholera toxins in Vibrio cholerae, inhibit glycosyltranferases 
in Streptococcus mutans and DNA synthesis in Proteus vulgaris. Naringenin, a 
flavonone present in citrus fruits has been reported to have antibacterial activities against 
methicillin resistant Staphylococcus aureus (MRSA) and Streptococci, which is likely 
associated with the reduction of membrane fluidity in the bacterial cells. Licochalcones 
A and C, chalcone flavonoids from licorice extracts have also been reported to have 
antimicrobial activities against S. aureus and Micrococcus luteus.84, 85  
 
 
1.5.2.3 Potential of Chalcones 
 
Chalcones are one of the most diverse classes of flavonoids, they exist as either 
intermediates or end products of flavonoid biosynthesis. Structurally, they can be 
described as 1,3-diaryl-2-propen-1-ones which may exist as a cis or a trans isomer, with 
the latter being more thermodynamically stable.86, 88 It is interesting to note that several 




trials for the treatment of cancer, viral and cardiovascular disorders. The α,β-unsaturated 
moiety of the chalcones is regarded as the main pharmacophore and research has shown 
that there is a loss of bioactivity when this functionality is removed.86 The most widely 
studied biological activities of the chalcones include their antioxidant, anti-
inflammatory, anticancer and anti-infective properties. As anti-infective agents, 
chalcones have been shown to have antiviral, antifungal, antiparasitic and antibacterial 
activities. The screening of chalcones against both Gram positive and Gram negative 
bacteria has shown that several naturally occurring chalcones possess low MICs 
(µg/mL) against several clinically relevant species including S. aureus, E. coli, 
Mycobacterium tuberculosis, Bacillus subtilis and Pseudomonas aeruginosa.88 The 
chalcone framework serves as an attractive structure that can be further optimized to 
achieve increased potency useful in the development of novel anti-infective therapies. 
 
 
1.5.3 Allicin  
1.5.3.1 Garlic-Derived Thiosulfinates 
 
Garlic extracts serve as a valuable source of sulfur-containing NPs which have a wide 
range of biological activities. The chemical basis of the distinctive characteristics of 
garlic which include its pungent taste and odour, lachrymatory ability and biological 
effects on humans and microbes have been studied as far back as the 19th century.89 
Cavallito and Bailey were responsible for identifying the main bioactive component of 
garlic to be allicin in 1944 from analyzing steamed-distilled ethanolic garlic extracts.89 
This then led to the chemical structure and chemical properties of allicin being 
elucidated over a series of papers by Cavillito and colleagues at The Winthrop Chemical 
Company.90-94 Research in allium chemistry took off in later years with notary work in 
the field carried out by pioneers including Eric Block and Larry D. Lawson whose 
research careers were focused on studying the chemistry and biology of allium-derived 
thiosulfinates. Garlic is the most widely studied member of the allium family because of 
its pharmacological potential which include its anticancer, antithrombotic, anti-




component of garlic, accounts for approximately 75% of the thiosulphinates found in 
garlic extracts.96 It is a pale yellow, oily, volatile, and highly unstable liquid with a 
characteristic garlic odour.  
  
Unlike other secondary metabolites found naturally in plants, thiosulfinates are only 
produced when plant tissues of alliums are damaged, resulting in the enzymatic activity 
of alliinase on S-alk(en)nyl-L-cysteine sulfoxides.95 The dominant sulfoxides present in 
alliums are alliin, isoalliin and methiin which are found in garlic, onion and chive 
respectively (Figure 15).95 Due to the relative instability of thiosulfinates, they are 
spontaneously converted to linear dialk(en)yl polysulfides e.g. the degradation of allicin 
to ajoene. Ajoene is the most widely studied bioactive derivative of allicin. Not only is it 
more stable than allicin, but it also possess pharmacological properties similar to those 
of allicin.97, 98 Upon heating, thiosulfinates also degrade to form allyl alcohol and 
heterocylic polysulfides (Figure 15).95 The composition of steamed-distilled oils from 
different species of allium has various sulfides which are characteristic of each member 







Figure 15: Sulfur-containing compounds in Alliums and their transformation 
products. Alliin, isoallin and methiin are the main sulfoxides naturally occurring in 
garlic, onion and chive. They can be transformed to other sulfur-containing compounds 





The biosynthesis of allicin in garlic was elucidated by Stoll and Seeback in the 1940s. 
They showed that the non-protein amino acid, alliin (S-(allyl)-L-cysteine sulfoxide) was 
transformed into allicin in a two-step mechanism (Figure 16). Firstly, alliin is converted 
to allyl sulfenic acid, pyruvic acid and ammonia by the PLP-dependent enzyme, allinase 




sulfenic acid results in the formation of allicin. This enzymatic reaction can occur within 
10-15 minutes at room temperature.  
 
 
Figure 16: Conversion of alliin to allicin. Two-step mechanism by: (1) which alliin 




Building up on this previous work, Granroth used radioactive labelling experiments to 
elucidate two possible pathways for the biosynthesis of allicin from serine and 
glutathione in garlic (Figure 17).  His data showed that 14C-labelled serine was 
incorporated into the formation of 14C-labelled S-allyl-cysteine which would further be 
used to produce alliin. Additionally, Granroth was able to detect S-allyl-glutathione and 
S-allyl-γ-glutamyl-cysteine which suggest that gluthathione was involved in the 
formation of alliin via a second pathway. The source of the allyl group of alliin still 
remains unclear. On the formation of S-allyl-cysteine, it is further oxidized to form 
alliin, which then gets enzymatically hydrolysed by allinase to produce sulfenic acid. 









Figure 17: Biosynthesis of allicin. The proposed biosynthetic pathways of allicin start 
from serine and glutathione. The source of the allyl group is still unclear. Both pathways 
lead to the formation of the S-allyl-cysteine intermediate. This intermediate is then 




1.5.3.3 Antimicrobial Properties  
 
Garlic extracts have been used for thousands of years for their antimicrobial properties 
against bacteria, fungi, virus and protozoa.95, 100 Louis Pasteur was one of the first 
scientists who deliberately used garlic extracts as an antibacterial agent.99 Garlic extracts 
have antibacterial activities against several species of  Gram positive, Gram negative and 
acid-fast bacteria (Table 2).99 Studies have also shown that the allicin present in freshly 
prepared garlic extracts is the main thiosulfinate that is responsible for the antimicrobial 
properties of garlic. To support this fact, there has also been good correlation between 
the percentage concentration of crude garlic and pure allicin extracts used in several 
investigations aimed at assessing the antimicrobial activities of allicin.99 
 
The antimicrobial potential of allicin and aqueous garlic extract (AGE) in comparison 
with other clinically effective antibiotics has also been assessed in a number of studies. 
In Fugisawa’s study, the anti-staphylococcal potentials of allicin and AGE were 
observably stronger than that of streptomycin and vancomycin. Additionally, AGE and 
allicin were found to be more effective against E. coli than colistin.101 Synergism 
between allicin and other antibiotics has also been reported in the literature.100, 102-105 In 
more recent years research has been focused on understanding the mechanism(s) 
responsible for the antimicrobial activities of allicin and garlic extracts.  
 
In order for allicin to be an effective antibacterial agent, it first needs to be able to reach 
its target within the cell. Allicin meets this criterion, as it can rapidly diffuse through the 
bacterial cell wall and the cell membrane. Once inside the cell, it is believed to react 
with key intracellular thiol-containing proteins required for life, via a disulfide 
exchange-like reaction (Figure 18).106 This is further supported by the fact that 
sulfhydryl compounds such as cysteine and glutathione are able to cancel out the 







Table 2: Antimicrobial activity of allicin and garlic extracts against Gram positive 
and Gram negative bacteria. The experimental systems used to assess antimicrobial 
activity are defined as: complete growth inhibition in liquid culture (A); growth 
inhibition zones (B); soaked filter discs on top of seeded agar (C); directly pipetted onto 
bacteria-seeded agar (D); pipetted into wells punched out of the agar (E); LD50 (50% 
lethal dose) determination (F).  
 
Bacteria Gram Source of Allicin Amount of Allicin Experimental 
System A,B,C,D  




























+ Garlic extract 0.04-0.62 µmol107 B,E 
Enterococcus 
faecium 
+ Pure allicin extract >100 µg/mL100 F 
Salmonella 
typhimurium 








- Garlic extract 1.72 µmol B,D 




- Garlic extract 1.72 µmol B,D 
V. cholerae - Pure allicin extract 80 µM94 
 
A 
Proteus mirabilis - Pure allicin extract 15-30 µg/mL100 F 
Pseudomonas 
aeruginosa 
- Pure allicin extract 15 µg/mL100 F 
Klebsiella 
pneumonaie 
- Pure allicin extract 8 µg/mL100 F 
Acinetobacter 
baumanii 











Figure 18: General reaction of allicin with thiol-containing proteins. Free thiols can 
react with the thiosulfinate moiety of allicin to give S-allylthio derivatives with sulfenic 
acid as the side product. 
 
A number of important enzymes which are involved in primary metabolic processes 
from microbial sources have been shown to be inhibited by allicin (Table 3). These 
include thiol-containing enzymes like cysteine proteinases, the NAD+-dependent alcohol 
dehydrogenases, thioredoxin reductases and the non-microbial enzyme papain. Other 
bacterial enzymes that have been found to be inhibited by allicin includes acetate kinase 
and phophotransacetyl-CoA synthetase in a non-covalent and reversible manner.109  
 
Table 3: Inhibition of microbial enzymes by allicin in vitro. Enzymes from four 
different microbial sources including bacterial and small parasites show inhibition by 
allicin in a thiol-dependent manner, with the exception of acetate kinase (the bacterial 








































The antimicrobial activity of allicin has also been believed to arise from inhibition of 
RNA, DNA and protein synthesis in microbes. Studies carried out by Feldberg et al. in 




Salmonella typhimurium. Using 3H-labelled uridine, leucine and thymidine, Feldberg 
was able to show that there was a decrease in the uptake of these building blocks 
required for RNA, DNA and protein synthesis in the cells treated with allicin.108 Lipid 
and fatty acid biosyntheses were suggested to be affected by allicin due to the observed 
inhibition of acetyl-CoA synthase from different sources.109 
  
 
Part III: Protein Targets of Natural Product Inhibitors 
1.6 Sortases  
1.6.1 Biological Role  
 
Sortases are cysteine transpeptidases found in Gram positive bacteria. They are 
responsible for the covalent attachment of a diverse array of proteins on the bacterial cell 
wall which facilitate interaction with their environment.113, 114 These interactions include 
iron acquisition, host invasion and signaling.113-115 The sortases identified to date have 
been classified into four sub-families (A-D), based on sequence homology, the cell wall 
sorting motif of the peptide substrate and their nucleophile substrate (Table 4).116 Sortase 
A (SrtA) from S. aureus was the first cysteine transpeptidase to be identified in 1999 by 
Schneewind and colleagues.117 This class of sortases is also known as the 
‘housekeeping’ enzymes and is highly conserved in Gram positive bacteria. These 
enzymes are able to recognise protein substrates with an LPXTG motif at the C-terminus 
and attach them to the pentaglycine crossbridge of the peptidoglycan layer via a lipid II 
molecule which serves as the second substrate for SrtA enzymes (Figure 19; Figure 21). 
The protein substrates are expressed in the cytoplasm with an N-terminal signal 
sequence, a positively charged C-terminal tail and a conserved five amino acid cell wall 
sorting motif. An active site cysteine residue of SrtA is able to cleave the amide bond 
between the threonine and glycine residues to generate a thioester intermediate.  This 
acyl-enzyme intermediate undergoes nucleophilic attack by the amino group of the 
pentaglycine crossbridge of lipid II resulting in the formation of a lipid II-linked 




Table 4: Classification of sortases. The four families of sortases are based on substrate 
specificity of the cell wall sorting motif of their protein substrates, cell wall precursor 









LPXTG Lipid II Adhesion, immune evasion, 

































Figure 19: Mechanism of sortase-mediated surface protein anchoring to the cell 
wall in Gram positive bacteria.118 The sortase is membrane-anchored and contains an 
active site cysteine residue which plays a crucial role in the cleavage of the peptide bond 
between the threonine and glycine residues of the cell wall sorting signal. Nucleophilic 
attack by a terminal amine on lipid II resolves the thioacyl intermediate to produce a 





Sortase B (SrtB) class of enzymes are expressed from the srtB gene, which is a part of 
the iron-regulated surface determinant (isd) gene cluster of Bacilli, Clostridia, Listeria 
and Staphylococci. SrtB is only expressed under conditions where iron is limited.119 This 
class of enzymes is responsible for anchoring proteins involved in heme-iron uptake that 
harbours the unique NP(Q/K)TN cell wall sorting motif to the crossbridge amino group 
of the assembled peptidoglycan. The mechanism is very similar to that of SrtA 
enzymes.119 The cross-linked, haem-containing structures are anchored near membrane 
transporters to carry out their function in iron transport.120 Sortase C (SrtC) enzymes on 
the other hand are involved in pili polymerization. The srtC gene is only found in spore-
forming Gram positive bacteria.  The pilin subunits harbour a C-terminal sorting signal 
similar to that of class A enzymes. SrtC enzymes link together two to three pilin 
subunits via isopeptide bonds to form the long thin shaft of the pili. The shaft is then 
attached to the cell wall by class A enzymes which results in a termination of the 
polymerization reaction. 118 Class D enzymes (SrtD) are the least studied sortases. They 
are expressed in spore-forming Gram positives e.g. Bacillus spp. and Streptomyces spp. 
SrtD enzymes are able to recognize proteins with the LPNTA sorting motif at the C-
terminal end and attach the cleaved product to the diaminopimelic acid moiety of the 




1.6.1.1 Sortase A in Oral Streptococci  
 
Sortases play a major role in Streptococcus adherence and colonization to its hosts.122 In 
a microbiology review on Streptococci by Nobbs, it was shown that most of the cell 
wall-anchored and surface-associated proteins expressed by Streptococci bear a C-
terminal cell wall sorting motif that can be recognized by sortases.122 The scope of this 
study only allows a review of the SrtA enzyme from the oral bacterium, S. mutans, 





The genome of S. mutans reveals the presence of a single sortase enzyme, SrtA which 
has been demonstrated to be involved in the surface attachment of six proteins expressed 
by the bacterium with the C-terminal sorting signal (Table 5).123-127  Studies carried out 
by Igarashi over a series of four publications between 2003 and 2004 have shown that a 
deletion or an inactivation of the srtA gene results in the inability of S. mutans to anchor 
these proteins to the cell wall resulting in a loss of the cariogenic properties of these 
proteins e.g. aggregation in the presence of saliva and reduced biofilm formation. 
Additionally, the ∆srtA genotype is not lethal, which suggests that the srtA gene is not 
essential for bacterial growth.123, 124, 128-130 These findings are very significant to the Oral 
Microbiology field, as S. mutans has been implicated as the main etiological agent of 
tooth decay in humans. 131 
 
Another interesting feature of S. mutans is that it adopts a biofilm lifestyle in the mouth 
contributing to the formation of dental plaque, which is an important first step in the 
formation of tooth caries. The initial stages of biofilm formation require bacterial 
adherence to oral surfaces which is mediated by surface proteins.126 Dextranase (Dex) 
for instance plays a further role in biofilm formation as it not only controls adhesive 
properties, but also the ability of S. mutans to utilize extracellular glucan as a nutrient 
source.124, 129 Additionally, the inactivation of dexA, the gene responsible for the 
expression of Dex also results in reduced cariogenicity in a rat model.132 In addition to 
these observations in S. mutans, mutant strains of S. gordonii, (a closely related species) 
that lacked the srtA gene, were observably less likely to colonise oral cavities of mice in 
comparison to the wild-type strain.133 These studies therefore suggest that SrtA-mediated 
interactions in oral Streptococci are associated with their pathogenesis.122 This then 










Table 5: Surface proteins expressed by S. mutans and anchored by sortase A 
enzyme. Six surface proteins expressed by S. mutans contains the C-terminal cell wall 
sorting motif (LPXTG) which is recognized by SrtA. They are all anchored to the cell 





1.6.2 Structure and Catalysis 
 
The three-dimensional structure of various sortases resolved by NMR spectroscopy and 
X-ray crystallography revealed that sortases adopt a unique eight-stranded β-barrel core 
fold, which contains three short helices and random coil loops. This structural 
arrangement retains high structural conservation among isoforms A, B and C despite 
class differences (Figure 20). Structural studies of S. aureus SrtA also revealed a highly 
conserved catalytic triad made up of Cys184, His120 and Arg197 (Figure 20 inset).120, 
134, 135 Cys184 is the only cysteine residue in the sequence of the protein and is 
Protein Abbreviation Uniprot Code Function 
Glucan-binding protein C GpbC Q8DTF1 Dextran-dependent bacterial 
aggregation 
 
Wall associated protein A WapA P11000 Binds collagen for 
coaggregation 
 
Wall associated protein E WapE Q8DU58 Binds collagen for 
coaggregation 
 
Antigen I/II Pac/P1/AgB P11657 Binds collagen, laminin, 
fibrinogen, salivary and 
fribronectin 
 
Dextranase Dex/DexA Q54443 Hydrolyses glucan and promotes 
glucan-mediated adherence 
 





responsible for the cleavage of the amide bond between the threonine and glycine 
residues of the LPXTG motif of the protein substrate. This residue is essential for 
catalysis, as its inhibition by thiol-reactive reagents and mutagenesis renders the enzyme 
inactive. His120 serves as a general base and Arg197 is believed to stabilise the 
oxoanion intermediate formed during catalysis.135, 136 Subsequent mutagenesis 
experiments of His120 and Arg197 also confirmed that these two residues are essential 





Figure 20: Representative three-dimensional structures of sortase A, B and C. The 
microorganism, enzyme name and PDB ID are as follows: (Blue) S. aureus SrtA, 1T2P; 
(Green) S. aureus SrtB, 1NG5; and (Magenta) S. agalactiae SrtC, 3O0P. The Cys-His-
Arg catalytic triad is also highly conserved among sortase isoforms (inset).  
 
 
A general mechanism is proposed for sortases based on the catalytic studies of S. aureus 
SrtA which involves the His-Cys-Arg catalytic triad. The mechanism involves a 
thioesterification step followed by a transpeptidation step (Figure 21). It has been 
proposed that the protein substrate for attachment is secreted from the cytoplasm via the 
Sec secretion pathway and comes in contact with the membrane-bound sortase before 




have His120 existing in its imidazolium form and the Cys184 in its thiolate form. The 
LPXTG substrate binds to the active site where it is stabilized by surrounding residues 
including Agr197. The thiolate form of the cysteine residue then cleaves the amide bond 
between the threonine and glycine residues of the LPXTG motif via the formation of a 
tetrahedral thioacyl intermediate stabilized by Arg197. This intermediate then undergoes 
nucleophilic attack by the terminal amino group of the pentaglycyl side chain of lipid II 
of the peptidoglycan layer to form a second tetrahedral intermediate which is stabilsed 
through hydrogen bonding to Arg197. Collapse of the intermediate then results in the 
formation of a transpeptidation amide product, returning the enzyme to its resting 
state.134, 135  
 
The orientation of His120 and Arg197 in the earlier structures of S. aureus SrtA led to 
inconclusive roles of His120 and Arg197 in catalysis. However, later structural studies 
of S. pyogenes SrtA revealed a novel arrangement of the catalytic residues that led to the 
accepted roles of His120 as a general base that protonates the leaving group of the 
tetrahedral intermediate and Arg197 involvement in stabilizing the oxyanion 
intermediate, substrate binding and substrate orientation through hydrogen bonding.136 
The sortase mechanism was also confirmed for SrtB enzymes in the structural studies of 




































































































































































































































































1.6.3 Biological and Chemical Potentials of Sortase A 
1.6.3.1 Labelling of Biomolecules 
 
Sortases serve as very useful tools in biotechnology, as they are able to catalyse the site-
specific conjugation of diverse array of compounds including small molecules, resins, 
gels, peptides, sugars, DNA etc. to target proteins.141 This technique takes advantage of 
the canonical function of SrtA which involves breaking the peptide bond between the 
threonine and glycine residues in the primary sequence LPXTG in proteins and making 
new peptide bonds between the threonine residue and an α-amino group of the 
pentaglycine side chain of lipid II.139 Molecules for conjugation are usually 
functionalised synthetically with oligoglycine tags or LPXTG peptide motifs, making 
them suitable nucleophiles or SrtA substrates respectively for conjugation to proteins. 
The range of applications for this technique has expanded over the years, likewise there 
has been several variations and modifications in the type of substrates used.141-144 Not 
only is the sortase-catalysed conjugation method site-specific, but it is also robust and 
reliable due to the promiscuous nature of the enzyme and ease of purifying soluble, 
active recombinant enzyme. 
 
 
1.6.3.2 Target for Anti-Infective Therapy 
 
SrtA has in recent years attracted significant interest as a potential drug target because 
earlier studies have shown that inactivation of the srtA gene had a significant impact 
upon the pathogenesis of infections caused by several clinically relevant Gram positive 
pathogens. These include S. aureus, L. monocytogenes, S. pyogenes and S. 
pneumonia.116 Due to the emergence of antibiotic-resistance strains, infections caused by 
Gram positive bacteria have posed a challenge for treatment. The attachment of Gram 
positive bacteria to hosts cells and tissues has been identified as a crucial first step in 
pathogenesis which is facilitated by sortase-anchored surface proteins. SrtA is therefore 
considered a universal virulence factor in Gram positive bacteria, and compounds that 




pathogenic Gram positive bacteria.113, 116, 145 Several classes of sortase A inhibitors have 
been identified over the past 20 years since the discovery of these enzymes.116 These 
include small molecules from synthetic libraries138, 146-148, rationally designed 
peptidomimetics148, 149 and natural products150-153. Recently, Schneewind and colleagues 
were able to identify a new class of mechanism-based inhibitors, aryl(β-amino)ethyl 
ketones (AEEK) from a screen of over 135 000 compounds which irreversibly modify 
the active site cysteine residue of SrtA and SrtB.147 The AEEK inhibitors form covalent 
adducts with the SrtB via the active site cysteine residue between the β-carbon of the 
inhibitor and the cysteine residue while readily undergoing β-elimination (Figure 22).147 
 
 
Figure 22: Aryl (β-amino)ethyl keotnes inhibitors of sortase A. (A) Molecular 
structures of the AEEK inhibitors that fromed crystal complexes with Bacilli SrtB. (B) 
Mechanism of sortase inhibition by AEEK inhibitors, (a) active site base of sortase 
carries out deprotonation of α-carbon, (b) β-elimination of dimethylamine, (c) Michael-
type conjugate addition of thiol from the active site cysteine to generate AEEK thioether 







1.6.3.3 Target for Natural Product Inhibitors  
 
NP screening efforts haved resulted in promising sortase inhibitors from several 
different classes of NPs (Table 6). The most recent report of  NPs with inhibition 
activity against S. mutans SrtA identified two flavonoids, morin154 and curcumin145, 155 
with IC50 values of 27.39 µg/ml and 13.8 µg/ml respectively. Collectively, the results 
from these studies merit further investigation in identifying NPs that can be further 
developed for anti-infective therapy. Of equal importance would be further studies 
aimed at investigating the mechanism of inhibition of sortases by these classes of natural 
products so as to obtain a better understanding into the kinetics, specificity, affinity and 
































Table 6: Plant extracts that show inhibition against sortase A in vitro. Medicinal 
plant extracts were tested for anti-sortase activity by monitoring the cleavage of a 
synthetic fluorogenic peptide. IC50 values represent the concentration that reduces 
enzyme activity to 50% relative to a 1% DMSO control. 
 
Compound Source IC50 (µg/ml) 
Extract Rhus verniciflua 3.22 
Discorhabdins  Sceptrella sp. 6.5 
Extract Fritillaria verticillata 8.41 
Berbine chloride Coptis chinensis 8.7 
β-Sitosterol-3-o-glucopyranoside  Fritillaria verticillata 18.3 
6-hydroxydihydro-β-carboline  Hyrtios sp. 67 
Palmatine chloride  Coptis chinensis 12.7 
Kurarinol  Sophora flavescens 30.5 
Aaptamines  Aaptos aaptos 3.7-23.5 
Curcuminoids  Curcuma longa  13.8-23.8 
Cadiolides  Synoicum sp. 78.8 
Β-carboline alkaloids  Synoicum sp. 146.4 
Sesterterpenes  Coscinoderma sp. 36 
Bis (indole)alkaloids  Spongosorites sp. 15.67 
Morin  Rhus verniciflua 37.39 
Extract Achyranthes bidentata 15.48 
Extract Benincasa cerifera 21.57 
Extract Cibotium barometz 39.40 
Extract Cocculus trilobus 1.52 
Extract Coptis chinensis 16.73 
Extract Cuscuta austrailia 21.12 
Extract Evodia officinalis 13.51 
Extract Gleditsia japonica 27.74 
Extract Liriope platyphylla 7.96 





1.7 Aims and Objectives 
 
This thesis reports data from three independent studies that cover topics introduced in 
chapters 3 to 5.  
 
Chapter 3 focuses on the structural studies of the putative AOS enzyme, TamD from the 
tambjamine biosynthetic pathway. In this investigation the objectives were to: 
1. Clone, express and purify the TamD enzyme from genomic DNA of P. tunicata.  
2. Characterise TamD by substrate binding, spectroscopy amd mass spectrometry 
techniques. 
3. Determine the x-ray crystal structure of the enzyme in order to understand the 
structural relationship and molecular dynamics between the proposed ACP and 
AOS domains.   
 
Chapter 4 focuses on analysising the molecular basis of SrtA inhibition by trans-
chalcone. The objectives of this study were to: 
1. Clone and purify SrtA from S. mutans with an N-terminal truncation of the first 
40 amino acids in order to obtain soluble and active protein. 
2. Characterise the enzyme using a FRET-based assay which monitors the cleavage 
of a fluorogenic peptide substrate by the enzyme. 
3. Analyse the inhibitory properties of trans-chalcone against S. mutans SrtA in 
vitro and investigate the mechanism of inhibition using a combination of mass 
spectrometry, enzyme kinetics and x-ray crystallography. 
4. Determine the structure of S. mutans SrtA and in complex with trans-chalcone. 
5. Investigate the impact of chalcone inhibitors on biofilm formation by S. mutans. 
 
Chapter 5 focuses on studying the antimicrobial properties of garlic-derived allicin 
against the multi-resistance pathogen Bcc. The objectives of this study were to: 
1. Quantify the amount of allicin present in the freshly prepared garlic extracts and 





2. Determine the MICs and MBCs of aqueous garlic extract (AGE) and aqueous 
allicin standard (AAS) and correlate this activity to the concentration of garlic-
derived allicin. 
3. Determine the efficacy of various assays including broth/agar dilution, paper 
disc and agar well diffusion in analyzing the antimicrobial potential of AGE and 
AAS against Bcc.  
4. Use high resolution mass spectrometry to determine the reaction mechanisms of 





Chapter 2: Materials and Methods 
The three projects used common techniques, methods and reagents. Where appropriate, 
the target-specific methods for allicin, TamD and SrtA have been outlined. 
2.1 Materials and Reagents 
 
All reagents, chemicals and media were purchased from Sigma-Aldrich, Fisher or Bio-
Rad. All primers were purchased from Sigma Genosys and competent cells and pET 
plasmids from Novagen and Invitrogen. Chromatography columns were purchased from 
GE Healthcare. HPLC column was purchased from Phenomenex. The P.tunicata 
genomic DNA was purchased from DSMZ, Germany. Synthetic gene for S. mutans 
recombinant sortase A was purchased from GenScript, USA. Allicin was purchased 
from LKT Laboratories, Germany and bacterial sortase II substrate was purchased from 
Cambridge Biosciences, UK. 
 
2.1.1 Competent E. coli Cell Lines 
 
Table 7: Bacterial strains and applications  
 









F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1 
Transformation 




2.1.2 Growth Media  
 
Growth media and LB-agar plates were prepared by dissolving the components in 
distilled water (Table 8), adjusting the pH to 7.5 and sterilising by autoclaving for 20 








2.1.3 Solutions and Buffers 
 
Buffers were prepared by dissolving the required components from stock solutions in 
distilled water according to Table 9. All buffers were passed through a 0.2 μm filter and 
degassed before using for chromatography. Buffers were stored at 4 oC and used with 
two week of preparation. The stock solutions were prepared as follows: 
1 M tris(hydroxymethyl)aminomethane (Tris-HCl), pH 8.0  
5 M Sodium Chloride 
1M Imidazole 
0.5 M Ethylenediaminetetraacetic acid (EDTA) 
25 mM PLP 
0.5 M Potassium Phosphate (KPhos) pH 8.0 











Luria Bertani (LB) Tryptone (10 g/L), yeast extract (5 g/L), sodium chloride  
(10 g/L) 
SOC Tryptone (20 g/L), yeast extract (5 g/L), sodium chloride  
(10 mM), potassium chloride (2.5 mM), magnesium chloride 
(10 mM), magnesium sulphate (10 mM), glucose (2% w/v) 
LB-Agar Tryptone (10 g/L), yeast extract (5 g/L), sodium chloride  








A 25 mM Tris-HCl, 500 mM NaCl, 125 μM PLP, 10% glycerol, pH 8 
B 50 mM Tris-HCl, 500 mM NaCl, 50 μM PLP, 10% glycerol, 1 mM DTT, pH 8 
C 20 mM MES.NaOH, 20 % glycerol, pH 6.2  
D 20 mM MES.NaOH, 2M NaCl, 20 % glycerol, pH 6.2 
E 20 mM MES.NaOH, pH 6.5, 150 mM NaCl 
F 50 mM Tris-HCl, 500 mM NaCl, 20 mM imidazole, pH 7.5 
G 25 mM KPhos, 500 mM NaCl, 1 mM DTT, pH 8 
H 50 mM Tris-HCl, 500 mM NaCl, 250μM PLP, 1 mM DTT, pH 8 
I 25 mM Tris-HCl, 1mM EDTA, pH 8.5 
J 50 mM NH4Ac, pH7.5  
 
K 20 mM MES.NaOH, pH 6.5, 125 mM NaCl,  5 mM NH2-Gly3 and 2 mM DTT 
L 50 mM CAPS, 50 mM MES, 100 mM Tris 
M 50 mM acetic acid, 50 mM MEs, 100 mM Tris 
 
 
2.1.4 Antibiotics  
 
All stocks were prepared by dissolving the required amount of antibiotic in distilled 
water and then filter sterilised by passage through a 0.22µm filter. Antibiotic was added 
to cool media to the desired final concentration based on Table 10. 
 
Table 10: Preparation of antibiotics solutions 
 
Antibiotic Protocol 
Ampicillin 100 mg/mL stock solution was prepared and stored at 4 oC. The 
required volume was added to media to give a final 
concentration of 100 μg/mL 
Kanomycin 30 mg/mL stock solution was prepared and stored at 4 oC. The 
required volume was added to media to give a final 







2.2  DNA Amplification  
2.2.1 Plasmids 
 
The following plasmids outlined in Table 11 were used for cloning and protein 
expression. 
 
Table 11: Plasmids and their application 
 




Cloning in E. coli Compatible with blue/white screening to identify 
transformants with ligated DNA product. Provides 




Expression in  
E. coli 
Protein can be expressed with a  
C-terminal hexa-histidine tag. 
pET-28a Expression in  
E. coli 






Primers used in polymerase chain reaction (PCR) for amplification were designed to be 
between 20-30 base pairs in length (Table 12). Primer oligonucleotides were purchased 















Table 12: Primers used for molecular cloning and PCR. Bases in bold lettering are 
the sites of mutagenesis. 
 
Primer Sequence (5’-3’) 
TamD forward CATATGACAGACAATAAAAACACCG 
TamD reverse CTCGAGTGCCACAAAACCGGGTAATTTCA 
H139A forward GCTAGCGCTCATGTTTTTGGTATGACCG 
H139A reverse AAAACATGAGCGCTAGCAAGAGCATAA 
G94A forward GTAATTGCCGGAATTGCCATTCCAGACTTA 










2.2.3 Polymerase Chain Reaction (PCR) 
 
The reaction mixture was prepared on ice by mixing forward primer (1.5 μL), reverse 
primer (1.5 μL), dNTP (1 μL), reaction buffer (5 μL, 10 ×), DNA template (2.5 μL), Pfu 
Hotstart DNA polymerase (1 μL, 2.5 U) and filter sterilised water (37.5 μL) to obtain a 
final volume of 50 μL. The thermal cycling protocol was then carried out in a PCR 
machine according to the steps in Table 13. For A-tailing reaction, the 50 μl reaction 
from above was added to PCR tube with one Taq Ready-To-Go PCR beads and 
incubated for 20 mins at 72 oC. The reaction is then terminated by adding DNA loading 
dye (2 μl, x5) and the product purified by electrophoresis, which is then cloned into 










Table 13: PCR protocol for sequencing 
 
Step Cycle Temperature/ oC Time/min 







54 1  
68 1min/kbp 
Final Extension 1 68 10  
 
 
2.2.4 Site Directed Mutagenesis (SDM) 
 
SDM reactions were performed using primers with overlap extension156 and the 
thermostable Turbo Pfu polymerase which exhibits a high fidelity 3’-5’ proof reading 
ability. Each reaction was assembled as follows: Pfu 10x buffer (5 μl), dNTP mix (1 μl), 
turbo cloned Pfu polymerase (1 μl), forward and reverse primer (2.5 μl) and template 
DNA (2 μl). The final reaction volume was made up to 50 μl with sterile distilled water 
and placed in the thermocylcer based on the programme in Table 13.  
 
 
2.2.5 DpnI Digest 
 
DpnI digest was performed on the SDM reaction on completion of PCR cyle by adding 
DpnI mix (1 μl) and DpnI buffer (5 μl) to the reaction mixture and incubating for 1 hour 
at 37 ᴼC to destroy template DNA. The newly synthesized DNA with mutation (4 μL) 
was transformed into C2987 competent cells (50 μL). 
 
 
2.3 DNA Purification and Analysis 
2.3.1 Gel Electrophoresis 
 
Agarose (1 g) was added to TAE buffer (100 mL, x1), the mixture was heated until the 
agarose dissolved. Upon cooling to approximately 50 oC, gelred (Cambridge Bioscience) 




agarose was then poured into a casting mould and allow to set at room temperature. The 
gel was then transferred to an electrophoresis tank containing TAE buffer (x1).  DNA 
samples containing DNA loading dye (final dilution of x1) was added to gel along with 
the appropriate DNA marker in separate lanes. Samples were run at a constant voltage of 
100 volts for 50-60 mins. 
 
 
2.3.2 Gel Extraction 
 
The DNA of interest was cut from the agarose gel then weighed and purified using the 
gel extraction QIAquick kit (QIAGEN). In summary, three volume (3 times the weight 
of the gel slice) of QG buffer was added to the gel slice and the sample incubated for 50 
oC until the agarose dissolved. One volume of isopropanol was then added to the sample 
which was transferred to a spin column and centrifuged. The supernatant was discarded 
and the column washed with 500 µL of QG buffer followed by 750 µL of PE buffer. The 
residual buffer was removed by centrifuging for 1 minute and the purified DNA was 





The amplified gene obtained from purification step (3 μL) was incubated with plasmid 
(1 μL), T4 ligase (1 μL, 1 x 106 ligations/unit), T4 ligase buffer (1 μL, x10) and dH2O (4 
μL) for 2 hours at room temperature. The ligation product (4 μL) was then used to 
transform C2987 competent cells (50 μL). DNA cloned into pGEM T-Easy vector were 
grown on S-Gal agar plates supplemented with ampicillin (100 μg/mL) for blue/white 










2.3.4 Restriction Digest 
 
The following reaction mixture was assembled for a single analytical restriction digest. 
DNA (8 µL), restriction buffer (1 µL, x 10, New England Biolabs), restriction 
endonuclease (1 µL, New England Biolabs). BSA (1 µL, x 10) was added to the reaction 
mixture for enzymes that required it for activity. Reaction components were scaled up 
for large scale reaction.  The components were mixed and then incubated at 37 oC for 2 
hours and the reaction terminated by adding DNA loading buffer. The digestion products 





Plasmid DNA was purified from overnight cultures by following the steps outlined in 
the manufacturer’s protocol which is summarised as follows. Overnight culture grown in 
LB media (5 mL) was centrifuged at 3000 rpm for 10 mins at 4 oC. The supernatant was 
discarded, the pelleted cells resuspended in buffer P1 (250 µL) and then transferred to a 
sterile eppendorf. The mixture was vortexed until it was homogeneous, after which 
buffer P2 (250 µL) was added and the sample thoroughly mixed by inverting the tube 6 
times. Buffer N3 was then added to the sample followed by another thorough mixing. 
The resulting mixture was centrifuged for 10 mins at 13 000 rpm and the supernatant 
decanted into a QIAprep spin column. The sample mixture was then centrifuged for an 
additional minute, the flow through was then discarded and the spin column washed 
with buffer PB (500 µL). The spin column was further washed with buffer PE (750 µL), 
centrifuged for 1 minute and the flow through discarded. The residual wash buffer was 
removed by centrifuging for an additional 1 minute. The spin column was then placed in 
a clean 1.5 mL microcentrifuge tube and the plasmid DNA eluted with buffer EB (50 









A PCR was carried out to verify the DNA sequence using thermostable turbo Pfu 
polymerase. The sample for sequencing was prepared by mixing the DNA template (5 
µL), pET or pGEM primer (1 µL, 10 µM stock) (Table 14), sequencing buffer (2 µL) 
and Big Dye master mix version 3.1 (2 µL). The sequencing reactions were done in pairs 
with the forward primer used for one reaction and the reverse primer for the second 
reaction. The sequencing programme consisted of 25 cycles with the following steps: 95 
oC for 30 seconds, 50 oC for 20 seconds and 60 oC for 4 minutes. Samples were then 
analysed by GenePool at the Ashworth Building, The University of Edinburgh. 
 
Table 14: Primers used for sequencing DNA in pET and pGEM vectors 
 
Primer Plasmid Sequence (5’-3’) 
pET forward pET TTAATACGACTCACTATAGGG 
pET reverse pET CTAGTTATTGCTCAGCGGT 
pGEM T7 forward pGEM TAATACGACTCACTATAGGG 
pGEM T7 reverse pGEM ATTTAGGTGACACTATAGAA 
 
 
2.4 Protein Expression  
2.4.1 Transformation 
 
Plasmid DNA (2 μl) was added to competent E. coli cells (25 μl) and incubated on ice 
for 20 minutes followed by heat shocking cells for 40 seconds at 42 oC. The cells were 
then placed on ice for a further 2 minutes. SOC media (100 μl) was added to the cells 
which were then incubated at 37 oC while shaking at 200 rpm for 1 hour. Using sterile 
techniques, 30 μl of the culture was evenly spread on LB Agar plates supplemented with 







2.4.2 Single Expression 
 
A single colony was picked into LB broth (500 ml) supplemented with ampicillin (100 
μg/mL) or kanomycin (30  μg/mL), and grown overnight at 37 oC. The overnight culture 
was used to inoculate fresh LB media (1 L) and cells were grown to an OD600 of 
approximately 0.6 at 37 oC before induction with IPTG to a final concentration of 0.1 
mM. The cultures were incubated for a further 4 hours at 20 oC after which they were 
harvested by centrifugation at 5000 × g for 15 minutes. The supernatant was discarded 
and the cell pellet was stored at -80 oC until needed for purification. 
 
 
2.4.3 Cell Lysis by Sonication 
 
The cell pellet was resuspended in lysis buffer with one EDTA-free protease inhibitor 
cocktail tablet (Roche). The cell suspension was sonicated on ice 15 min with 30s 
intervals. The resulting crude lysate was centrifuged at 18 000 rpm for 20 min at 4 oC. 
 
 
2.5 Protein Purification  
2.5.1 Protein Purification for Chapter 3 
2.5.1.1 Nickel Resin Purification  
 
The supernatant after the centrifugation step in section 2.4.3 was incubated on 
equilibrated Ni-NTA resin with an addition of 10 mM imidazole for 1 hour at 4 οC.  The 
resin was washed with buffer A containing 50 mM imidazole and the protein eluted with 




2.5.1.2 Tev Protease Cleavage 
 
The pEHISTEV construct and the Tev Protease used for this step were gifted from the 




TamD was expressed from a pEHISTEV construct (Figure 23), which consists of an N-
terminal hexa-histidine tag followed by a Tev protease site. An N-terminal cleavage at 
the Tev Protease site was performed following the protocol of Liu and Naismith.157 In 
summary, the purified protein after dialysis in buffer B was incubated with His-tagged 
TEV protease (1 mg/mL of protease for 10 mg of protein) for 16 h at 4 ᴼC with mild 
agitation. The digest reaction mixture was incubated with equilibrated Ni-NTA beads for 
45 mins and the cleaved protein eluted with buffer B containing 500 mM imidazole. The 
protein was then extensively dialysed overnight in buffer B to remove excess imidazole. 
 
 
Figure 23: pEHISTEV Plasmid Map. Sequence details of the cloning and expression 
region of the pEHISTEV vector showing the hexa-histidine and TEV protease 
recognition sites highlighted in red.157 
 
 
2.5.1.3 Size Exclusion Chromatography (SEC) 
 
The Superdex S200 16/60 column (GE Healthcare) was equilibrated with 1.5 column 
volumes (CV) of buffer B. The concentrated protein sample (5 mL) was injected on to 




approximate molecular mass of the purified protein was calculated using a calibration 
curve of known molecular masses (Figure A2). 
 
 
2.5.2 Protein Purification for Chapter 4  
2.5.2.1 Cation Exchange Chromatography 
 
The cell free extract was prepared as previously described in section 2.4.3. Then it was 
loaded onto a MonoS 5/50 cation exchange column (GE Healthcare) equilibrated with 
buffer C at 1 ml/min. This was followed by a wash of the column with 15-20 mL of 
buffer C. The protein was then eluted with an increasing concentration of buffer D over 
20 column volumes.  
 
 
2.5.2.2 Size Exclusion Chromatography 
 
The fractions containing the protein of interest from the cation exchange purification 
step were pooled and concentrated to 5 mL. The concentrated protein was further 
purified by SEC using a Superdex S200 column 16/60 (GE Healthcare) equilibrated with 
buffer E.  
 
 
2.5.3 Protein Purification for Chapter 5  
2.5.3.1 Purification of BCP 
 
A cell free extract was prepared from the cell suspension in buffer F as described in 
section 2.4.3. The resulting supernatant was filtered (0.45 μM) and loaded onto a 
HisTrap FF 1 mL column pre-equilbrated in buffer F. The His-tagged BCP protein was 
eluted from the nickel column with increasing imidazole concentration in buffer F. The 






2.6 Protein Analysis 
2.6.1 SDS-PAGE 
 
Protein samples were denatured by the addition of 2 × SDS sample buffer and boiling 
for 5 mins. The samples (10 μl) were loaded onto the gel along with low molecular 
weight (LMW) marker (GE Health Care) which was used for detecting the approximate 
molecular weights of the proteins. Gels were run in 1× TGS running buffer at 200 V and 
180 mA for 50 mins. They were then stained with coomassie blue stain at 37 oC while 
shaking gently for an hour and destained by microwaving for 15 mins in water. The 
acrylamide gel consisted of two layers, running and stacking gels (Table 15).  
 
Table 15: Preparation of acrylamide gels for SDS-PAGE analysis 
 
Component 15% running gel 4% stacking gel 
dH2O 5.7 ml 2.9 ml 
40% acrylamide 6 ml 0.75 ml 
1.5 M Tris (pH 8.8) 4 ml - 
0.5 M Tris (pH 6.8) - 1.25 ml 
SDS (10% w/v) 150 µl 50 µl 
APS (50 mg/ml) 300 µl 100 µl 
TEMED 20 µl 5 µl 
 
 
2.6.2 Concentration using Absorbance, A280 
 
Protein concentrations were determined by measuring the UV absorption at 280 nm 
using a Varian’s Cary 50 UV-Vis spectrophotometer. Calculations were done using the 
Beer-Lambert’s law, (Equation 1). The extinction coefficient (ε) for each protein was 
determined from the VectorNTI protein analysis software. Spectrum measurements were 
taken between 200-800 nm.  
 




(A) = absorbance at 280 nm; (ε) = molar extinction coefficient (M-1cm-1); (c) = protein 
concentration (M), (l) = the path length of the sample (1 cm).  
 
 
2.6.3 Spectroscopic Measurement 
 
This section is specific for TamD analysis. Excess PLP was removed from all protein 
samples by passing the concentrated purified sample through a PD10 (Sephadex G-25M) 
desalting column (GE Healthcare) and eluting with buffer G before UV/vis analysis. All 
UV-visible measurements were done using 500 µl of sample at 37 oC unless otherwise 
stated. A Varian’s Cary 50 UV-Vis spectrophotometer was used for measuring the UV-
visible spectra of all samples and the Cary WinUV software (Varian) used for analysis 
of results. Samples were analysed with quartz cuvettes with a pathlength of 1 cm from 
200-700 nm.  
 
 
2.6.3.1 Dissociation Constant, Kd 
 
The dissociation constant of TamD was determined in buffer G (38 μM) made up with 
L-serine (0-100 mM) to a final volume of 400 μl. The reactants were mixed and allowed 
to equilibrate for 15 mins at room temperature.  The absorbance maximum at 426 nm 
was measured at different concentrations of L-serine and the values plotted against 
substrate concentration. The data points were fitted to hyperbolic saturation curve 
(Equation 2) using Sigma Plot software: 
 
∆Aobs = ∆Amax [L-serine] 
        Kd + [L-serine]   (Equation 2) 
 








2.7 Protein Chemistry  
2.7.1 Reactions for Chapter 3 (TamD Analysis) 
 
All reactions for this section are specific for TamD unless otherwise stated. Samples 
were prepared for the detection of the Lys residue to which PLP forms an internal 
aldimine with the AOS domain of TamD by reduction with NaBH4 and DTT followed 
by LysC digest as described in the following sub-sections.  
 
 
2.7.1.1 Reduction with NaBH4 and DTT 
 
TamD (5 mL, 4 mg/mL) was dialysed for 1 h into buffer H and excess PLP removed 
using PD-10 desalting column. The protein (450 µL, 11.23 µg) was then mixed with 
NaBH4 (50 µL) to give a final concentration of 1 mM and incubated on ice. The reaction 
was monitored by UV/vis spectroscopy until there were no more visible spectral changes 
at 426 nm. The reduced protein was then denatured with DTT using the following 
assembly: TamD (5 µL, 11.23 µg), dH2O (25 µL), buffer I (×5, 10 µL) and DTT (200 
mM, 2 µL). The reaction mixture was incubated for 45 mins at 60 ᴼC and then allowed 
to coold to room temperature before adjusting the volume to 50 µL with dH2O. 
 
 
2.7.1.2 LysC Digest 
 
The protein digest with Lys-C endoproteinase was performed according the protocol 
outline by the supplier Roche. In summary, lyophilised Lys-C was reconstituted with 50 
µL of dH2O to give concentration of 0.1 µg/µL. The Lys-C proteinase (0.5 µg, 5µL w/v) 
was added to the reaction mixture from section 2.7.1.1 which contained the reduced 
TamD (11.23 µg) and incubated for 18 h at 37 ᴼC. The final enzyme to protein ratio in 
the digest reaction was ~ 1:20. The reaction sample was then analysed by liquid 
chromatography-electron spray ionization-mass spectrometry (LC-ESI-MS) as outlined 





2.7.1.3 Phosphopantetheinylation Reaction 
 
Recombinant TamD was reacted with malonyl-CoA or CoA as a substrate in an attempt 
to convert the apo-ACP domain into its holo-form using AcpS or Sfp (PPTase). TamD 
(60 μM) was added to reaction buffer J (50 mM ammonium acetate, pH 7.5), with the 
specific PPTase (1 μM), 1 mM MgCl2, 250 μM CoA or Malonyl-CoA in a final volume 
of 250 μL. This reaction mixture was incubated overnight at 37 °C followed by LC-ESI-
MS analysis.57  
 
 
2.7.2 Reactions for Chapter 4 (SrtA Analysis) 
 
All reactions for this section are specific for SmSrtA unless otherwise stated. 
 
2.7.2.1 Reaction with trans-chalcone  
 
SmSrtA (5 µM) was incubated with trans-chalcone (0-100 µM) at 4 ᴼC and a sample 
removed after 1, 2, 4, 8 and 16 h.  The sample incubated with 100 µM of the inhibitor 
molecule for 16 h was further incubated with DTT (10 mM) for 6 h, followed by dialysis 
into buffer E for 2 h. All samples were analysed by electrospray ionisation Fourier 




2.8 Analysis of Garlic Extracts for Chapter 5 
 
All analyses for this section are specific for BcBCP unless otherwise stated. 
 
2.8.1 Sample Preparation and HPLC Analysis  
2.8.1.1 Aqueous Garlic Extracts (AGE)  
 
Garlic was purchased from Sainsbury grocery store and stored at 4 oC. Equal weights of 




produce an aqueous garlic extracts (AGE). The homogenate was then strained through a 
muslin cloth to remove large debris and centrifuged for 40 minutes at 4 ᴼC at 20 000 
rpm and then filter sterilised. The supernatant was then passed through a PD10 column 
and the small molecular weight fraction was collected and stored at -80 oC.159  
 
 
2.8.1.2 Aqueous Allicin Standards (AAS) 
 
A stock solution of aqueous allicin standard (AAS) was prepared by dissolving 10 mg of 
allicin (LKT Laboratories, Germany) in 1 mL of sterile distilled water. Standards that 
ranged from 8-1000 µg/mL were prepared by serial dilution. All standards were stored at 





Four capsules (722 mg) of AllicinMaxTM (Allicin International Ltd.) were dissolved in 
HCl (0.1 M, 1 mL HCl) and the resulting mixture was allowed to shake for 2 h, 200 rpm 
at 37 oC. After an hour, a half of the mixture was neutralised with NaOH (0.5 mL, 0.1 
M) and then centrifuged for 10 mins at ×13000 g. The sample was diluted with water 
(dilution factor 10) and filtered (0.45 μm). These steps were repeated with the second 
half of the original sample after incubation of 2 hr. Both the 1 hr and 2 hr samples were 
analysed by HPLC using the same method outlined in the quantification of allicin. 
 
 
2.8.1.4 RP-HPLC Analysis  
 
The allicin content in the AGE was analysed using a published method by Lawson and 
Wang which is summarized as follows.160 The RP-HPLC method was first standardised 
using the AAS standards ranging from 8-1000 µg/mL (Column dimensions: 250 × 4.6 
mm, 3.6 μ, C18 Aeris Peptide from Phenomenex).  A volume of 20 μL was injected onto 




(60:40, v/v) was used for elution with an isocratic gradient at a constant flow rate of 1 
mL/min. UV detection at 240 nm was used to analyse eluted fractions.  
 
 
2.8.2 Reactions with B. cenocepacia BCP (BcBCP) 
 
2.8.2.1 BCP and AAS 
 
The purified recombinant BcBCP protein (10 μM) was incubated with AAS (0.1 mM 
and 1 mM) at 37 oC for 1, 5, 30, 60, 120 and 180 mins. Each reaction was quenched with 
0.1 % formic acid and then analysis by ESI FT-ICR MS. Reversibility of the reaction 
was determined by incubating BCP (10 μM) with AAS (1 mM) at 37 oC for 1 hour, then 
TCEP was added to the reaction mixture to a final concentration of 2 mM.  
 
 
2.8.2.2 BCP and AGE 
 
Freshly-prepared AGE (3.38 mg/mL was passed through a PD-10 (Sephadex G-25M) 
desalting column, the low molecular weight fraction was collected and incubated with 
BcBCP (50 µM) for 1, 5, 30, 60, 120 and 180 mins at 37 oC. To isolate the modified 
enzyme from the incubation mixture, the mixture was shaken with equilibrated Ni-NTA 
resin (1 mL) for 50 mins followed by elution of the protein from the resin with 300 mM 
imidazole. Excess imidazole was removed from protein samples using a PD-10 column. 
The eluent was concentrated and analysed by ESI FT-ICR MS.  
 
 
2.9 Kinetic and Inhibition Studies 
2.9.1 FRET Analysis for Chapter 4 
2.9.1.1 Basic Principles 
 
Fluorescence or Förster resonance energy transfer (FRET) involves energy transfer 




FRET to occur, the donor and the acceptor have to be within a distance of 10-100 Å 
from each other and there has to be a good overlap of the emission spectrum of the 
donor with the absorption spectrum of the acceptor. The Förster radius (R0) is the donor-
acceptor distance at which the energy transfer is 50%. Within this radius, a transfer of 
energy between both molecules results in the reduction of fluoresence. As the donor and 
acceptor get further away from each other, i.e. exceeding the Förster radius, there is a 
reduction in FRET efficiency. This results in the generation of a fluorescent signal 
which can then be monitored spectroscopically. The application of this principle is a 
very powerful tool for biological analysis and can be used as a ‘spectroscopic ruler’ to 
measure the distance between biological molecules of interest when tagged with a FRET 
pair.161 
 
The FRET assay has been routinely used in measuring the activity of sortases by 
monitoring the rate at which a flourogenic peptide having the LPXTG recognition motif 
is cleaved between the threonine and glycine residues. The self-quenching peptide 
substrate used in this study is 4-([4-(dimethylamino) phenyl]azo)-benzoyl(Dabcyl)-Gln-
Ala-Leu-Pro-Glu-Thr-Gly-Glu-Glu-[(2-aminoethyl)-amino]naphthalene-1-sulphonyl 
(Edans) (Dabcyl-QALPETGEE-Edans) (Figure 24A). There is very good overlap of the 
emission spectrum of Edans (Amax = 340 nm; Em: ~490 nm) and the absoprtion 
spectrum of Dabcyl (Amax= ~490 nm).  Fluorescence of Edans fluorophore within the 
uncleaved peptide is quenched by Dabcyl due to their close proximity described above. 
Cleavage of the peptide by sortase, between the threonine and glycine residues results in 
an increased distance between the two molecules and the generation of a fluorescence 
signal (Figure 24B). The increased fluorescence can be observed as the reaction 






Figure 24: Schematic representation of the proteolytic cleavage a FRET peptide 
substrate to generate a fluorescence signal. (A) Chemical structure of Dabcyl-
QALPETGEE-Edans. (B) Cleavage of Dabcyl-QALPETGEE-Edans. The fluorogenic 
substrate is self-quenching due to the close proximity of the donor and the acceptor 
molecules resulting in no fluorescent signal. Upon cleavage at a recongnition site by the 
enzyme, the distance between the donor and acceptor molecules increases generating a 















2.9.1.2 Kinetic Analysis of SmSrtA  
 
Dabcyl-QALPETEE-Edans was dissolved in dimethyl sulfoxide (DMSO) to prepare a 
master stock of concentration 3.39 mM. This was then diluted with sterile distilled water 
so that the final concentration of DMSO in the reaction was kept below 5%. The assay 
was carried out at 37 oC in a reaction buffer K (20 mM MES.NaOH, pH 6.5, 125 mM 
NaCl, 5 mM NH2-Gly3 and 2 mM DTT). Assays were performed in a 96-well plate and 
peptide cleavage was monitored as an increase of fluorescence using a Biotek Synergy 
HT plate reader. Wells contained 5 µM purified enzyme and varying concentrations of 
peptide substrate (0.8 -212 µM) in a final reaction volume of 200 µl. The increase in 
fluorescence intensity was recorded as a function of time using an excitation wavelength 
at 360 nm and recording emission at 485 nm. Changes in fluorescence were converted to 
molar velocities using a calibration curve of an equimolar mixture of free Dabcyl and 
Edans which had a net gain of 23 F.U./µM upon conversion of substrate to product. The 
initial velocities for substrate cleavage were determined from the progress curves at 
various substrate concentrations and were fitted to the Michaelis-Menten equation to 
determine the kinetic parameters Km, Vmax and kcat using GraphPad Prism 6 software. All 
reactions were performed in triplicates and the mean values reported. 
 
 
2.9.1.3 Inhibition Analysis of SmSrtA 
 
The inhibitory activity of SmSrtA by trans-chalcone was analysed by measuring the rate 
at which the synthetic fluorescent peptide substrate Dabcyl-QALEPETGEE-Edans was 
cleaved in the presence of the inhibitor at various concentrations, using the fluorescent 
assay described previously in section 2.9.1.2.155 The reactions were performed on a 200 
µL scale in buffer E, triglycine (5 mM), peptide substrate (25 µM), 5 µM recombinant 
SmSrtA and varying concentrations of trans-chalcone (1-100 µM). trans-chalcone was 
dissolved in DMSO and added to reaction mixture so that the final concentartion of 
DSMO was <1%. Appropriate blanks containing all of the above reagents except for 








2.10 Mass Spectrometry (MS) 
All MS procedures were performed in collaboration with Dr. David Clarke at the School 
of Chemistry MS facilities, University of Edinburgh. 
 
2.10.1 FT-ICR MS 
 
General MS method used in chapters 3 to 5. 
  
Protein samples were analysed by LC-MS using an Ultimate 3000 HPLC system 
(Dionex Corporation, Sunnyvale, CA), equipped with a monolithic PS-DVB (500 μm x 
5 mm) analytical column (Dionex Corporation). Mobile phases A and B comprised 
2:97.95 and 80:19.95 acetonitrile:water with 0.05% formic acid respectively (v/v/v). 
Samples were injected onto the analytical column, washed with buffer A for 5 min, 
followed by a 20 min linear gradient elution (20 μl/min) into buffer B. MS data was 
acquired on a Bruker 12 Tesla Apex Qe FT-ICR (Bruker Daltonics, Billerica, MA) 
equipped with electrospray ion source (ESI). Desolvated ions were detected between m/z 
600 and 2000 for 0.5 s to yield a broadband 512 Kword time-domain data. Fast Fourier 
Transforms and subsequent analyses were performed using DataAnalysis (Bruker 
Daltonics) software. All m/z spectra were deconvoluted using MaxEnt software in 
DataAnalysis (Bruker Daltonics).   
 
 
2.10.2 Peptide Mass Finger-Printing (TamD)   
  
To detect the peptide that contains the proposed lysine residue of TamD that binds PLP, 
samples of the purified enzyme were prepared and digested as described in section 2.7.1. 
The resulting peptide mixture was analysed by LC-ESI-MS and the data analysed by 
DataAnalysis software (Bruker Daltonics). A mass list was created using the SNAP 2.0 








2.10.3 Top-Down FT-ICR (SrtA) 
 
Top-down fragmentation was used to determine the amino acid residue of SrtA to which 
trans-chalcone was covalently bound. Top-down fragmentation was performed on a 
Bruker 12 Tesla Apex Qe FT-ICR (Bruker Daltonics, Billerica, MA). First the +24 ion 
species of the chalcone-modified SmSrtA was isolated with the instrument’s mass 
resolving quadrupole. MS/MS was then performed using collision-induced dissociation 
(CID) or electron capture dissociation (ECD). For CID, the collision voltage was 
typically set between 20 and 35 V. ECD, 1.8A was applied to the dispenser cathode 
filament and 20 V to the lens, and a pulse of 4-9 ms was employed. Fragmentation data 
were the sum of 250-750 scans, and data analyses were performed using DataAnalysis 
(Bruker Daltonics). The SNAP algorithm was used for automated peak picking, and the 
resulting top-down fragment mass lists were searched against the primary sequence of 
SmSrtA using Prosight-PTM software. Mass error tolerances were for all Prosight 
searches at 10 ppm. 
 
 
2.10.4 Direct Infusion MS (Allicin)  
 
The mass of the AAS was confirmed using direct infusion mass spectrometry. Typically, 
AAS was analysed at a concentration of 10 µM from a solution of water/acetonitrile 
(50:50, v/v). Spectral data were collected on an electrospray micro-ToF mass 









2.11 Structural Biology  
2.11.1 Basic Principles of Protein Crystallisation 
 
X-ray crystallography is a useful tool for the structural determination of proteins, 
providing a highly detailed picture of the macromolecule at the atomic level. Proteins 
exist in their native state generally in a fluid environment. In the crystalline state, the 
molecules self-assemble to form ordered, flexible crystals, held together by weak 
intermolecular interactions. Crystal stability is a function of building block size and 
intermolecular properties. Therefore, the inherent flexibility of most proteins and the 
weak and sparse intermolecular interactions can reduce the likelihood of crystallisation. 
Additionally, protein molecules have irregular shapes, disordered termini and flexible 
loops which hinder the protein molecules from stacking and assembling into a regular, 
periodic lattice. Therefore, many trials are usually required and optimization of 
crystallization conditions to obtain well-diffracting crystals with good atomic 
resolution.162  
 
The crystallization process begins with a highly concentrated protein solution with 
precipitants added to reduce protein solubility. The solution then becomes supersaturated 
and metastable once the solubility limit is exceeded. In the metastable solution collisions 
between the molecules increase and form transient nuclei, but no spontaneous nucleation 
occurs (heterogeneous nucleation zone). As super-saturation increases, the nuclei 
become stable resulting in homogeneous nucleation.  These conditions promote the 
formation of nucleation sites. Crystal growth then continues and stops when equilibrium 
is reached between the crystals and the saturated protein solution (Figure 25A).162 
Vapor-diffusion is one the most common method to obtain a super-saturated protein 
solution, using a hanging drop or sitting drop format (Figure 25B).  In the vapor-
diffusion method, water vapour from a crystallization drop containing protein and 
precipitant absorbs into a larger reservoir which contains a higher concentration of the 






Figure 25: Schematic representation of the protein crystallization. (A) As protein 
and precipitant concentrations increases a solution that is supersaturated and metastable 
forms, producing the conditions favourable for homogeneous nucleation/spontaneous 
crystallisation. (B) Vapour Diffusion method is used to obtain a supersaturated protein 
solution for crystallisation by either the classic hanging drop or the variant sitting drop 
set-up. (Taken from reference 159) 
 
 
2.11.2 Structural Studies for Chapter 3 (TamD) 
2.11.2.1 Protein crystallization and data collection 
Native TamD (after Tev cleavage of hexa-histidine tag) from P. tunicata was screened 




(SSPF) in collaboration with Professor J. Naismith and Dr. Stephen McMahon. Protein 
for crystallisation was concentrated to 24 mg/mL after purification. The crystallization 
conditions were screened using a nano-drop crystallization robot (Art Griffin). Over 
2000 conditions were tested from commercially available sparse-matrix screens using 
the sitting-drop vapour-diffusion method in a 96-well plate format at 20 ᴼC. Each well 
had a volume of 100 µL. Drop sizes of 0.2 µL and 0.3 µL were used in a 1+1 (0.1 µL of 
protein and 0.1 µL of well solution), 2+1 (0.2 µL of protein and 0.1 µL of well solution)  
and 1+2 (0.1 µL of protein and 0.2 µL of well solution) format. Several conditions 
produced crystals and these were optimized. Crystals of TamD were grown over the 
course of two weeks. The optimum growth conditions are 0.1 M NaOAc, pH 4.6, 40 % 
(w/v) PEG 2000. Protein to precipitant ratio was 1:1. Prior to data collection the crystals 
were cryo-cooled in mother liquor doped with 20% glycerol. All crystallographic 
datasets were collected on beamline I24 at the Diamond synchrotron light source, 
Oxfordshire, England and processed within the Xia2package in an automated manner 
using the programs XDS and ScalaData. The output from xia2 was used for solving the 
structure using PHASER. 
 
 
2.11.3 Structural Studies for Chapter 4 (SrtA) 
2.11.3.1 Protein crystallisation and data collection 
 
The H139A mutant S. mutans SrtA (∆N40 truncated construct) was used for structural 
studies in collaboration with Dr. Jon Marles-Wright at the Institute of Structural and 
Moleuclar Biology, University of Edinburgh. SrtA was concentrated to 11 mg/ml after 
purification. Concentrated protein was crystallised by hanging drop vapour diffusion in 
drops of 2 μl protein plus 2 μl crystallisation solution (30 % w/v PEG 4000, NaOAc pH 
4.6, 0.2 M (NH4)2SO4), over 1 ml of the latter. Crystals were obtained in 5 days grown at 
20 ᴼC; these were harvested from the well using a LithoLoop (Molecular Dimensions 
Limited), transferred briefly to a cryoprotection solution containing well solution 
supplemented with 20 % w/v PEG200, and the crystals were subsequently flash cooled 




at Diamond Light Source (Didcot, UK) at 100 K using Pilatus 6M detectors. Diffraction 
data were integrated and scaled using XDS and symmetry related reflections were 
merged with Aimless.128. The resolution cut off used for structure determination and 




2.11.3.2 Structure solution and analysis 
 
The structure of SmSrtA_H139A mutant was determined by molecular replacement 
using S. pyogenes SrtA (PDBID: 3FN5)136 as the search model, this was modified to 
match the sequence of the target protein using Chainsaw.164 A single solution 
comprising a monomer in the asymmetric unit was found using Phaser.165 The initial 
model was rebuilt using Phenix.autobuild166 followed by cycles of refinement with 
Phenix.refine166 and manual rebuilding in coot167. The final model was refined with 
anisotropic B-factors for the protein chain and isotropic B-factors for ligands and water 
molecules. The model was validated using MolProbity168. Structural superimpositions 
were calculated using Coot. Crystallographic figures were generated with PyMOL.169 
 
 
2.11.3.3  Molecular Modelling 
 
The molecular modelling work was carried out in collaboration with Dr. Jon Marles-
Wright. Both the R- and S- form of the proposed trans-chalcone cysteine Michael 
adduct on Cys205 of SrtA were built and their geometry was optimized using Jligand.170 
Geometry description files were output as cif format files and Cys205 was modified in 
coot with both forms of the trans-chalcone. The His139 residue was modeled to 
minimize steric clashes with other side-chains and the ligand. The resulting models were 






2.12 Antimicrobial Assays  
2.12.1 Antimicrobial Analysis for Chapter 4 
2.12.1.1 The ACTA Active Attachment Biofilm Model 
 
The ACTA active attachment (AAA) model is a novel high-throughput screening model 
for testing preventive compounds against oral pathogens. The model was developed by 
the Academic Centre for Dentistry in Amsterdam in 2010. The assembly consists of a 
stainless steel lid with 24 plastic clamps that contain glass cover slips (Figure 26). This 
is used as a substratum for growing biofilms after being conditioned with sterile saliva. 




Figure 26: Assembled lid with glass slides used in AAA model for biofilm growth. 
Glass slides are sterilized and used as a substratum for growing biofilms after being 
conditioned with sterile saliva. 
 
 
2.12.1.2 Biofilm Growth 
 
The antimicrobial assays for S. mutans were performed in collaboration with Dr. 
Amarnath Maitra at Wrigley’s Global Innovative Centre, Chicago. S. mutans culture was 
grown overnight in 10 mL of brain heart infusin broth (BHI) with or without 
actives/inhibitors at 37 °C. The culture was diluted to a final optical density (OD600) of 
0.05 for use as an inoculum. The assembled AAA apparatus was incubated with 1.5 mL 
of sterile 50-fold diluted saliva for 2 h at 37 °C. The glass discs were inoculated with S. 
mutans culture (OD600 = 0.05) grown in 1.5 mL of BHI containing 0.2% sucrose for 2.5 




placed in fresh media (without bacteria) and biofilm was grown for a period of 18 h. The 
S. mutans culture was treated with the actives/inhibitors at every stage of growth 
(planktonic to biofilm) at concentrations between 0-500 µM. 
 
 
2.11.1.3 Biofilm Growth Analysis 
 
After 18 h of biofilm growth, the glass discs with the biofilm were transferred into a 24-
well plate containing 1.5 mL of 0.05% crystal violet solution for staining up to 10 mins. 
The discs were then washed with 2 mL of phosphate-buffered saline (PBS) and allowed 
to air dry. They were then de-stained in 2 mL of 95% ethanol and the absorbance of each 
well solution (corresponding to a glass disc) was then measured at 600 nm. The 




2.12.2 Antimicrobial Assays for Chapter 5 
 
The assays performed in this section with AGE and AAS were carried out in 
collaboration with Professor John Govan and Dr. Cathy Doherty at the Centre of 
Infectious Diseases, School of Medicine, University of Edinburgh.  
2.12.2.1 Agar Dilution  
 
The MICs of AGE against the 38 isolates were investigated by the agar dilution method 
as recommended by the National Committee for Clinical Laboratory Standards 
(NCCLS). In summary the bacterial strains were cultured overnight at 37 ᴼC in Muller-
Hinton broth (MHB) to obtain a bacterial inoculum of 106 CFU/mL. Muller-Hinton agar 
(MHA) plates were prepared by adding AGE at concentrations between 0.1-10 % AGE 
from concentrated stock solution (AGE neat stock was made from 1g crushed garlic per 
1 mL of distilled water). Agar plates were incubated overnight at 37 ᴼC and examined 





2.12.2.2 Microtitre Broth Dilution 
 
The MICs and MBCs for AAS against representative members of the strain panel were 
determined by microtitre broth technique recommended by the NCCLS.171 In summary 
MHB (50 µL) was aliquoted to each well of a 96-well microtitre plate. AAS (50 µL) was 
added to the first well and a 2-fold serial dilution performed in subsequent wells 
(concentration range:  0.125-128 mg/mL for AAS). Standardized broth inoculum (106 
CFU/mL) was added to each well. An absorbance reading at 625 nm was recorded for 
each well pre- and post-incubation at 37 ᴼC for 16-18 h. The lowest concentrations of 
AAS which showed no increment of absorbance readings after incubation were 
considered as the MIC values. The lowest concentrations which did show any bacterial 
growth upon spotting on MHA plates after overnight incubation at 37 ᴼC were 
considered as the MBC values. 
 
 
2.12.2.3 Agar Well and Paper Disc Diffusion 
 
The susceptibility of B. cenocepacia C3168 to AGE was  demonstrated by agar well 
diffusion and impregnated paper disc diffusion analysis.159 Isosensitest agar (Oxoid Ltd., 
Basingstoke, UK) plates were flood seeded using a 106 CFU/mL isosensitest broth 
culture of C3168. 10 µL undiluted AGE was added to a well cut in the agar or used to 
impregnate sterile paper discs. Plates were then incubated at 37 ᴼC for 16-18 h followed 








The tam cluster identified in the genome of the marine bacterium P. tunicata contains 21 
ORFs that encode 21 protein products, 19 of which are involved in the biosynthesis of 
the tambjamine, YP1. Kjellberg and colleagues cloned this cluster in E. coli and showed 
that it was capable of producing YP1 in this recombinant host.39 Among the genes in this 
cluster is the tamD gene which encodes a putative AOS enzyme, TamD. The TamD 
protein comprises of 536 amino acids and sequence analysis and homology predict that 
the enzyme exists as a natural fusion protein, with an ACP domain at its N-terminus and 
a PLP-binding AOS domain (Figure 27). This arrangement is unusual for the AOSs, as 
their associated ACP partners are usually expressed as discrete proteins, e.g. the S. 
wittichii SPT and its ACP partner.57 An analysis of the tambjamine biosynthetic pathway 
suggests that TamD is involved in the incorporation of a malonyl unit via the ACP 
domain and a seryl unit from L-serine via the AOS domain to produce a bipyrrollic 






Figure 27: Schematic representation of TamD primary sequence. (A) The typical 
gene organisation of  AOS and ACP resulting in discrete protein products.57 The tamD 
gene from tambjamine biosynthetic pathway which encodes for the TamD protein 
produces a natural fusion protein with an ACP and an AOS domain. (B) The primary 
sequence of TamD has a predicted ACP domain at the N-terminus (underlined in green) 
separated from the predicted AOS domain (underlined in red) by a short linker region.  
 
 
The AOS domain of TamD is expected to have the conserved structure observed in the 
other members of the AOS family determined to date. These include SPT56, 57, AONS50, 






symmetric homodimers belonging to the α-group and the fold type 1 superfamily of 
PLP-dependent enzymes (Figure 28).65 They also share a similar topology, with each 
monomer consisting of three domains: an N-terminal domain, a central catalytic domain 
which binds PLP and a C-terminal domain. The N-terminal domain consists of an α-
helix and a three-stranded antiparallel β-sheet, while the central domain is made up of a 
seven-strand β-sheet, usually flanked on both sides by α-helices. The residues of the C-
terminal domain interact closely with both the N-terminal and the catalytic domains of 
the same monomer. Both monomers are tightly interlocked with residues from each 
monomer involved in dimer formation.50, 53, 55, 56, 59 
 
The sequence alignment of TamD with AOSs shows high conservation of the key 
catalytic residues in the active site and those responsible for PLP binding, which suggest 
a common reaction mechanism and active site geometry (Figure A3). Each monomer 
binds a PLP molecule forming a Schiff base/internal aldimine via a conserved lysine 
residue in the active site. Other residues which are involved in PLP binding include 
His216 and Asp213 which stabilize the pyridinium ring through hydrogen bonding and 
salt bridge formation respectively. Additionally His139, which is found at the beginning 
of a three-residue motif (His139-Ala140-Ser141) stacks on one face of the pyridinium 
ring through hydrophobic interactions in all AOS enzymes.  
 
The ACP domain of TamD has very low sequence homology to both FAS and PKS 
ACPs (Figure A4). A BLAST search from the PDB suggests that TamD-ACP has the 
closest structural homology to B.subtilis ACP (PDB code 1HY8), although they have a 
21% similarity in sequence indentity.172, 173  This unique feature of the TamD enzyme 
has sparked interest into further investigations of the topological arrangement and 
protein-protein interactions of the ACP and the AOS domains. Information from the 
three-dimensional structure of TamD will be useful in providing insights into the process 
and mechanism involved in the sequestering of acyl-ACP substrates from the ACP to the 







Figure 28: Crystal Structures of AOSs. (A) Rhodobacter capsulatus ALAS (PDB 
code: 2BWN); (B) V. cholerae CqsA (PDB code: 2WK8); (C) E. coli KBL (PDB code: 
1FC4); (D) Sphingomonas paucimobilis SPT (PDB code: 2JG2); (E) E. coli AONS 








The structure of the natural fusion protein TamD is very crucial to the understanding of 
the biophysical interactions between ACPs and their AOS partners.  The aim of this 
study was to characterize TamD and determine the three-dimensional structure of its 
apo, holo and acylated forms by x-ray crystallography. With the dynamic nature 
proposed for TamD and the predicted high disorder in the N-terminal region where the 
ACP domain is located, another aim was to optimise suitable crystallographic conditions 
to obtain a high resolution x-ray crystal structure of the enzyme.  
 
 
3.2 Results and Discussion 
3.2.1 Cloning tamD from Genomic DNA 
 
The tamD gene was amplified from the genomic DNA of P. tunicata using forward and 
reverse primers appended with Nde1 and Xho1 restriction sites respectively to give a 
PCR product of ~1.6 kpb (Figure 29A). The gene was sequenced for confirmation and 
cloned into the pET22b expression vector that would translate into the TamD protein 
with a C-terminal hexa-histidine tag. Additionally, the gene was also cloned into a 
pHISTEV plasmid via the Nco1 and Xho1 restriciton sites to obtain a translated protein 
product with a cleavable N-terminal hexa-histidine tag. The pHISTEV plasmid has an 
N-terminal TEV protease site located downstream from the hexa-histidine site (Figure 
23), therefore upon cleavage with TEV protease, a native protein would be obtained.  
 
Since the tamD gene encodes for a didomain protein (ACP and AOS domains), attempts 
were made to amplify both domains separately. The ACP domain is estimated to be 
approximately 280 bps in length from the start of the gene, while the remaining gene 
product is expected to encode the AOS domain and a short disordered linker region, 




other ACPs (Figure 29B). These gene fragments were subsequently cloned into pET11a 
and pET22b expression vectors, respectively, after amplification. 
 
 
Figure 29: Amplification of tamD gene from P. tunicata genomic DNA (A) PCR 
product of tamD gene which is ~1.6 kbp in length. (B) PCR products from the 
amplification of the gene squences encoding ACP and the AOS domains of TamD which 
are ~ 280 bp and ~1400 bp in length. 
 
 
3.2.2 Protein Expression and Purification 
3.2.2.1 TamD/pET22b Construct 
 
Full-length tamD was expressed in an E. coli host, strain BL21 (DE3) to give a C-
terminal hexa-histidine tagged protein, after induction with 0.1 mM IPTG and 
incubating for 4.5 hours at 20 oC.  The protein was isolated from cell free extract (CFE) 
by nickel affinity chromatography eluting with increasing imidazole concentration.  
SDS/PAGE analysis of the elution fractions under reducing conditions resulted in a band 
at ~59 kDa which corresponding to the TamD monomer (Figure 30A). Further 
purification and oligomeric analysis by size exclusion chromatography (SEC) gave a 
symmetric peak corresponding to the theoretical mass of ~ 120 kDa which suggests that 

















Figure 30: Purification of Full-Length TamD with C-terminal His-tag. (A) SDS-
PAGE analysis TamD purified by Ni-NTA Chromatography. LMW: low molecular 
weight marker; CP: cell pellet; CFE: cell free extract; FT: flow through E1: elution with 
20 mM imidazole; E2: elution with 40 mM imidazole; E3: 60 mM imidazole; E4: 200 
mM imidazole. TamD present in elution fractions. (B) Elution profile of TamD purified 
by SEC on Superdex S200 16/60.TamD is highlighted with red arrow. Elution fractions 







3.2.2.2  TamD/pHISTEV Construct 
 
The TamD with an N-terminal HISTEV tag was expressed as previously described in 
section 3.2.2.1. The advantage of using this construct for expression is that it allows for 
removal of the His-tag after purification by cleavage at the TEV protease site resulting 
in the production of native protein. The purification process involved an initial isolation 
of the HISTEV-tagged TamD from the CFE by nickel affinity chromatography using the 
same protocol described in the section above. The tag was cleaved by overnight 
incubation of the protein at 4 ᴼC with TEV protease using enzyme to protease ratio of 
10:1. The N-terminal His-tag and TEV protease were subsequently removed from the 
protein sample, by a second nickel affinity purification step (Figure 31A), giving a final 
yield of ~70 mg/mL per 5L of culture. Further purification by SEC resulted in the 












Figure 31: Purification of TamD with N-terminal His-tag. (A) SDS-PAGE analysis 
TamD purified by Ni-NTA Chromatography. LMW: low molecular weight marker; 1: 
TamD before Tev protease cleavage; 2: TamD after Tev protease cleavage; 3: His-
tagged fraction eluted from resin after cleavage reaction. (B) Elution profile of TamD 
purified by size exclusion chromatograpy on Superdex S200. Elution fractions analysed 
by SDS/PAGE to give a band at ~59 kDa corresponding to the monomer (inset). 
 
 
3.2.2.3 TamD-ACP and TamD-AOS Constructs 
 
The TamD-AOS/pET22b construct was expressed in E. coli (BL21 DE3) and the AOS 
domain was purified in the same manner as the intact protein described in section 3.2.2.1 
by nickel affinity chromatography and SEC. The protein eluted as a dimer with a 
monomeric mass of ~ 49.5 kDa as confirmed by SDS-PAGE analysis and LC-ESI-MS 
yielding ~42 mg/mL per 5L of culture. The expression and purification of the TamD-
ACP construct was unsuccessful. This could be due to the fact that the protein was 
unstable without its AOS domain present. Therefore new constructs with less/more 
truncation will have to be explored in order to find a suitable fragment which can 




3.3.3 Characterisation by UV/vis Spectroscopy 
 
3.3.3.1 Spectroscopic measurement of PLP-bound TamD  
 
Purified TamD has a yellow colour due to the presence of bound PLP, which can be 
analysed spectroscopically as PLP absorbs within the UV/visible range (Figure 32A). 
After converting all of the isolated protein to the holo-form by incubation with PLP, 
excess cofactor was removed by passing the enzyme through a desalting PD-10 column 
before spectroscopic measurements. The absorption spectrum was examined by 
scanning the protein sample from 200-800 nm. The TamD spectrum revealed prominent 
absorption maxima at 330 nm and 426 nm corresponding to the absorbance of the 
internal aldimine which is formed from PLP covalently bonding to the Lys380 residue of 
TamD (Figure 32B). This observation correlates well to other AOS PLP-dependent 
enzymes which have characteristic spectral peaks of 330-340 nm and 415-426 nm which 
corresponds to the tautomeric forms of the bound PLP cofactor.174 The enolamine form 
(λmax 330 nm) and the ketoenamine (λmax 426 nm) existing in equilibrium, with the latter 
form being more dominant in TamD. Upon addition of L-serine, the amino acid 
substrate of TamD, there is the formation of an external aldimine with PLP which results 
in an increase in absorbance at ~426 nm and a spectral shift to left of ~2 nm (Figure 






Figure 32: PLP-bound TamD after purification. (A) Photograph showing that TamD 
has a characteristic yellow colur after purification and removal of excess PLP by PD-10 
desalting column. This is due to the presence of the bound PLP cofactor via a Schiff 
base to the active site lysine residue. (B) The UV/vis spectrum shows absorbance 
maxima at 330 nm and 426 nm corresponding to the enolamine and ketoenamine 
tautomeric forms of PLP respectively, with the latter being more dominant in TamD.  
Spectra were recorded on Varian’s Cary 50 UV/vis spectrophotometer and the Cary 
WinUV software used for analysis of results. Samples were analysed in a quartz cuvette 
with a path length of 1 cm from 200-700 nm.  
 
 
3.3.3.2 Binding Constant of L-serine 
 
The ability of TamD to bind L-serine and form an external aldimine was measured 
spectroscopically by adding increasing concentrations of L-serine (ranging between 0 
and 100 mM) to the enzyme (25 µM). This addition resulted in an equilibrium shift to 
the ketoenamine form of PLP with a distinct increase in the peak at 426 nm and a shift to 
the left by ~2 nm. By measuring the changes in absorbance at the ketoenamine-specific 
wavelength, the apparent L-serine binding constant (Kd) was determined to be 5.01 ± 





(Kd=1.1 mM), another well characterized AOS enzyme which utilizes L-serine as a 
substrate. 
 
Figure 33: Binding of L-serine to TamD. (A) UV/vis spectroscopic measurements 
confirmed that L-serine is a substrate of TamD forming an external aldimine with the 
enzyme resulting in spectral changes that can be monitored at 426 nm. (B) Plot showing 
dissociation constant of L-serine for TamD. Scans were done with a Varian Cary 50 
UV/vis spectrophotometer and the Cary WinUV software used for analysis of results. 




3.3.4 Characterisation by Mass Spectrometry  
3.3.4.1  TamD Analysis by ESI-MS 
 
Purified TamD was analysed by LC-ESI-MS under reducing conditions. The mass 
spectrum confirmed the mass of TamD to be 59516 Da, this mass was +2 Da higher than 
the predicted mass of recombinant TamD based on the amino acid sequence (59514 Da). 
Another peak at 59385 Da was also observed which corresponds to the loss of the N-
terminal methionine (Figure 34). It was not possible to obtain a more accurate mass of 
the protein due to its large size. The observed mass was representative of the apo-form 
of the enzyme, with no bound PLP detected. Therefore further MS analysis was carried 










Figure 34: Positive ion mass spectrum of purified tamD.  Two peaks were observed 
for apo-TamD expressed with and without the N-terminal methionine which was 
cleaved after expression giving masses of 59516 Da and 59385 Da respectively. 
 
 
3.3.4.2  Peptide Mass Fingerprinting 
 
The primary sequence of TamD was confirmed by MS analysis after fragmentation in 
solution with trypsin and LysC. The observed peptides covered ~80% of the protein 
sequence (Figure A5). In order to identify the lysine residue of TamD which forms an 
internal aldimine with PLP, NaBH4 was used to reduce the imine bond formed between 
the amino group of the lysine side chain and the aldehyde of PLP to an amine (Figure 
35A). This reaction was monitored spectroscopically with a characteristic reduction of 
the absorbance maxima at 426 nm and the formation of a new peak at 330 nm. The 
reduction reaction was followed by digestion of the reduced PLP:enzyme adduct in 
solution with LysC endoproteinase, which cleaves the protein after every lysine residue 
(Figure 35B). Analysis of the peptide fragments by MS identified the peptide fragment 




+231.03 Da which corresponds to the mass of the reduced PLP adduct (Figure 36). This 
confirmed Lys380 as the active site residue which forms an internal aldimine with PLP. 
 
 
Figure 35: LysC digestion and analysis of TamD after reduction with sodium 
borohydride. (A) Reaction scheme for the reduction of TamD-PLP aldimine with 
NaBH4 to form an amine adduct. (B) UV/vis spectrum of TamD-PLP aldimine 
reduction. TamD has absorbance maxima at 426 nm and 334 nm due to the PLP cofactor 
which forms an internal aldimine with the active site lysine (solid black line). The 
addition of NaBH4 (1 mM) results in a covalent TamD-PLP adduct with a characteristic 
increase of the peak at 330 nm (dotted trace) and reduction of the ketoenamine peak at 





Figure 36: Mass spectrum of TamD peptide fragment with PLP adduct. (A) Mass 
spectrum of peptide consisting of amino acids 370 to 381 with PLP adduct: +2 charge 
state, m/z = 679.8311 and average mass 1359.6622 Da. (B)  Simulated mass spectrum of 
theoretical mass of  peptide fragment of residues 370 to 381 with PLP adduct. Isotopic 
envelop of the theoretical mass corresponds to that of the observed mass. 
 
 
3.3.4.3 Analysis of phosphopantetheinylation of TamD 
 
The MS analysis of TamD suggested that the enzyme is expressed with its ACP domain 
in the apo form. Attempts were therefore made to convert the TamD-ACP domain to its 
holo form using a modified version of the method described previously by Raman which 




incubated with Bacillus Sfp, MgCl2, DTT and malonyl-CoA/CoA overnight at 37 ᴼC. 
The acylation reaction was then analysed by LC-ESI-MS. The resulting spectrum from 
the reaction mixture was very complex indicating several species present in solution 
which included the apo, holo and the acylated forms of TamD-ACP. All three forms of 
TamD were identified with and without the N-terminal methionine (Figure 37). The use 
of E. coli AcpS in the acylation reaction did not result in any modification of the apo 
TamD-ACP, which suggests that the NRPS PPTase (Sfp) was more readily recognized 
as a partner for TamD-ACP than the FAS PPTase (AcpS). In addition to the attempts to 
acylate TamD in vitro, the enzyme was also coexpressed in vivo with Bacillus Sfp with 
the aim of obtaining acylated TamD upon purification. MS analysis of purified TamD 
after co-expression with Sfp resulted in holo TamD with and without the N-terminal 












Figure 37: Positive ion mass spectrometry of TamD after acylation reaction.  Apo 
TamD was phosphopantetheinylated by Bacillus Sfp in the presence of Mg2+ and 
malonyl-CoA. The complex mass spectrum shows species expressed with and without 





Figure 38: Positive ion mass spectrometry analysis of purified TamD co-expressed 
with Sfp. TamD was coexpressed Bacillus Sfp to produce holo enzyme with and 




3.3.5 Structural Determination of TamD 
3.3.5.1 Crystallisation 
 
The structural study of TamD was done in collaboration with Professor J. Naismith and 
Dr. Stephen McMahon in St. Andrews. TamD was concentrated to 24 mg/mL prior to 
crystallisation trials. The crystals were grown by vapour drop diffusion at 20 ○C over the 
course of two to three weeks (Figure 39). The optimal conditions for crystal growth were 
18.6 % PEG 3350 and 0.7 M MgSO4 at a protein to precipitant ratio of 2:1. The crystals 
appeared yellow in colour which suggests that the PLP cofactor was present as a ligand. 
Another apparent physical feature of the crystals was their needle-like shape, which was 
not improved upon several rounds of optimization screening. The crystals also appeared 
to be ‘soft and bendy’ potentially suggesting mis-alignment of unit cells within the 
crystal lattice. This feature may be due to the flexible and dynamic nature of the ACP 




domain. The probability of disorder within the protein was analysed using regional order 
neutral network (RONN) algorithm,175 which suggests residues 98-131 have a higher 
than 50% likelihood of being disorderd (Figure 40). These residues corresponded to the 
predicted linker region between the two domains. If this prediction is correct and this 




Figure 39: Crystals of TamD. Crystals were grown by vapour drop diffusion at 20 ○C. 
The optimal growth conditions for crystal growth were 18.6 % PEG 3350 and 0.7 M 











Figure 40: Probability of residue disorder in TamD. Residues 98-131 have the 
highest probability of disorder >0.5.  Analysis was performed using the regional order 




3.3.5.2 Data Collection and Structural Solution   
 
Despite a less than ideal morphology, the crystals diffracted weakly to a resolution of 
4.98 Å, at beamline i24 at the DIAMOND synchrotron source, Didcot, Oxfordshire. The 
data collected were processed in an automated manner using xia2176 and the statistics for 
these data are presented in Table 16. That the crystals diffracted only to this resolution 
may be partly due to a high solvent content and weakly packed lattice structure. Taking 
the output from xia2 a structure was solved by molecular replacement using the program 
Phaser165 incorporated within CCP4177 using a search model from Sphingobacterium 
multivorum SPT monomer (PDB code: 3A2B).178 The Matthew’s coefficient of 3.14 
suggested that the expected number of molecules in the asymmetric unit was 4 in the P41 
space group with a solvent content of 60.8 % (Figure A6). The solution from Phaser was 
refined in REFMAC and a concomitant decrease in R-factor and R-free was observed, 




REFMAC was visualized in COOT.167 No further refinement of the model was 
performed. The data collection and partial refinement statistics are summarised in Table 
16. 
 
Table 16: Data refinement and statistics for TamD. Statistics for the highest-
resolution shell are shown in parentheses. 
 
Wavelength (Å) 0.9686  
Unit cell parameters (Å) a=b=129.9, , c=174.1, alpha=beta=gamma=90ᴼ 
Space group P41 
Resolution range  (Å) 43.3 – 4.98 (5.11 – 4.98) 
I/σ(I) 8.4 (2.0) 
R merge  0.116 (0.624) 
Completeness (%) 98.2 (99.8) 
Multiplicity 3.5 (3.8) 
R factor  0.383 
R free  0.448 
 
3.3.5.3 Structural Analysis 
 
The electron density obtained for TamD was insufficient to build a complete model of 
the structure.  Unfortunately, the N-terminal domain was not visible and only traceable 
density for the ‘SPT-like’ AOS domain was detected (Figure 41). An analysis of the 
TamD primary sequence suggests that the protein is dimeric and belongs to the PLP-
dependent aspartate aminotransferase (AAT) superfamily (fold I). The AOS domain 
dimer was visible in the low resolution crystal structure of TamD.  
 
The low resolution data obtained for TamD at 4.98 Å, was also insufficient to support 
the level of details required to accurately describe the topology of the ACP domain in 
relation to the AOS domain of TamD. There are two postulated arrangements of the 
ACP domain relative to the AOS domain of the two monomers, head-to-head or head-to 




AOS1 from the same monomer (Figure 42A), whereas in the head-to-tail arrangement, 
ACP1 from monomer 1 interacts with AOS2 from monomer 2 (Figure 42B). A 
comparison of these two models with the low resolution crystal structure of a TamD-
AOS dimer suggests that the more likely arrangement would be the head-to-tail topology 
(Figure 42C). This conclusion was drawn based on the position of the N- termini of each 
monomer (where the ACP domain would likely be found) relative to the likely location 
of the active site of the AOS domain (PLP-binding domain).  Crystallographic analysis 
of TamD at a higher resolution should be able to provide more convincing evidence to 
substantiate this conclusion. Such data so far has been elusive, as the ACP domains were 
not visible from the electron density map of TamD. 
 
 
Figure 41: Crystal structure of TamD. The crystals diffracted to a resolution of 4.98 
Å. Four molecules are present in the asymmetric unit (coloured in magenta, yellow, blue 
and red). Clear electron density exists only for the AOS domain as shown in sections of 






Figure 42: Schematic representation of the arrangment of the ACP and AOS 
domains of TamD. (A) In this head-to-head topology, the ACP domain of one monomer 
interacts with the AOS domain of the same monomer. (B) In the head-to-tail topology, 
the ACP domain of one monomer partners with the AOS domain of the second 
monomer. (C) The x-ray crystal structure likely suggests a head-to-tail arrangement 
based on the positions of the N and C termini of AOS monomers. ACP domain is absent 

























3.4 Conclusion and Future Work 
 
In this investigation, a novel AOS enzyme, TamD, from the tambjamine biosynthetic 
pathway was characterized using UV/vis spectroscopy and MS. This enzyme is 
predicted to catalyse the condensation between L-serine and a pyrrolyl-β-ketoacyl-S-
ACP intermediate of the tambjamine biosynthetic pathway to give a bipyrrole product, 
HBM, in a PLP-dependent reaction.   One interesting structural feature of the enzyme is 
the presence of an ACP domain at its N-terminus which is unsual for this family of 
enzymes. Extensive structural studies were carried out on the enzyme to determine the 
topological relationship between the ACP domain and the AOS domain. It is likely that 
the ACP domain of one monomer interacts with the AOS domain of the second 
monomer within the TamD dimer. However, this conclusion would be better supported 
with data from a crystal structure of a higher resolution than 4.98 Å.  
 
In order to carry out further structural analysis on TamD, it is necessary to produce a 
construct where the residues of the ACP domain are well-ordered and in contact with the 
AOS domain. One approach in achieving a more ordered complex is to trap the acylated 
ACP domain by crosslinking it to the AOS domain. A mechanism-based ACP acyl 
substrate can be used to facilitate an active site-selective covalent crosslinking to a 
residue of the AOS domain. There are two possible histidine residues in the active site 
which are involved in PLP stabilization and may likely interact with the synthetic ACP 
substrate crosslinker, His273 and His349. A similar strategy was employed by the 
Burkhaart group, where E. coli AcpP was crosslinked to FabA, a fatty acid 3-
hydroxyacyl-ACP dehydratase via a sulphonyl-3-alkyne-based probe.79 Such a construct 
will more likely form a more ordered protein lattice that may improve the likelihood of 
diffraction at higher resolutions. Other approaches that may be useful in the biophysical 
characterisation of the protein-protein interaction between the ACP and the AOS 
domains include isothermal titration calorimetry (ITC) and surface plasmon resonance 
(SPR). Additionally, solving the structures of the ACP domain and the AOS domain 




Although the AOS domain was over produced and isolated in this study, attempts at 
crystallising the protein were unsuccessful. Another difficulty that was faced in this 
investigation was the phosphopantetheinylation of the ACP domain of TamD with the 
promiscuous PPTases, Sfp and AcpS. To overcome this problem, the dedicated PPTase 
from the Tam cluster, denoted as TamS was cloned. However, due to time constraints, 
the protein was not over produced in E. coli. Therefore in future studies, the isolation of 




Chapter 4: Inhibition of Sortase A by trans-Chalcone 
4.1 Introduction 
4.1.1 Aims and Objectives 
 
New approaches for the treatment and prevention of bacterial infections require an 
understanding of the molecular mechanisms by which protein targets interact with 
inhibitors. Sortases are attractive targets because of their role in the cellular location of 
multiple virulence factors in Gram Positive bacteria. Our collaborators on this project 
were interested in identifying flavonoids that could inhibit S. mutans sortase A, without 
the bactericidal effect on the organism. Before this study there was no biophysical data 
available on S. mutans SrtA. Therefore one of the aims of this study was to determine 
the three-dimensional structure of the enzyme and carry out its biochemical 
characterization. The inhibitory activity of trans-chalcone was also explored with the 
aim of gaining insights into the molecular basis of inhibition of the chalcone flavonoids 
using a combination of biophysical techniques: mass spectrometry, x-ray 
crystallography and molecular modelling. It was also of interest to investigate the impact 




4.1.2 S. mutans SrtA 
 
Sortases are membrane-associated transpeptidases which are highly conserved in Gram 
positive bacteria.113, 179 They are responsible for covalently attaching surface proteins 
involved in adherence to host cells, iron acquisition, invasion, signalling and pili 
formation to the bacterial cell wall.113-115  In S. mutans, SrtA has been implicated in 
contributing to biofilm formation and the cariogenicity of the bacteria, where SrtA-
deficient strains show reduced ability to colonise oral surfaces and cause infections.129, 
130, 132 These data suggest that SrtA makes a good target for the development of oral anti-
infective therapies.116  S.aureus SrtA was the first cysteine transpeptidase of this family 




spectroscopy. Since then, several other structures of sortases from different Gram 
positive bacteria have been determined, some in complex with peptide substrate 
analogues and other small molecules (Table 17).135 Sequence analysis has also shown 
that there is high structural homology among the S. mutans SrtA and other SrtA enzymes 
(Figure A8). The N-terminus region of sortases possesses hydrophobic residues which 
are membrane-associated and functions as a signal peptide for secretion as well as a stop 
transfer signal for membrane anchoring, while the C-terminal region, which is located 




Figure 43: Annotated Primary Sequence of S. mutans SrtA. SmSrtA consists of 246 
amino acids, with the first 40 hydrophobic residues membrane-associated (highlighted 
with a red box). The conserved catalytic triad (Cys-His-Arg) is located in the C-terminal 
region (highlighted with blue triangles).  
 
 
The most recent report of  natural products with inhibition activity against S. mutans 
SrtA identified two flavonoids, morin154 and curcumin.145, 155 Other flavonoids have also 
been reported in the literature to have inhibitory activities against other sortases.153, 154 
This is by no means surprising as flavonoids are known to display a broad spectrum of 
biological activities.85 However, there is no information available on the mechanisms by 




chalcone, a widely occurring flavonoid precursor was selected as potential inhibitor of S. 
mutans SrtA and antibiofilm forming agent. This current study investigates the 
mechanism by which trans-chalcone interacts with S. mutans SrtA in vitro using a 
combination of techniques including mass spectrometry, enzyme kinetics and x-ray 
crystallography. 
 
Table 17: Members of the sortase family whose structures have been determined to 
date. Structures of isoforms A, B and C have been determined by x-ray crystallography, 
some in complex with peptide ligands and small molecules. 
 
Family Name Ligand Organism PDB Code 
A SrtA∆59 none S. aureus 1IJA 
A SrtA∆59 LPETG Peptide S. aureus 1T2W 
A Sp-SrtA∆81 none S.pyogenes 3FN5 
A SrtA∆59 (PHQ)LPA(B27) 
Peptide 
S. aureus 2KID 
A SrtAH139A∆N40 none S.mutans 4TQX 
B Sa-SrtB none S. aureus 1NG5 
B Sa-SrtB MTSET S. aureus 1QWZ 
B Sa-SrtB E-64 S. aureus 1QX6 
B Sa-SrtB Gly3 S. aureus 1QXA 
B Ba-SrtB AAEK1 B.anthracis 2OQW 
B Ba-SrtB AAEK2 B.anthracis 2OQZ 
B Sa-SrtB (CBZ)NPQ(B27) 
Peptide 
S. aureus 4LFD 
C SrtC-1 none S.pneumoniae 2W1J 
C SrtC-2 MES S.pneumoniae 3G66 
C SrtC-3 none S.pneumoniae 2W1K 
C SrtC-1 
H131D 
none S.pneumoniae 2WTS 
C SrtC-1 none S. agalactiae 3O0P 
C SrtC-1 none S. suis 3RE9 




4.2 Results and Discussion 
4.2.1 Cloning and Expression 
4.2.1.1 SmSrtA-N40 (SmSrtA)  
 
The sequence of the wild-type SrtA from S. mutans G-S5 strain (SmSrtA WT) has a 
length of 741 bp which encodes a full length protein of 246 amino acids.128 Homology 
searches in the NCBI data base revealed several sortase homologues in Gram positive 
bacteria with highly conserved active site residues. The gene sequence for SmSrtA WT 
was downloaded from the GeneBank database (accession number AB089932) and used 
as a template for designing a synthetic gene (GenScript), with the DNA sequence 
modified to remove the first 120 bp and insert the restriction endonuclease sites Nco1 
(5’) and  Xho1 (3’).  This allowed for the insertion of the synthetic gene into a pET28a 
vector for protein expression. Overexpression of pET28a/SmSrtA-N40 produced an 
untagged recombinant protein with an N-terminal truncation of the first 40 amino acids 
(SmSrtA). This specific truncation was chosen to increase the likelihood of the 
recombinant enzyme being soluble upon expression and purification in E.coli, as the N-
terminal domain is known to possess hydrophobic residues which are membrane-
associated. 128, 180 134 In previous studies similar constructs of other SrtA homologues 
were cloned, without the hydrophobic N-terminal region to produce soluble and active 
protein. Optimal expression was obtained from E. coli BL21 (DE3) cells grown at 20 oC 
and induced for 5 hours with 0.1 mM IPTG. 
 
 
4.2.1.2 SmSrtA Mutants (H139A and G94A) 
 
Two other constructs of SmSrtA were made with alanine substitutions at the G94 and 
H139 positions, so as to improve protein stability. The G94A mutation was chosen based 
on the hypothesis that the WT enzyme was being proteolysed around residues 90-95 
(LPVIGG). This 6-amino acid sequence bears similarities to the 5-amino acid cleavage 
site (LPXTG) that is recognized by sortase enzymes in their peptide substrates. The 




activity, which should in turn improve protein stability.181 The pET28a plasmids 
encoding the mutant enzymes were purified, sequenced for confirmation and then used 
to transform E. coli BL21 (DE3) for protein expression.  
 
 
4.2.1.3 SmSrtA-N88 H139A 
 
A third construct with a further truncation of 48 additional amino acids from the N-
terminus of SmSrtA was produced from the gene encoding for the H139A enzyme. This 
construct was produced in an effort to investigate the role of the N-terminal domain in 
the reactivity of the enzyme towards covalent modifying small molecules. The gene was 
amplified with the restriction endonuclease sites Nco1 (5’) and Xho1 (3’) appended. This 
allowed for the insertion of the gene into a pET28a expression plasmid. Overexpression 
of this construct produced an untagged recombinant protein with an N-terminal 
truncation of the first 88 amino acids. 
 
 
4.3.1 Protein Purification and Analysis 
4.3.1.1 SmSrtA 
 
SmSrtA was isolated from cell free extract (CFE) by cation exchange chromatography 
which was possible due to the protein’s high isoelectric point (pI) of 9.01. The protein 
eluted from a MonoS 5/50 column with increasing concentration of NaCl in 45-50% of 
Buffer D (Figure 44A). The fractions containing SmSrtA were pooled and further 
purified by SEC on a Superdex S200 16/60 column to give a symmetric peak 
corresponding to the monomeric mass of SmSrtA, approximately 23 kDa (Figure 44B). 
SDS/PAGE analysis of the purified enzyme showed a band corresponding to the enzyme 
running at ~28 kDa. SrtA enzymes usually run higher on SDS/PAGE gels due to the 
positive nature of these proteins. SDS-PAGE analysis of WT SmSrtA also revealed 






Figure 44: Purification of recombinant SmSrtA from E. coli. (A) Elution profile of 
enzyme by cation exchange chromatography and SDS-PAGE analysis of purified 
enzyme (inset). (B) Elution profile of enzyme by size exclusion chromatography on 
superdex S200 16/60 and SDS-PAGE analysis of purified enzyme (inset). 
 
 
4.3.1.2 G94A and H139A    
 
Both mutant enzymes, G94A and H139A, were purified using the protocol described 
above in section 4.3.1.1 for the WT enzyme via cation exchange chromatography 
























enzyme’s degradation, which suggests that the cleavage site may not be between Ile93 
and Gly94. Large aggregates were also observed in the elution profile on purification 
(Figure 45A). On the other hand, the H139A mutant which is expected to be 
catalytically inactive showed no signs of auto-proteolysis upon purification. This 
suggests that protease activity was abolished, which resulted in increased stability of the 
protein on purification. The H139A mutant eluted in the same volume of buffer as the 
WT enzyme (~85 mL) (Figure 45B). No degradation products were observed from 
SDS/PAGE analysis, which also suggests improved stability over the WT enzyme. This 









Figure 45: Purification of S. mutans SrtA mutants. (A) Elution profile of SmSrtA 
G94A mutant showing a symmetric peak for the protein eluted over 60 mL of buffer off 
a Superdex S200 16/60. Fractions 26-31 were analysed by SDS-PAGE to give a 
monomeric mass of ~23 kDa (inset). (B) Elution profile of SmSrtA H139A showing a 
similar elution pattern as that of WT SmSrtA, under similar purification conditions.  














SmSrtA-N88 was purified using the same protocol described above in section 4.3.1.1 for 
the WT enzyme via cation exchange chromatography followed by gel filtration resulting 
in soluble monomeric protein in solution. However, the protein degraded readily upon 
purification. This could be due to the fact that the construct was unstable without the 
additional 88 amino acids at its N-terminus, which may contribute to enzyme stability. 
 
 
4.3.2 Enzyme Activity 
 
All enzyme activity assays were performed using the SmSrtA construct. 
4.3.2.1 Transpeptidation Reaction 
 
The purified enzyme SmSrtA was first analysed for its ability to cleave peptide bonds 
between a threonine and a glycine residue and form a new amide bond between two 
glycine residues. This was done by incubating the purified enzyme (5 µM) with the 
peptide substrate analogue, dabcyl-QALPETGEE-edans (25 µM) for 16 h in a reaction 
buffer containing 20 mM MES.NaOH, 150 mM NaCl and 5 mM DTT.139 The substrate 
peptide analogue has the LPXTG motif (where x is glutamic acid) tethered to a 
fluorophore (Edans) and a fluorescence quencher (dabcyl) at either ends of the short 
peptide.  The transpeptidation reaction mixture was incubated in the presence of NH2-
Gly3 (5 mM) which acted as the nucleophile substitute for the natural substrate, lipid II 
which bears a pentaglycine side chain. The reaction mixtures were then analysed by LC-
ESI-MS. In the absence of the NH2-Gly3, SmSrtA cleaved the peptide substrate between 
the threonine and glycine residues to generated two fragments, dabcyl-QALPET and 
GEE-edans, with observed average masses of 909.9 Da (calculated mass, 909.0 Da) and 
581.2 Da (calculated mass, 581.6 Da) respectively (Figure 46A). In the presence of NH2-
Gly3, SmSrtA generated a new peptide, dabcyl-QALPET-Gly3 of mass of 1081.0 Da 
(calculated mass, 1080.2 Da) (Figure 46B). The masses of the peptide fragments are 




reported in the literature.139 These data suggest that the truncated enzyme has the ability 
of recognizing the synthetic substrates to catalyse the transpeptidation reaction. 
 
 
Figure 46: Mass spectrometry analysis of sortase activity of SmSrt. (A) Mass 
spectrum of the cleavage reaction of dabcyl-QALPETGEE-edans, showing the charge 
distribution of a singly charged ion for the peptide fragments of average masses 582.18 
Da and 909.9 Da. (B) Charge distribution for the transpeptidation product formed 




4.3.2.2 pH Optimisation of Sortase Activity 
 
The optimal pH of SmSrtA activity was determined using the FRET assay described 
previously.  The assay was performed at different pH values ranging from pH 4.0-9.0. 
The purified enzyme (5 µM) was incubated in buffer L (50 mM acetic acid, 50 mM 
MES, 100 mM Tris) adjusted to pH 4.0-5.5 or buffer M (50 mM MES, 100 mM Tris, 50 
mM CAPS) adjusted to pH 5.5-9.0 in 0.5 pH unit increments. SmSrtA was found to be 
soluble and active over the pH range that was tested. Interestingly, it was found that 
SmSrtA had a greater activity at a lower pH and cleaved its peptide substrate at an 
optimum pH of 4.5 (Figure 47). pH 6.5 was used in subsequent studies since the enzyme 
degraded more rapidly in buffers of pH ≤ 5.5 after 18 h at 4 ᴼC.  
 
 
Figure 47: pH Profile of SmSrtA Activity. The activity of SmSrtA was analysed using 
the FRET assay at pH values ranging from 4-9. The enyme had maximum activity at pH 








4.3.3 Kinetic Analysis of SmSrtA 
4.3.3.1 Calibration Curve for FRET Assay 
 
The established FRET assay was used to measure the rate at which SmSrtA cleaved the 
fluorogenic peptide substrate, Dabcyl-QALPETGEE-Edans. Standards containing an 
equimolar mixture of free Dabcyl and Edans ranging from 0-10 µM were used to 
prepare a standard plot of relative fluorescence intensity vs concentration of Edans. This 
analysis was repeated using standards of only free Edans. The standard curves for both 
solutions gave straight lines with correlation coefficients of r2 = 0.9964 and 0.9955 
respectively and gradients of 19.03 ± 0.261 and 21.88 ± 0.336 (Figure 48). In the 
presence of high concentrations of Dabcyl, the fluorescence signal of Edans is lowered. 
However, this effect was minimal at lower concentrations of both molecules (0-3 µM) as 
less molecules of Dabcyl are present in solution to quench the fluorescence signal of 
Edans. The standard curves showed good agreement at lower concentrations, which fall 
within the range of concentration values that would be analysed in this study. Based on 
the Edans/Dabcyl standard plot, the net gain was measured to be equivalent to 23 













Figure 48: Standard curves for Edans and Dabcyl/Edans. Standards contained an 
equimolar mixture of free Dabcyl and Edans ranging from 0-10 µM. The standard 
curves for both solutions gave straight lines with correlation coefficients of r2 = 0.9964 
and 0.9955 respectively and gradients of 19.03 ± 0.261 and 21.88 ± 0.336. 
 
 
4.3.3.2 Km and Vmax  
 
The established FRET-based assay was used to measure the rate at which SmSrtA 
cleaved the fluorogenic peptide substrate. The purified WT enzyme (5 µM)  was 
incubated with different concentrations of the peptide substrate ranging from (0-212 
µM) and the increase in fluorescence was measured over 3 h at 1 min intervals at a 
wavelength of 485 nm.182 To determine the rates of peptide cleavage (μM/min), the 
increase in fluorescence intensity (RFU) was plotted over time (min) using data points 
from only the linear portion of the hydrolysis curves for each concentration. The slope 
from these plots were converted to molar velocities using the net gain of 23 FU/µmol as 
obtained from the calibration curve of an equimolar mixture of free dabcyl and edans 
standards (Figure 48). The kinetic constants Km and Vmax for the hydrolysis reaction by 
SmSrtA were calculated from the Michaelis-Menten plot (Figure 49). SmSrtA exhibited 
Km and Vmax values of 90.4 ± 4.7 µM and 4.46 × 10





Figure 49: Kinetic analysis of SmSrtA using the FRET assay. Initial velocity was 
determined from the linear portions of the curves obtained from monitoring the cleavage 
of the peptide substrate. These were converted to µmol/sec using the net gain of 23 
FU/mol. Curve was fitted to the Michaelis-Menten equation to obtain Km and Vmax 
values. All reactions were performed in triplicate.  
 
 
4.3.3.3 Inhibition of SmSrtA by trans-Chalcone  
 
Purified SmSrtA (5 µM) was incubated with trans-chalcone (0-100 µM) for 16 h. The 
activity of the pre-treated enzyme was measured using the FRET assay described 
previously by monitoring the cleavage of the Dabcyl-QALPETGEE-Edans peptide. The 
% activities at the different inhibitor concentrations were then plotted against the 
corresponding concentration of trans-chalcone and the IC50 of the inhibitor determined. 
The inhibitory activity of trans-chalcone is defined as the concentration giving 50% 
inhibition of SmSrtA activity, relative to 1% DMSO which was considered as the 
negative control. Curcumin and morin served as positive controls in the experiment. 
Trans-chalcone inhibited S. mutans SrtA with an IC50 value of 5.0 ± 0.6 µM (Figure 51). 
This low value suggests that trans-chalcone is a tight binding inhibitor of the enzyme. 
The IC50 of trans-chalcone was also lower than the values observed for other flavonoids 




µM)155. In this study, the IC50 of morin and curcumin were determined as 36.3 ± 1.5 µM 























Figure 50: Concentration-dependent inhibition of SmSrtA trans-chalcone, morin 
and curcumin.  Inhibition of SmSrtA by trans-chalcone (1) after overnight incubation 
with varying concentrations of the inhibitor at 4°C. Inhibition activity was monitored in 
the FRET assay with 25 µM of the dabcyl-QALPETGEE-edans peptide substrate. The 
IC50 of trans-chalcone was determined as 5.0 ± 0.6 µM. Morin (2) and curcumin (3) 
were used a positive controls. Enzyme activity was assessed using the FRET assay and 









4.3.3.4 Rate of inhibition 
 
The rate of inhibition was measured in a time-dependent study by incubating 5 µM of 
the purified SmSrtA with excess trans-chalcone for varying time points (1, 2, 4, 8 and 
16 h).  Analysis of the enzyme activity revealed that the inhibition of SmSrtA by trans-
chalcone was very slow and it took up to 16 h to reduce enzyme activity by 90% (Figure 
51). Enzyme activity was not restored upon extensive dialysis of the enzyme against 20 
mM MES.NaOH, 250 mM NaCl, pH 6.0. The data from the concentration- and time-
dependent studies suggested that trans-chalcone may be a slow tight binding inhibitor of 
SmSrtA. This nature with which the inhibitor interacted with SmSrtA led to the 




Figure 51: Time-dependent inhibition of SmSrtA by trans-chalcone. Inhibition of 
SmSrtA by 100 µM of trans-chalcone monitored at varying time points (1, 2, 4, 8 and 16 
h). Enzyme activity was assessed using the FRET assay and all reactions were 









4.3.3 Mass Spectrometry Analysis 
 
All MS analysis in this chapter were done by Dr. David Clarke at the School of 
Chemistry, The University of Edinburgh.  
 
4.3.4.1  ESI-MS of SmSrtA 
 
The mass of SmSrtA was confirmed by ESI-MS resulting in an average mass ([M+H]+) 
of 22, 767 Da  in accordance with the molecular mass deduced from the SmSrtA gene 
sequence minus the N-terminal methionine which is post-translationally cleaved during 
expression in E. coli (Figure 52). This mass corresponds to the monomeric form of the 
protein. 
 
Figure 52: Mass spectrum of truncated SmSrtA. The main figure shows the charge 
state distribution obtained for SmSrtA. This corresponds to a deconvoluted molecular 
mass of 22, 767 Da, ([M+H]+) see insert, which was consistent with the predicted 
theoretical mass based on the amino acid sequence of the protein (theoretical [M+H]+, 






4.3.4.2 SmSrtA Inhibition by Trans-chalcone 
 
In order to test the hypothesis that trans-chalcone was covalently modifying SmSrtA, 
MS was used to analyse the samples from the concentration- and time- dependent 
reactions described previously. The mass spectra from the concentration-dependent 
studies revealed a peak of 22, 767 Da for the mass of SmSrtA and an additional peak at 
22, 975 Da (Figure 53A). This new peak represents a mass increase of +208 Da, which 
corresponds to the formation of a covalent adduct between trans-chalcone (208 Da) and 
SmSrtA (22, 767 Da). Further confirmation of the new peak resulting from the reaction 
of the enzyme with trans-chalcone was obtained by monitoring the change in the charge 




Figure 53: Mass spectrometry analysis of the time-dependent inhibition of SmSrtA 
by trans-chalcone. (A) Deconvoluted mass spectrum of trans-chalcone (208 Da) reacted 
with SmSrtA (22, 767 da) to form a covalent adduct (22, 975 Da) in a time-dependent 
manner after 16 h of incubation at 4 ᴼC. (B) Changes in charge distribution over time as 




highlighted with red dots is for SrtA (22, 767 Da) and the distribution for the adduct is 
highlighted with blue dots (22, 975 Da). 
 
 
Adduct formation was observed to be dependent on the concentration of the inhibitor as 
the species of mass 22, 975 Da increased in abundance as higher concentrations of trans-
chalcone were incubated with the enzyme. A similar result was observed for the samples 
analysed from the time-dependent study, where the new peak at 22, 975 Da also 
increased in abundance for samples incubated for longer periods (Figure 54).  
 
 
Figure 54: Mass spectrometry analysis of the concentration-dependent inhibition of 
SmSrtA by trans-chalcone. The % of modified SmSrtA increased when the 
concentration of trans-chalcone was increased in the reaction mixture. ~ 90% 
modification of SmSrtA by the inhibitor was observed on incubation of the enzyme with 
100 µM of trans-chalcone for 16 h.  
 
 
4.3.4.3 H139A SrtA-Chalcone Adduct 
 
Despite being inactive in the transpeptidase assay, the SmSrtAH139A mutant reacted 
with trans-chalcone in the same manner as the WT SmSrtA, forming a covalent adduct 
of mass increase of 208 Da (Figure 55). This suggests that the H139A residue was not 






Figure 55: Mass spectra of H139A mutant before and after incubation with trans-
chalcone. (A) Deconvoluted mass and chare distribution for SmSrtAH139A 
corresponding to the predicted monomeric mass of 22, 705 Da. (B) The mutant enzyme 
was incubated overnight with trans-chalcone giving a modified species with mass of  
22, 914 Da (M+Chal+H+). 
 
 
4.3.4.4 Top-down Fragmentation 
 
The most reactive residue in the primary sequence of SmSrtA that would likely undergo 
modification by trans-chalcone is expected to be the active site residue Cys205. To 
investigate this hypothesis, top-down fragmentation MS experiments were performed. In 
these experiments, SmSrtA (5µM) was incubated with excess trans-chalcone (100 µM) 
for 16 h, followed by ESI ionisation of the sample. The +24 charge state of the protein 




modified by trans-chalcone (Figure 56A). This isolated charge state of the modified 
enzyme was further fragmented by collision induced dissociation (CID) and electron 
collision dissociation (ECD) sources (Figure 56B). The product ions from the 
fragmentation experiments were analysed using the Prosight search software against the 
primary sequence for the truncated SmSrtA. The combined product ion maps from both 
the ECD and the CID experiments had very good correlation of fragmentation (Figure 
56C). The y425+ ([C207H333N60O64S1(C15H12O)]
5+) and y436+ 
([C211H341N61O66S1(C15H12O)]
6+) fragment ions from the CID experiment were used for 
























































Figure 56: Mapping the location of the trans-chalcone modification in SmSrtA by 
top down MS. (A) Typical mass spectrum of a single isolated charge state of chalcone-
modified sortase. Here the 24+ charge state is shown. Inset, Isotope distribution of the 
24+ species. The ion has an isotope pattern consistent with the addition of chalcone 
(+C15H12O). The simulated isotope pattern is displayed in orange 
([C1023H1634N276O311S7]
24+). (B) Typical top-down mass spectrum. Here the CID 
spectrum of the 24+ species is shown.  (C) Combined top down fragment map showing 
all of the assigned product ions from all fragmentation experiments. Fragments resulting 
from CID are displayed in red, fragments resulting from ECD are displayed in blue. 





4.3.5 Reaction Mechanism 
4.3.5.1 Trans-Chalcone and SmSrtA  
 
The proposed mechanism for the reaction of trans-chalcone with SmSrtA is via a 
Michael addition. A Michael addition reaction is characterized as a 1,4 conjugation 
addition which results when a strong nucleophile attacks the β-carbon of an α,β-
unsaturated carbonyl to produce an adduct (Figure 57). The chalcone flavonoids have a 
characteristic α,β-unsaturated carbonyl system between two aromatic rings which can 
readily react with strong nucleophiles to produce Michael adducts. In the case of 
SmSrtA, the active site consists of a reactive thiol, Cys205 which serves as a strong 
nucleophile to carry out an attack on the β-carbon of trans-chalcone yielding a chalcone-
SrtA adduct (Figure 57). This proposition was further strengthened by analyzing 
reactions of SmSrtA with dihydrochalcone (average mass: 210 Da) (Figure 58A), the 
saturated analogue of trans-chalcone, by FRET assay and MS. Dihydrochalcone showed 
no inhibition of enzyme activity (Figure 58B), likewise no additional peak of mass 
increase of +210 Da was observed in mass spectrum which would correspond to  SrtA-
dihydrochalcone adduct (Figure 58C). These observations therefore suggest that the α,β-
unsaturated system of trans-chalcone is required for reaction with SmSrtA and supports 










Figure 57: Proposed mechanisms for the reaction of trans-chalcone with SmSrtA. 
Michael adduct formed between trans-chalcone and SrtA, with nucleophilic attack of the 
cysteine residue across double bond of the α,β-unsaturated system to produce an adduct 






















Figure 58: SrtA incubated with trans-chalcone and dihydrochalcone. (A) Chemical 
structure of dihydrochalcone. (B) Fluorescence intensity obtained from SrtA incubated 
with of trans-chalcone (100 µM) and dihydrochalcone (100 µM) for 16 h and analysed 
by FRET assay. (C) Mass spectrum of SrtA control (5 µM) incubated with (i) trans-
chalcone (100 µM), (ii) dihydrochalcone (100 µM) and (iii) mixture of trans-chalcone 








4.3.5.2 Reversibility of the SrtA-modification 
 
The MS analysis confirmed the formation of SrtA-chalcone adduct involving the active 
site residue, Cys205 via a Michael addition reaction. With extensive dialysis, enzyme 
activity was not restored, which suggests that adduct formation was irreversible. To 
further confirm that this reaction is irreversible, the inhibited enzyme was incubated with 
the reducing agent DTT (10 mM), which is expected to convert the modified Cys205 
residue to its reduced state and restore activity, if the modification is reversible.  In a 
previous experiment, it was observed that DTT also has the ability to increase the 
activity of SmSrtA by two-folds in the absence of an inhibitor molecule. Addition of 
DTT to SmSrtA-chalcone sample did not restore enzyme activity. However, the ~10% 
activity that remained in the inhibited enzyme was doubled in the presence of DTT, 
similar to that observed for the uninhibited enzyme (Figure 59A). MS analysis of the 
sample incubated with DTT showed a single peak of mass 22, 975 Da corresponding to 
the modified enzyme (SmSrtA-chalcone adduct) which further confirmed that the 














Figure 59: Effect of DTT on SmSrtA and SmSrtA-chalcone adduct. (A) SrtA (5 µM) 
was treated with trans-chalcone (100 µM) and incubated for 16 h. The overnight sample 
was incubated with DTT (10 mM) for a further 6 h, then dialysed against 20 mM MES, 
pH 6.5 and 125 mM NaCl and assayed for sortase activity. A SrtA control sample 
without the treatment of trans-chalcone was assayed with and without DTT (10 mM). 
(B) Positive ion mass spectrum of SrtA-chalcone adduct after incubation with DTT. A 
peak of mass 22, 975 Da was detected which corresponds to modified enzyme. 
 
 
4.3.6 Structural Biology 
 
All crystallographic analyses and molecular modeling in this chapter were carried out in 
collaboration with Dr. Jon Marles-Wright at the Institute of Structural and Molecular 
Biology at The Unversity of Edinburgh. The refined crystal structure and molecular 
models were also processed by Dr. Jon Marles-Wright. 
 
 
4.3.6.1 Protein Crystallisation  
 
Attempts were made to crystallise the purified WT enzyme, SmSrtA; however these 
crystal trials were unsuccessful due to the instability of the enzyme which observably 
underwent auto-proteolysis upon purification. However, the more stable SmSrtAH139A 




method. After 3 days, a single crystal was observed in the well solution containing 0.2 
M (NH4)2SO4, 25 % w/v PEG 4K and 0.1 M NaAc pH 4.6 (Figure 60A). Optimisation 
screens were prepared from these conditions by varying the percentage of each buffer 
component. The concentrated protein was crystallised by hanging drop vapour diffusion 
in drops of 2 μl protein plus 2 μl crystallisation solution (30 % w/v PEG 4000, NaAc pH 
4.6, 0.2 M (NH4)2SO4), over 1 ml of the latter within 5 days (Figure 60B). Several other 




Figure 60: Crystals of SmSrtAH139A mutant. (A) Crystals were grown over 3 days 
in 0.2 M (NH4)2SO4, 25 % w/v PEG 4K and 0.1 M NaAc pH 4.6. (B) Crystals grown 
over 5 days in 30 % w/v PEG 4000, NaAc pH 4.6, 0.2 M (NH4)2SO4. (C) Crystals grown 
over 14 days in 0.1 M HEPES pH7 and 30 % Jeffamine Ed-2001. (D) Crystals were 







4.3.6.2 Data Collection and Structural Solution  
 
The crystals of the SmSrtAH139A mutant diffracted to a resolution of 1.6 Å. They 
belong to the P42212 space group with one molecule in the crystallographic asymmetric 
unit. The crystal structure of the enzyme (PDB code: 4TQX) was determined by 
molecular replacement using the structure of S. pyogenes sortase A, its closest 
homologue (66% homology), as the starting model (PDB code: 3FN5).136 The 
refinement and statistics data for SmSrtAH139A are summarised in Table 18. The 
electron density map at residues 49-53 at the N-terminus was ambiguous; therefore the 
assignment of these residues remains undefined and they were omitted from the final 
model. This may suggest some degree of flexibility in the N-terminal domain. The final 
model of SmSrtAH139A contains 202 amino acids, inclusive of Ala41 to Glu48 and 
Lys54 to Phe246 (Figure 61). SmSrtA has a canonical eight stranded β-barrel core 
flanked by loops, coils and three α-helices.183 The catalytic domain is located in the β-
barrel core and is highly conserved among the other members of the sortase 
superfamily.135 All of these structures have a similar relative orientation of the catalytic 
domain. The SmSrtA construct lacks the predicted forty amino acids of the trans-
membrane domain, however, in addition to the conserved catalytic core (residues 88-
206), the structure of SmSrtA also revealed a unique N-terminal α-helix (residues 69-89, 
relative to the full length enzyme). The helix is connected to the catalytic core by a short 
















Table 18: Data refinement and statistics for SmSrtA. Statistics for the highest-
resolution shell are shown in parentheses. 
 
Wavelength (Å) 0.92  
Unit cell parameters  (Å) a=b=82.822 c=57.87, alpha=beta=gamma=90ᴼ 
Space group P 42 21 2 
Resolution range  (Å) 47.44 – 1.37 (1.419 – 1.37) 
 I/σ (I) 25.19 (1.12) 
Completeness (%) 99.85 (99.98) 
Multiplicity 25.6 (26.0) 
Total reflections 1094198 (109542) 
Unique reflections  42782 (4216) 
Wilson B-factor (Å2) 19.25 




Reflections used for R-free (%) 5 
R-work  0.1450 (0.2806) 
R-free 0.1792 (0.3296) 
No. of non-hydrogen atoms 1837 
  macromolecules 1585 
  ligands 22 
  water 230 
Protein residues 201 
RMS (bonds) (Å) 0.009 
RMS (angles) ᴼ 1.22 
Ramachandran favored (%) 98 
Ramachandran allowed (%) 2 
Ramachandran outliers (%) 0 
Clashscore 1.24 
Average B-factor (Å2) 27.50 
  Macromolecules (Å2) 25.80 
  Ligands (Å2) 49.60 






Figure 61: Crystal structure of SmSrtAH139A mutant (PDB code: 4TQX). (A) 
Cartoon model of the crystal structure of SrtA H139A mutant showing the catalytic 
domain made up of an eight-stranded β-barrel core and a unique α-helix at the N-
terminus. Residues 49-53 remain unassigned. The structure was determined by 
molecular replacement with S. pyogenes SrtA (PDB: 3FN5). 
 
 
This unique N-terminal helix has not been observed previously in other SrtA structures 
present in the PDB.  An N-terminal helix is observed in the crystal structure of S. aureus 
SrtB (PDB code: 1NG5). However in contrast to the SmSrtA structure, this helix is 
hinged at Asp41 in SrtB and places it in an equivalent position to the C-terminus of SrtA 
and in close proximity to the β-barrel core (Figure 62A).120 These structural differences 
may suggest a dynamic role of the N-terminal helix in positioning of the catalytic 
residues of sortases with its substrates for the efficient transpeptidation to take place. 
This study therefore reports the first structural evidence of a unique N-terminal domain 
of sortase enzymes which may function to position the catalytic core above the 









The active site of SrtA enzymes consists of three highly conserved residues: His139, 
Cys205 and Arg214 which are essential for catalysis (numbering of residues is based on 
the sequence of SmSrtA). The crystal structure of the H139A mutant did not show any 
observable architectural compromise of the active site as a result of the mutation of 
His139 to an alanine residue (Figure 62B). The relative positions of the active site 
residues are also highly conserved. The only significant difference is seen between the 
orientation of the cysteine residue of S. aureus SrtB and the other sortase enzymes. In 
SaSrtB, Cys205 points towards the histidine residue in the active site, whereas in the 
other sortases the cysteine residue points away from His139 with a distance of ~7 Å.  
 
 
Figure 62: Overlay of sortases. (A) Stereo view of sortase structures showing the 
highly conserved core fold. (SmSrtA, 4TQX, blue; SpSrtA, 3FN5, raspberry; SaSrtB, 
1NG5, yellow; SpnSrtC, 2W1J, green). SmSrtA has a unique N-terminal helix 
arrangement which is distinct to those seen for the other sortase family enzymes, N-
terminus of SmSrtA indicated with an ‘N’ and SaSrtB indicated with an arrow. (B) 
Stereo view of the active site residues of the sortase structures as in (A), with residue 
numbers labelled for the SmSrtA. The only significant difference in active residues is 
seen between the SaSrtB active site cysteine and the other sortase family proteins, where 




4.3.6.3 Molecular Modelling of SrtA with Symmetry-Element 
 
In the crystal structure of the SmSrtAH139A mutant, Cys205, His/Ala139 and Arg214 
are positioned on three neighbouring  β-strands, β-7, β-4 and β-8 respectively which 
forms a tunnel-like hydrophobic catalytic pocket, similar to that described in other SrtA 
enzymes.134 The catalytic pocket of SrtA is designed to accommodate the two bulky 
hydrophobic subtrates, the pentaglycine side chain of lipid II and a protein substrate 
consisting of the LPXTG motif at the N-terminal. Both substrates enter the active site 
from either side of the cleft to make contact with the catalytic triad (Cys-His-Arg). In 
addition to the natural peptide substrate, the hydrophobic cleft can also accommodate 
other molecules including peptides with similar surface properties. Interestingly, when 
viewing the unit cell of SmSrtA, the N-terminus α-helix (residues 69-89) from a 
symmetry-related molecule makes extensive contact with the active site cleft/binding 
groove of SmSrtA resulting in a “non-physiological dimer” (Figure 63). Two very 
significant contacts are observed between the aromatic side chains of Phe67 and Phe69 
of the N-terminal helix and the active site. Both residues sit in close apposition to the 
active site cysteine and arginine residues, resulting in an obstruction of the active site 
cysteine residue (Figure 63 inset). These serendiptidous “non-physiological dimers” 
involving the active site offer a structural rationale as to why the WT SmSrtA undergoes 
auto-proteolysis. Although it does not contain a canonical “sortase motif” it appears that 
the N-terminus of SmSrtA binds to the active site and this self-recognition leads to 












Figure 63: Modelling of S. mutans sortase A with symmetry-related molecule. 
Surface representation of the SmSrtA (H139A mutant) with symmetry related molecule. 
The N-terminal region of one molecule is bound to the other through extensive contacts 
and an extended helix occludes the active site cleft. (Inset) Experimental electron density 
map. Experimental 2mFo-DFc map contoured at 1.5 σ showing residues of the N-
terminal helix within the active site cleft. Phe 67 and Phe69 sit in close apposition to the 
active site Cys and Arg residues.  
 
 
4.3.6.4 Molecular Modelling of SrtA with trans-chalcone 
 
Although milligram quantities of the chalcone-modified SmSrtA H139A enzyme were 
prepared, it was difficult to handle at high concentrations and failed to crystallise. 
Therefore a model of trans-chalcone bound in the active site of SrtA was built in order 
to understand the interactions within the binding cleft between the active site residues 
and the inhibitor. Model construction was guided by the the positions of the bound side 




crystal structures of the S.aureus SrtA-LPETG peptide complex (PDB: 1T2W) and 
B.anthracis SrtB-AEEK complex (PDB: 2OQZ). The 1T2W complex was chosen as it 
describes the substrate binding pocket where the scissile T-G bond of the peptide 
substrate would be positioned (Figure 64A).134 Likewise the 2OQW complex describes 
the binding pocket of the AEEK inhibitor molecule that irreversibly forms a covalent 
adduct with the active site cysteine or SrtB (Figure 64B).147  
 
 
Figure 64: Surface plot representation of sortase showing binding cavity for 
substrates and inhibitors. (A) The LPETG peptide (coloured in yellow) buried in the 
deep binding pocket of SaSrtA. (B) The AEEK2 inhibitor (coloured in yellow) forms 
covalent adduct with active site cysteine residue and is buried in the peptide binding 
pocket of BaSrtB. The figure was generated using PyMol. 
 
In the SrtA-chalcone adduct, a new bond is expected to be formed between the sulphur 




Michael product. The positions of the bound Phe67 and Phe69 phenyl ring side chains 
from the symmetry-related partner in the SmSrtA structure were used to place the two 
aromatic rings of the inhibitor covalently bound to the thiol of Cys205. The positions of 
rings A and B of chalcone in the active site can exist in two conformations to give both 
the R and S addition products (Figure 65). There appears to be no significant constrains 
on the orientation of trans-chalcone within the active site in the model, which makes 
free rotation possible about the C-S bond. In Figure 65, the red model shows the A-aryl 
ring of trans-chalcone bound in the LPXTG pocket and the B-aryl ring in the Lipid II 
pocket, while the blue model shows trans-chalcone with the B-aryl ring in the LPTXG 




Figure 65: Modelling of SmSrtA with trans-chalcone. Model of the Michael adduct of 
trans-chalcone bound in the active site of SmSrtA in two different conformations. The 
red model shows the A-aryl ring of (S-form) trans-chalcone bound in the LPXTG pocket 
and the B-aryl ring in the Lipid II pocket. The blue model shows (R-form) trans-




A comparison of the SrtA-chalcone model with that of SrtB-AEEK structure (Figure 65, 
yellow model) reveals a difference in orientation of the active site residues. The active 




sites, whereas in the SrtB a tyrosine residue, Tyr235 (which is absent in SrtA) obstructs 
one side of the binding cleft, after the SrtB-AEEK adduct is formed. These structural 
differences suggest a possible strategy for exploiting more structurally diverse chalcones 
from the flavonoid family as isoform-specific sortase inhibitors.  
 
 
4.3.7 Antimicrobial Activity of Trans-chalcone 
4.3.7.1 Biofilm Assay 
 
SrtA modulates the cell-surface-related properties of S. mutans including the cell’s 
biofilm formation ability.128, 129 With strong evidence that trans-chalcone inhibits 
S.mutans SrtA in vitro, investigations were carried out to assess the effect of the 
inhibitor on the formation of biofilm by S. mutans. Using the AAA model, S. mutans 
biofilm was grown on a saliva-coated glass slide for 16-18 h in BHI medium 
supplemented with 0.2% sucrose in the presence of trans-chalcone (0-500 µM). The 
biofilm biomass was then stained with crystal violet and the optical density of the stain 
measured at 600 nm. A reduction in biofilm mass was suggestive of an inhibitory effect 
of trans-chalcone on biofilm formation. Morin, a known biofilm disruptor was used as a 
positive control. The data showed that biofilm formation was reduced in the presence of 
trans-chalcone in a concentration dependent manner up to 250 µM, with efficacy tailing 
off at higher concentrations (Figure 66). These data may suggest that there is a point of 
saturation of trans-chalcone with its biological target (s) in S. mutans biofilm, which 
may cause reduced growth of bacterial cells. At the same time, it could be that at high 
concentrations, trans-chalcone may induce a response which overrides the inhibitory 
effect of the molecule and causes bacterial cells to adapt a biofilm lifestyle for survival. 
Since biofilm formation is a complex and dynamic process that involves changes in 
microbial metabolism and signalling, this encouraging result suggests that the exact 
mechanism of chalcone inhibition in vivo requires further in-depth investigations to fully 





Figure 66: Effect of trans-chalcone on biofilm formation by S. mutans. (A) 
Photograph of crystal violet stain after destaining of S. mutans biofilms grown on 
saliva-coated glass slides in the presence of trans-chalcone. Cells were grown in BHI 
media containing trans-chalcone (0-500 µM). A stronger purple colour indicates that 
more biomass was present on glass slide before destaining as is seen in the wells 
containing 25 µM and 5 µM trans-chalcone. (B) Quantification of biofilm mass. The 
optical density of crystal violet stain was read at 600 nm. The values represent the 
average experiments performed in triplicate. DMSO was used as the negative control 
and morin (50 µM) as the positive control. (C) % Inhibition of biofilm formation in 
the presence of trans-chalcone. Biofilm formation was reduced in the presence of 
trans-chalcone in a concentration dependent manner up to 250 µM, with efficacy 
tailing off at higher concentrations.  The OD600 for the DMSO sample was compared 
with the results for 250 µM trans-chalcone using the unpaired t-test. DMSO plot 
(n)=3, 250 µM trans-chalcone (n)=3, (df)=2, T value=24.1524, p<0.0002. This 







4.4 Conclusion and Future Work 
 
In this study, the structure of the H139A mutant of SrtA from S. mutans was determined 
which revealed a highly conserved catalytic core consisting of an eight β-stranded 
architecture. Additionally, the structure revealed a unique N-terminal domain consisting 
of an α-helix which may have an intrinsic flexible property necessary for the positioning 
of the active site with its substrates. It would be of interest to obtain the structure of the 
SrtA-chalcone adduct by setting up further crystal trials. Future work may involve the 
use of a thiol sepharose resin as a medium to immobilize unreacted SrtA after incubation 
with trans-chalcone, in an effort to obtain a higher concentration of pure modified 
enzyme. This structure would further confirm if the conclusions drawn from the SrtA-
chalcone model are correct. 
 
The inhibition studies carried out with trans-chalcone revealed the need to carry out 
further studies to screen other flavonoids for anti-sortase activity possessing a greater 
degree of specificity. This may also address the issue of identifying a molecule with high 
potency since trans-chalcone was only effective as an inhibitor at micromolar 
concentrations. Trans-chalcone was also found to possess antibiofilm properties against 
S. mutans, which suggests the potential application of the chalcone flavonoids as 
therapeutic agents for the control of biofilm-associated infections and highlights the 
need to carry out further studies to explore the mechanism by which biofilms are 
inhibited by this molecule. One possibility is that trans-chalcone, like other flavonoids 
may prevent the surface attachment of proteins involved in surface adherence of the 
bacterial cells via an inhition of the sortase enzyme responsible for this. This hypothesis 
can be further tested by performing western blot studies to identify these proteins in cell 
cultures grown in the absence and presence of trans-chalcone. In summary, the chalcone 
scaffold has provided insights into the mechanism of inhibition of SrtA by covalent 





Chapter 5: Allicin-Containing Garlic Extracts  
5.1 Introduction 
Garlic extracts have been used for a long time for their antimicrobial properties. Several 
microorganisms have shown sensitivity to crushed garlic preparations. The fresh extracts 
consist of several thiosulfinates with allicin being identified as the major biologically 
active component accounting for up to 75% of total thiosulfinates.96 Ajoene, a lipid-
soluble allyl sulfide derivative of allicin, found in oil-derived garlic extracts has also 
been reported to have a broad spectrum of microbial growth inhibition.185 Recently, 
ajoene has also been shown to inhibit quorum sensing in P. aeruginosa.186, 187 
Interestingly, we could find no published studies of the antimicrobial properties of 
garlic-related compounds on the Burkholderia cepacia complex (Bcc), a group of 17 
closely-related species distributed widely in soil, water and the plant rhizosphere.16 This 
is both surprising and ironic since as well as being important agents for bioremediation 
and biological control188, 189 the Bcc are the major phytopathogens for allium species.190  
 
In the last few decades, the Bcc has also emerged as an important opportunistic human 
pathogen, in particular as a cause of life-threatening lung infections in individuals with 
cystic fibrosis (CF) and chronic granulomatous disease.17, 18 Although patient 
segregation and strict infection control have reduced the incidence of Bcc infections in 
individuals with CF, such infections remain an important clinical problem. At present, 
the most predominant Bcc species responsible for CF infections are B. cenocepacia and 
B. multivorans.17, 22 Most transplant centres worldwide exclude individuals infected by 
B. cenocepacia from access to lung transplantation, the only proven treatment for severe 
CF lung disease. Thus, any new strategies that lead to the improved eradication of Bcc 
from an infected patient would be important. Unfortunately, a common feature of the 
Bcc is intrinsic resistance to most antibiotics19; hence antibiotic treatment presents a 
major challenge. At present, there is insufficient data to support the use of any specific 
antibiotic regimen against Bcc infection.191, 192 There is an even greater need to have 




aztreonam that failed to treat CF patients with Burkholderia spp. infection.23, 24 Thus, the 
availability of novel antimicrobial agents against Bcc would represent a major clinical 
advance for patients with Bcc infection.  
 
Bacterioferritin comigratory protein (BCP) belongs to a superfamily of peroxidase 
enzymes known as peroxiredoxins (Prxs). These enzymes carry out thiol-dependent 
reduction of peroxide substrates, which serve as a defense mechanism against reactive 
oxygen species (ROS). The BCP from B. cenocepacia (BcBCP), was previously 
characterized by Clarke et. al. in a mass spectrometry study.158 This enzymes protects 
Burkholderia from oxidative stress in a growth phase dependent manner via a 1-Cys 
catalytic pathway. This redox pathway was confirmed through experiments using 
iodoacetamide to covalently modify the free thiol groups resulting in the abolishment of 
the enzyme’s peroxidase activity. The primary sequence of BcBCP consists of only two 
cysteine residues, Cys-44 and Cys-98, which are highly conserved in the Burkholderia 
genome (Figure 67). Cys-44 was confirmed as the active-site peroxidatic residue in the 
thiol-dependent BCP by mass spectrometry, whereas Cys98 does not take part in 
catalytic activity. This cysteine residue (Cys-SH) is oxidized to a stable sulfinic acid 
(Cys-SOOH) on reaction with a peroxide substrate during the catalytic process. In the 
presence of a resolving partner, example, GSH, the oxidized enzyme is reduced to its 
native state.158 Therefore any reactive thiol reagent, including allicin and other allium 
thiosulfinates are likely expected to react with the free thiols of BCP and also abolish its 









Figure 67: Sequence alignment of BCP from Burkholderia. Sequences in red show 
universally conserved residues in Burkholderia BCP. The black triangle highlights the 
two highly conserved cysteine residues of BCP. 
 
 
5.1.1 Aims and Objectives 
 
Given the dearth of new antibiotics from conventional approaches within the 
pharmaceutical industry, the development of novel antimicrobial compounds derived 
from natural sources would be welcomed 29, 30; this is particularly relevant to the 
management of lung infections which are the primary cause of morbidity and mortality 
in the CF population. As previously indicated, the therapeutic potential and complex 
chemistry of alliums is well documented but remains enigmatic.159, 193 Therefore the 
antimicrobial potential of allicin-containing plant extracts against Bcc is worth 
investigating.  
 
Before this study, the antimicrobial activity of freshly prepared aqueous garlic extract 
(AGE) and aqueous allicin standard (AAS) against Bcc was unknown. Therefore this 
study was designed to investigate the antimicrobial potential of AGE and AAS against 




microbiology. This required an accurate and consistent quantification of the amount of 
allicin present in the freshly prepared garlic extracts in relation to aqueous allicn 
standards by HPLC. From this analytical analysis of AGE and AAS, determination of 
their MICs and MBCs would give some indication of their antimicrobial activities. 
Another objective of this study was to determine the efficacy of various assays including 
broth/agar dilution, paper disc and agar well diffusion in analyzing the antimicrobial 
potential of AGE and AAS against Bcc.  
 
The exact chemical mechanism(s) by which allicin exerts its antibacterial activity has 
been the subject of numerous studies, which suggest that allicin reacts with free thiols in 
important bacterial components essential for life. Indeed, allicin is known to covalently 
modify the free amino acid cysteine via the formation of allyl-disulfide species.194 Given 
previous evidence that allicin preferentially interacts with cysteine, it has been 
hypothesized that the allylthio moiety of allicin allows it to react with cysteine-
containing Burkholderia enzymes involved in key biosynthetic pathways. The exact 
targets of allicin are not known but it can be assumed that there will be many proteins 
that have the potential to be modified. As a relevant model protein, the Bcc-derived 
peroxidase enzyme, BCP, which has been previously shown to play a role in the 
detoxification of reactive oxygen species (ROS) within B. cenocepacia was used to 
study the reaction of allicin with thiol-containing proteins within the B. cenocepacia 











5.1 Results and Discussion 
5.2.1 Analysis of Garlic and Allicin Samples 
5.2.1.1 Allicin Standard  
 
An aqueous solution of pure allicin (AAS) obtained commercially was prepared and 
used as the primary standard for determining the allicin content in fresh garlic extract. 
The purity of AAS was confirmed using a published HPLC method with UV detection at 
240 nm on a C18 reverse phase column.160 Allicin eluted with a retention time of 4.1 min 
and an observed m/z of 185.0067 (consistent with the [M+Na]+ species; theoretical m/z 
185.0065; [C6H10OS2+Na]
+). Only the peak for allicin was detected with no appreciable 
degradation component based on the spectrum (Figure 68A). Allicin standards were 
prepared by dissolving allicin in sterile, distilled water to produce aqueous solution, 
ranging from 8-1000 µg/mL by serial dilution. An injection volume of 20 µL of the 
standards resulted in a range of 0-20 µg of allicin being loaded onto the column. A 
standard curve for these solutions gave a straight line with a correlation coefficient of r2 





















Figure 68: Analysis of standard aqueous solutions of allicin. (A) Chromatogram of 
AAS (1mg/mL) as obtained by HPLC with UV detection at 240 nm. Allicin elutes at 4.1 
mins from a C18 reverse phase column at a flow rate of 1 mL/min using a linear gradient 
of MeOH:water (60:40). (B) Calibration curve of AAS as obtained by HPLC-UV 
analysis. Standards ranged from 8-1000 µg/mL. Each run was done in triplicate. A 












5.2.1.2 Aqueous Garlic Extracts 
 
Aqueous garlic extract was prepared from homogenizing garlic bulb in sterile, distilled 
water (1 g of garlic bulb per 1 mL of water). The freshly prepared garlic extracts were 
also analysed using the same HPLC conditions described above for AAS. The elution 
profile of AGE revealed a complex mixture with several well-resolved peaks including a 
sharp peak for allicin at 4.1 mins (Figure 69). The thiosulfinates present in aqueous 
garlic homogenates have been previously characterized and quantified in a study 
conducted by Lawson et al.96 The amount of allicin in freshly prepared AGE, based on 
the standard curve, was determined as 67.6 ± 7.9 µg in 20 l, which equates to 3.38 mg 
± 0.39 mg/mL (allicin/AGE, w/v). This concentration is comparable to the amount 
reported by Fugisawa et al. (1.32 ± 0.43 mg/mL) and other literature reports of the 


















Figure 69: Analysis of AGE by HPLC. The chromatogram of neat AGE (1 g of garlic 
bulb per 1 mL of water) obtained by HPLC with UV detection at 240 nm shows a 
complex mixture. Allicin elutes at 4.1 mins from a C18 reverse phase column at a flow 






A number of garlic supplements e.g. AllicinMaxTM are on the market with claims that 
they contain similar amounts of active compounds as fresh garlic extracts in particular 
allicin, the main biologically active component of garlic. Since allicin does not exist 
naturally in garlic, these supplements normally contain allinase and the precursor 
molecule alliin which is enzymatically converted to allicin after consumption. However 
evidence from a study carried out by Lawson showed that many commercially available 
garlic supplements show poor release of allicin which may be partly due to the 
enzymatic conversion being significantly affected by gastric acid, intestinal proteases as 
well as the manufacturing process.160, 195, 196 With the aim of identifying pharmaceutical 
formulations of garlic extracts with potent antimicrobial activities similar to that of pure 
allicin and fresh garlic extract, an investigation of the bactericidal activity of the garlic 
supplement AllicinMaxTM against Bcc was carried out. This particular supplement was 
chosen as the manufacturer’s claim suggests that each capsule contains 180 mg of 100% 
stabilised allicin which is converted to allicin derivatives upon consumption. Extraction 
of the allicin was attempted by dissolving the capsules in 0.1 M HCl at 37 oC for 1 hour 
followed by the neutralisation of the extract with 0.1 M NaOH. The extract was analysed 
by HPLC with UV detection using the same protocol outlined for the analysis of AAS 
and AGE. HPLC and mass spectrometry analysis of AllicinMaxTM revealed a complex 
and diverse composition of chemical compounds with no quantifiable amounts of allicin 







Figure 70: Chromatogram of AllicinMaxTM extract analysed by HPLC with UV 
detection at 240 nm. Extract was prepared from the content of 4 capsules. No 
quantifiable amounts of allicin detected at the retention time of 4.1 mins. 
 
 
5.2.2 Antimicrobial Activity  
5.2.2.1 MIC for AGE 
 
The antimicrobial activity of freshly prepared AGE was assessed against 38 Bcc isolates, 
representing nine Bcc species and which included 30 isolates from an experimental Bcc 
strain panel. 197 The MICs were determined by the agar dilution method and gave results 
ranging from 0.5 to 3% (Table 19), where 100% equates to 10g of garlic bulbs 
homogenised in 10 ml of sterile, distilled water. Interestingly, comparison of the 
antimicrobial activity of independent AGE preparations showed little batch-to-batch 
variation, which correlates well with the high batch to batch reproducibility of the 
measured allicin content of AGE. Activity also remained stable when AGE was stored at 
4 oC for seven days or for at least 6 months at -80 oC. Aqueous solutions of allicin have 




be due to the hydrogen bonding between water and the reactive oxygen atom of 
allicin.107  This initial survey of the antimicrobial activity of AGE against Bcc confirmed 
sensitivity of the microbes to the extract.  It was noted that the epidemic, clinically-
relevant isolate B. cenocepacia C3168 was very sensitive to AGE (MIC = 0.5%). The 
amount of allicin present in garlic preparations used in this study can be quantified from 
these results. Using the MIC of 0.5 % for AGE against the B. cenocepacia C3168 



































Table 19: MICs (%) of AGE for Bcc. MICs were determined by the agar dilution 
method and gave results ranging from 0.5 to 3%, where 100% equates to 10g of garlic 
bulb homogenised in 10 ml of sterile, distilled water. 
 
Strain Edinburgh Lab No. LMG No. Strain Name AGE (%) 
B.cepacia J673 1222 ATCC 25416 2 
B.cepacia J675 2161 ATCC 2161 1 
B.cepacia C2970 17997  0.5 
B.cepacia C3159 18821 CEP509 0.5 
B.multivorans C1576 16660  0.5 
B.multivorans C1962 16665  0.5 
B.multivorans C3160 18822 C5393 1 
B.multivorans C3161 13010  1 
B.multivorans C3162 18825 CF-A1-1 1 
B.multivorans C3163 18824 JTC 0.5 
B.multivorans C3164 18823 249-2 0.5 
B.multivorans J2511 17588 ATCC 17616 1 
B. cenocepacia J415 16654  1 
B. cenocepacia C1394 16659  1 
B. cenocepacia J2315 16656  0.5 
B. cenocepacia J2524 18832 ATCC 17765 3 
B. cenocepacia C3165 18826 BC7 0.5 
B. cenocepacia C3166 18863 K56-2 1 
B. cenocepacia C3167 18827 C5424 0.5 
B. cenocepacia C3168 18828 C6433 0.5 
B. cenocepacia C3169 18829 PC184 0.5 
B. cenocepacia C3170 18830 CEP511 1 
B.stabilis C3171 14294  0.5 
B.stabilis C3172 18870 C7322 0.5 
B.stabilis C3173 18888  1 
B.stabilis C3174 14086  1 
B. vietnamiensis C2978 16232  1 
B. vietnamiensis C3175 18835 PC259 1 
B. vietnamiensis C3176 18836 FC441 3 
B. vietnamiensis C3177 10929  1 
B.dolosa J3358   1 
B.dolosa J3361   1 
B.ambifaria J3362   2 
B.ambifaria J3362   1 
B.anthina J3364   1 
B.anthina J3366   1 
B.pyrrocnia J3368   2 





5.2.2.2 MICs and MBCs for Allicin 
 
Since Bcc showed sensitivity to AGE, the next objective was to investigate the 
antimicrobial activity of AAS. In light of the high cost of pure allicin (€150 per mg), the 
Bcc panel for screening was restricted to five isolates including three representatives of 
B. cenocepacia, the most clinically relevant Bcc strain. In addition to MIC 
determination, MBC assays for AAS were also performed on this smaller panel using 
the microtitre broth technique recommended by the NCCLS.171 The MICs for AAS 
ranged from 8-62 µg/ml, with two B. cenocepacia strains, J2315 and C6433, being the 
most sensitive of the panel. The MBCs for AAS ranged from 31-62 µg/ml (Table 20).  
 
Table 20: MICs (µg/mL) and MBCs (µg/mL) of AAS for Bcc. The Bcc panel for 
screening was restricted to five isolates including three representatives of B. 
cenocepacia. 
 
Strain Edinburgh Lab No. LMG No. MIC MBC 
B. cenocepacia J2315 16656 8 31 
B. cenocepacia C6433 18828 8 31 
B. cenocepacia C3165 18826 16 31 
B. stabilis C3172 18870 16 31 
B.cepacia J673 1222 62 62 
 
 
This analysis allows for the comparison between the MIC of pure allicin (AAS) and 
AGE. For instance, the MIC of pure AAS against the B. cenocepacia isolate C6433 was 
determined as 8 µg/mL allicin and the MIC of AGE 0.5%, which equates to ~16.9 
µg/mL of allicin in the garlic extract. These values suggest that, against this isolate, 
allicin is the major antibacterial species in the AGE preparation. This study therefore 








5.2.2.3 Plate Diffusion Assay 
 
The antimicrobial activity of AGE was confirmed using impregnated paper discs and 
agar well diffusion assays. This experiment was carried out to provide further 
information on other suitable screening assays. An inoculum of 10 l (106 CFU/ml) was 
used per disc or well. Antimicrobial activity was determined by a zone of inhibition after 
overnight incubation of the microbes with AGE or AAS at 37 ᴼC. Both assays showed 
that B.cenocepacia was sensitive to AGE, confirming what was previously observed 
using the agar dilution method. No mutant strain resistant to allicin or AGE was 






Figure 71: Zones of inhibition. Antimicrobial activity against B. cenocepacia C3168 
demonstrated on seeded agar plates by AGE is indicated by clear zones where bacterial 
growth is inhibited. Freshly grown B. cenocepacia C3168 (106 CFU/mL) were 
embedded in 20 mL of warm agar in a Petri dish. Afterwards, a hole was punched out, 
0.6 cm in diameter (right) and filled with AGE or a paper disc impregnated with AGE 





5.2.3 Interactions of AAS and AGE with Burkholderia BCP  
5.2.3.1 Expression and Purification of BCP 
 
The recombinant WT BCP from B. cenocepacia J2315 (referred to here as BCP) was 
expressed in an E. coli BL21 (DE3) host with an N-terminal hexa-histidine tag as 
described by Clarke et. al.158 The protein was purified to homogeneity by nickel affinity 
chromatography to give pure sample that could be used directly for analysis without 
further purification by SEC. A small fraction of the sample was subjected to oligomeric 
analysis using an analytical grade Superdex 200 10/300 GL column, which gave a 
symmetric peak representing the monomeric enzyme with a mass of ~19 kDa. The mass 
of the protein was further confirmed by SDS/PAGE analysis and ESI mass spectrometry, 






Figure 72: Purification and MS analysis of B. cenocepacia BCP. (A) Elution profile 
of BCP from analysed by SEC to give a monomeric enzyme. SDS/PAGE analysis (inset) 
shows the mass of the enzyme to be ~19 kDa;  lane 1: low molecular weight marker; 
lane 2-4: fractions 8 to 10 for the peak that eluted in ~10 mL of elution buffer (50 mM 
Tris-HCl, 500 mM NaCl, pH 7.5) (B) Charge state distribution obtained for BCP. This 
corresponds to a deconvoluted molecular mass of 18992 Da (insert), which was 
consistent with the predicted theoretical mass based on the amino acid sequence of the 





 5.2.3.2 Reactions of BCP with AAS and AGE 
 
B. cenocepacia BCP has a mass of 18992 Da which confirms that both cysteine residues 
are in the reduced form (Cys-SH). N-gluconoylation is very commonly observed in 
proteins with an N-terminal histidine tag expressed in E. coli, this phenomenon was 
observed in purified BCP, evident by a small percentage of the purified enzyme having 
an additional mass of 178 Da (Figure 73A).198 Incubation of 20 µM BCP with 1 mM 
allicin led to the formation of mixed allyl-disulfide species with masses of 19064 and 
19136 Da after 60 mins. These observed increases in mass (+72 and +Da) are 
consistent with the addition of a single allyl thiol group from allicin (C3H5S) to either 
one or both cysteine residues (Figure 73B).  Incubation of modified BCP with the 
reducing agent TCEP at 1 mM resulted in reduction of the enzyme to its native 
unmodified state, which suggests the reaction between BCP and allicin is reversible. 
This result is not surprising as allicin is expected to react with the free thiols on BCP in a 
non-specific manner as shown by previous studies with cysteine, glutathione and 
papain.194 Incubation of BCP with AGE for 60 mins followed by repurification of the 
enzyme by nickel affinity chromatography also resulted in a similar mass increase as 
seen with pure allicin, which suggests that AGE and the AAS react with the protein 
target in the same manner (Figure 73C). The results from the proteomic analysis of BCP 
with the AGE were unexpected, as garlic extract is a complex mixture as observed from 
our HPLC analysis. This clearly-resolved data confirms that allicin is the main 
component of freshly prepared garlic that reacted with BCP. More importantly, this is 
the first study where AAS and AGE have been analysed by protein mass spectrometry 
with a relevant protein target from a bacterial pathogen. This study opens the door to 
apply this powerful analytical tool for identifying many of the protein targets that are 
modified by allicin within the proteome of Burkholderia and other pathogens. It could 
also prove useful to study other similar allylthio-containing natural products like ajoene 






Figure 73: MS analysis of Burkholderia BCP incubated with AAS and AGE. 
(A)  Purified Burkholderia BCP has a mass of 18, 992 Da, consistent with its predicted 
mass based on the amino acid sequence. (B) Burkholderia BCP after incubation with 1 
mM AAS for 1 h results in the formation of two covalently modified species of mass 
increases +72 Da and +144 Da. (C) Burkholderia BCP after incubation with AGE for 1 
h results in the formation of a covalently modified species of mass increase +144 Da 
corresponding to the addition of two allicin adducts. * denotes enzyme species that 
undergo α-N-gluconoylation during protein expression. 
 
 
5.2.3.3 Reaction Mechanism 
 
Allicin and AGE react with both Cys44 and Cys98 residues of BCP to give modified 
isoforms of the enzyme with masses 19, 064 Da and 19, 136 Da. These observed mass 
increases of 72 and 144 Da correspond to the addition of one and two allylthio groups 








BCP-allythio derivatives involve nucleophilic attack of a BCP cysteine thiol (either 
Cys44 or Cys98) on the more electrophilic sulfur of allicin to produce a new disulfide 
bond. A second molecule of allicin undergoes a similar reaction to add a second allylthio 
group, producing a sulfenic acid byproduct (Figure 74). Reduction of the modified BCP 
with excess reducing agent (tris(2-carboxyethyl) phosphine, TCEP) returned the enzyme 
to the unmodified form (18992 Da) which suggests that the reaction of allicin with BCP 
is chemically reversible in the presence of strong reducing agents. 
 
 
Figure 74: Proposed mechanism for the reaction of allicin with BCP. Formation of 
the BCP-allythio derivative involves nucleophilic attack of a BCP cysteine thiol (either 















In this study the allicin content of freshly prepared AGE was determined by HPLC 
analysis using pure allicin standard for quantification. The data from this analysis were 
consistent and correlated well with the trends observed in the antimicrobial activities of 
allicin and AGE. Together these results confirmed that the primary bacterial killing 
activity of fresh garlic extracts against B. cenocepacia lie with allicin. Production of 
antimicrobial compounds by plant alliums which target Burkholderia species, their 
principal bacterial pathogen, is not surprising. However, what is surprising is that, to our 
knowledge; such activity has not been reported or investigated previously. Therefore this 
study reports the first evidence for the antimicrobial activity of allicin against the Bcc, 
with killing activity against B. cenocepacia, the most prevalent and transmissible Bcc 
species isolated from CF infections. This finding is very significant as Bcc isolates 
exhibit intrinsic resistance to antimicrobial peptides and other antibiotics.19, 199, 200 This 
novel investigation suggests that further work is required to comprehensively describe 
the antimicrobial mechanisms of allicin and to assess allicin-containing formulations as 
adjuncts to conventional antimicrobial agents presently used against this challenging 
group of bacterial pathogens.  
 
Previous investigations of novel antimicrobial compounds against Bcc species have 
included mushroom extracts201, polyketides26, docosahexaenoic omega- 3 fatty 
acid202 and microbe-derived volatile organic compounds28. Our results demonstrating the 
inhibitory activity of allicin-containing garlic extracts against Burkholderia species 
provide another potential line of research that is particularly relevant to Bcc infection. 
Evidence from animal and human studies have shown that allicin-containing garlic 
homogenates, delivered orally, intravenously or intraperitoneally, act as potent 
antioxidants leading to reduction of neutrophil-mediated lung damage, a major 
mechanism of Bcc lung infection.203 The stability of the antimicrobial properties of AGE 
during storage at 4°C and −80°C coupled with the batch-to-batch reproducibility were 




plasma in the treatment of cardiovascular disorders204, 205 could be a particular advantage 
in the treatment of the life-threatening septicaemia that is characteristic of cepacia 
syndrome. Our investigation suggests that further work is required to comprehensively 
describe the antimicrobial mechanisms of allicin and to assess allicin-containing 
formulations as adjuncts to conventional antimicrobial agents presently used against this 




Chapter 6: General Conclusion 
 
With the impact of infectious diseases on the rise, there is a great demand for new 
antimicrobial therapies through the identification of lead compounds and novel 
antimicrobial targets. Current research has shown that NPs are still relevant sources for 
identifying lead compounds due to their complex functionalities and diverse chemical 
structures. Additionally, there are numerous gene clusters from natural sources, for 
which the corresponding NP has yet to be identified.1, 206 The connection between genes, 
enzymes and molecules are now being exploited through the current advancements in 
fast and inexpensive genome sequencing technologies, which are increasing our 
knowledge of the biochemistry involved in biosynthetic pathways of many plants, fungi 
and bacteria, the main sources of NPs. From the study of biosynthetic pathways, new 
classes of enzymes are emerging rapidly, with novel structures and functionalities, 
which have provided insight into the source of the diversity of NPs. The varied 
functionalities within the AOS family of enzymes are a typical example, as several 
natural products essential for and detrimental to life have emerged from their activities. 
In this thesis, we reported the characterization of the putative AOS, annotated as TamD 
from the tambjamine biosynthetic pathway in P. tunicata.  
 
Tambjamines are known to be potent biologically active molecules, with antimicrobial 
and anticancer properties. However, not much is known about the enzymes involved in 
the biosynthesis of these molecules. The TamD enzyme plays a very important role, 
existing as a didomain protein, incorporating both a malonyl unit and a seryl unit into 
the pathway for the formation of a bipyrrolic intermediate. The source of the enzyme’s 
specificity for L-serine remains unknown, which serves as a point of interest for future 
bioengineering to introduce additional diversity within the family of tambjamines, since 
the AOS enzymes are known to all utilize specific amino acids in their PLP-dependent 
condensation reactions. Additionally, the structure of TamD is very fascinating in that it 
bears an unusual ACP domain at the N-terminus that is absent in the other well-




this study to investigate the topological relationship between the ACP and the AOS 
domains of TamD, which would provide insight into how the other AOS enzymes 
interact with their respective ACP partner acyl substrates. This information is very 
important when it comes to further engineering of the enzyme. Due to flexible and 
dynamic nature of the N-terminal domain, our efforts to obtain a high resolution crystal 
structure of TamD were hindered. Future efforts to capture this important structure 
would therefore involve the production of a substrate analogue that can link both the 
ACP and the AOS domains in order to reduce disorder of the flexible residues within the 
enzyme and increase the likelihood of crystallization and diffraction. Also solving the 
ACP and AOS domains independently may result in further information of the 
topological relationship of both domains to each other. 
 
NPs are not only useful in identifying new leads and studying biosynthetic pathways. 
Existing NPs with known biological activities can also serve as pharmacological probes 
to identify novel antimicrobial protein targets and assess their underlying mechanisms of 
inhibition or activation. The classical molecules explored in this thesis with known 
biological activities were the flavonoid, trans-chalcone a plant NP and garlic-derived 
allicin. The chalcone flavonoids are known to have antimicrobial properties against a 
number of microbes including MRSA. However, not many microbial enzyme targets 
that interact with the chalcones have been investigated.  
 
In this thesis, sortase A, a promising target in Gram positive bacteria was observed to be 
inhibited by trans-chalcone in vitro. A study of the interaction between S. mutans SrtA 
and trans-chalcone led to the identification of a Michael adduct formed between the 
active site cysteine residue of the enzyme and the β-carbon of trans-chalcone using MS 
analysis. This modification contributes to the observed inhibition of the enzyme by 
trans-chalcone in vitro. From this study, we were also able to report the first crystal 
structure of the H139A mutant of S. mutans SrtA, which gave insights into the binding 
pocket that the diaryl molecule sits in the active site using molecular modelling 
techniques. Such data has implications for future design and identification of other 




Another interesting covalent adduct was also identified in this body of work between 
allicin and the peroxidase BCP from Burkholderia as described in chapter 5. The 
thiosulphinate derived from garlic extracts reacted with a catalytic cysteine residue of 
BCP to produce an allythio derivative. This result was very surprising, as we were able 
to show that crude garlic extract could be analysed with a biological enzyme probe 
(BCP) to fish out the active molecule from such a complex mixture. From this project 
we were also able to report for the first time that allicin and allicin-containing garlic 
extracts possess bactericidal activities against the Bcc. These findings merit further 
investigation as adjuncts to existing antibiotics to fight infections caused by Bcc in CF 
patients. 
 
Protein MS was utilisied extensively in this thesis which highlights the importance of 
this emerging tool in NP research. Modern MS techniques can facilitate the 
identification of covalently-bound adducts formed between various NPs and protein 
targets and also provide data that can support the elucidation and verification of 
mechanisms.207 This was very evident in determining the molecular basis for the 
inhibition of S. mutans SrtA by trans-chalcone. Plant NPs also presents a challenge in 
characterizing the bioactive molecules which are usually present in small quantities and 
in complex mixtures. However, the use of protein MS is an ideal analytical tool to 
identify bioactive molecules, using protein targets as biological probes. This approach 
was utilized in identifying allicin as the main bioactive component of garlic extract that 
interacted with BCP from Burkholderia. Additionally, the technique can be used to 
identify protein targets from complex proteomes using NPs as chemical probes.  
 
In summary, the work presented in this thesis has shown that NP investigations remain 
an active and diverse field of academic research as analytical techniques continue to 
evolve and whole-genome sequencing become more accessible. There are many lessons 
to be learnt from studies of classical plant NPs as well as novel compounds that are yet 
to be explored. With the need to combat infectious diseases, the future will likely see a 




discovery in an effort to identify bioactive molecules, to unravel the mechanism of new 
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Figure A2: Calibration curve for Superdex S200 16/60 column (GE Healthcare). 
Gel filtration standard (Biorad) contains thyroglobulin (670 kDa), γ-globulin (158 kDa), 
ovalbumin (44 kDa), myoglobin (17 kDa) and vitamin B12 (1.35 kDa). Buffer 







Figure A3: Sequence alignment of TamD predicted seryltransferase domain with 
members of the AOS family. TamD (A4C5W2), SPT (2JG2; Q93UV0), KBL (1FC4; 
B5YWB8), AONS (1DJE; C4ZXU7), ALAS (2BWN; P18079)) and CqsA (2WK8; 
C3NXB8). The secondary structure (coil for α-helix and arrow for β-strand) of KBL is 
shown above the sequences. Residues involved in PLP binding are indicated with blue 
triangle. This figure was produced using ClustalW2209 and ESPript.210 *The TamD 
sequence in this alignment starts at residue 117. PDB codes are in black and UniProt 












Figure A4: Sequence alignment of TamD-ACP domain with ACPs. (A) Alignment 
with FAS ACPs: R. norvegicus (1N8L; P12785), H. sapien (2CG5; P49327), B. subtilis 
(1HY8; E0TTR0), V. harveyi (2L0Q; DOXCG4), E. coli (1T8K; A0A0B5JX78). (B) 
Alignment with PKS ACPs: S. coelicolor (2K0Y; Q02054), S. rimosus (1NQ4; 
Q3S8R2), S. roseofulvus (1ORS; Q54996), S. erythraea (2JU1; Q03131). The conserved 
DSL/I motif is highlighted in red and residues with high sequence identity are 
highlighted in yellow which undergoes PTM by the addition of a phosphopantetheinyl 










Figure A5: Peptide map from TamD digest by enoproteinase LysC. The data was 
SNAPed and searched using MS Fit and error of 20 ppm. The sequences in red were 
observed peptides (79%). The matched peptides covered 79% of the protein sequence 





























1 MTDNKNTAIE QIHALVIDVV TEQTCYAESD LILDAPMEEG LGIDSIILAS IVSEIQKLFM FETRLNTGSF NTIQALLDIC 
 
81 HNAMLSDAGV QKLAQLGLAA APQAVCVSSQ PEPEQRSTQA QTMRDFVADG SPDLFSKVRK FDQFYKNQAE QGNFWYGMPL 
 
161 SSRCENRATI YDGYQKKERE FLMFASNNYL GLANDPRVIK AICDATQKYG ATNTGCRLIG GTNHLHLELE ARLAAFKGRE 
 
241 ACIVFPSGYS ANLGTISALT GPKDTVISDV YNHMSIQDGC KLSGAKRRIY KHNDMDSLEE VLKGCSESEG GKLIVADGVF 
 
321 SMHGNIVKLP EMVRLARKYQ ARILIDDAHS TGVLGAMGSG TAEHFNLKHE VDLELGTMSK TLAGMGGFVC GDKEVIEYLR 
 
401 FYANSYVFAA TIPANIAAGL IQCIDIIEKE PERISRLRQN ADYLRSALQE CGFNTGDSES AVIPVVIGDE AVAMAMGHQV 
 









Nmol/asym Matthews Coeff % solvent P(4.98) P(tot) 
1 12.56 90.21 0.00 0.00 
2 6.28 80.42 0.00 0.00 
3 4.19 70.63 0.03 0.02 
4 3.14 60.84 0.18 0.14 
5 2.51 51.05 0.48 0.45 
6 2.09 41.26 0.29 0.37 
7 1.79 31.47 0.01 0.02 
8 1.57 21.69 0.00 0.00 
9 1.40 11.90 0.00 0.00 
10 1.26 2.11 0.00 0.00 
 
 
Figure A6: Matthew's calculations for TamD. The number of molecules 
expected in the ASU is between 4 and 6 based on Matthew’s number calculations. This 
is consistent with Matthew’s coefficient between 2.09 and 3.14 and solvent content of 
41.3 and 60.8 %. The actual number of molecules in the ASU is 4, which is consistent 






























Ncyc Rfact Rfree 
0 0.4533 0.4775 
1 0.4533 0.4793 
2 0.4520 0.4785 
3 0.4507 0.4779 
4 0.4485 0.4761 
5 0.4448 0.4725 
6 0.4378 0.4666 
7 0.4190 0.4607 
8 0.4161 0.4589 
9 0.4038 0.4584 
10 0.3838 0.4482 
 
 
Figure A7: Refinement of TamD model. Ten refinement cycles were performed in 






















































Figure A8: Sequence alignment of sortases. Identical residues are highlighted in red, 
similar residues are highlighted with a blue box. Catalytic triad is indicated with a blue 
∆. S. mutans (SmSrtA) (4TQX; I6L907), S. pyogenes (SpSrtA) (3FN5; Q1JGU0) S. 
aureus (SaSrtA) (1T2P; D9RJF4) S. aureus (SaSrtB) (1NG5; A0A090LW34), .B. 
anthracis (BaSrtB) (2OQW; A0A0B5YM13) S. pnemoniae (SpnSrtC) (2W1J; 
G6LSC3), S. agalactiae (SagSrtC) (3O0P; SAS8MMM0), S. suis (SsSrtC) (3RE9; 







Figure A9: Mass spectrum of CID fragments ions used to assign site of modification 
in SmSrtA.  The isotopic distributions of the y425+ ([C207H333N60O64S1(C15H12O)]5+) and 
y436+ ([C211H341N61O66S1(C15H12O)]
6+) fragment ions allowed for the assignment the site 
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